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Abstract
Islet transplants have been successfully used as treatment for diabetes, but are
limited by shortages of cadaveric insulin-producing β-cells. An alternate source may be the
dedifferentiation, expansion, and subsequent redifferentiation of pancreatic islets or β-cells
using in vitro techniques prior to transplant. Based on protocols which described the
dedifferentiation of human islets to ductal-like cells, we hypothesized that neonatal mouse
islets could be similarly dedifferentiated in vitro.
Dedifferentiation

techniques

produced

significant

duct-like

cells,

but

redifferentiation to insulin-expressing cells was limited. RIPCre;Z/AP+/+ mice were
consequently utilized to lineage trace β-cell fate during culture by a human placental
alkaline phosphatase (HPAP) reporter.

The proportion of HPAP+ β-cells decreased

significantly in culture, but the rare remaining cells expressed the ductal marker CK19. Flow
cytometric sorting of β-cell subpopulations from whole pancreas showed that the
HPAP+CK19+ cells had derived from insulin-positive, glucose-transporter-2-negative
(Ins+Glut2-) cells, previously purported as insulin-expressing progenitor cells. In P7 mouse
pancreas, these Ins+Glut2- cells represent 3.5% of all insulin+ cells, the majority of which
were found outside of islets within β-cell aggregates (BCA, <5 β-cells). Ins+Glut2- cells
demonstrated greater proliferation rates in vivo and in vitro as compared to Ins+Glut2+ cells,
and a subset could differentiate into endocrine, ductal, and neural lineages. We sought to
quantify the presence of these progenitor cells throughout life in both mouse and human
pancreata, and how their abundance and location changes with age. The presence of
Ins+Glut2- cells in human and mouse pancreas demonstrated similar distributions and
ii

ontogenies, being more abundant in BCA than islets at all ages sampled, and decreasing
with age. Finally, neonatal rodents can regenerate β-cell mass after streptozotocin (STZ)
exposure, but this response is mitigated in adulthood. As STZ accesses the β-cell via Glut2,
we hypothesized that the β-cell regenerative capacity in early life involves mobilization of
Ins+Glut2- cells, and used RIPCreER;Z/AP+/+ mice to trace these during damage and
regeneration.

We found that Ins+Glut2- cells indeed survived STZ exposure, and

subsequently matured into Ins+Glut2+ cells.
These Ins+Glut2- cells represent a transitional cell type, the majority of which
contribute to pancreas maturation, and a subset of which retains multipotential lineage
capability.

Keywords

β-cell, cellular plasticity, development, diabetes, differentiation, duct, endocrine, Glut2,
insulin, islet, lineage tracing, progenitor cell, regeneration, stem cell, streptozotocin, tissue
culture
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CHAPTER 1
Introduction

1

1.1

Diabetes
Diabetes mellitus is a metabolic disease of the pancreas, characterized by increased

levels of glucose in the blood (hyperglycemia). It is caused by an insufficient production of
insulin, as found in Type I diabetes (T1D), or by cells that do not effectively or appropriately
respond to the insulin produced, as found in Type II diabetes (T2D). The hormone insulin is
secreted by pancreatic β-cells located in the islets of Langerhans, a spherical cluster of
endocrine cells containing predominantly insulin-producing β-cells. Without insulin, the
body cannot derive energy from carbohydrate metabolism for use in its target tissues,
including liver, muscle, and adipose. Patients with undiagnosed or untreated diabetes
typically present with fatigue, increased urination, increased thirst, and weight loss.
Diabetes was first described >3000 B.C. by the Egyptians, and later by Greek physicians
who coined the term diabetes, meaning, “to siphon”, referring to the large quantities of
urine produced. The disease had also been described in India 400 B.C. as “honeyed urine”
(1,2). For most of history, a diagnosis of type I diabetes was tantamount to a death
sentence; it was not until 1922 that Frederick Banting and colleagues Charles Best, James
Collip, and John Macleod discovered the hormone insulin, which was life-saving for patients
with the disease (3,4).
Today, diabetes affects more than 285 million people worldwide, 9 million of them living
in Canada with diabetes or pre-diabetes (5). This number is expected to surpass 438 million
people worldwide by 2030. The vast majority of new cases is due to T2D, and attributable to
a variety of factors, including an aging population, a sedentary lifestyle, and the worldwide
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obesity epidemic (5). The cost to the Canadian healthcare system is expected to reach
$16.9 billion by 2020 (5).
While a diagnosis of diabetes today does not carry with it the imminent death sentence
it did a century ago, it is still the fourth leading cause of death by disease globally, with a
morbidity rate of 4.6 million people annually (6). Death is associated with diabetes, but is
commonly ascribed to complications of the disease, and only rarely to acute metabolic
circumstances such as severe hyperglycemia and accompanying ketoacidosis, or its
opposite, hypoglycemia (7). The long term sequelae of the disease are broadly classified
into micro- and macro-vascular complications, as a result of both endothelial cell damage to
small vessels, and elevated blood lipids which are deleterious to large vessels (7). Sustained
exposure to hyperglycemia cause severe complications such as retinopathy (8,9),
neuropathy (10), cardiovascular disease (11), and nephropathy (12). The majority of people
with diabetes die of heart disease or stroke (6).
While the complications experienced are similar between diabetes types, <10% of all
patients with the disease have T1D. T1D differentiates from T2D in that it is an autoimmune
disease which specifically destroys the β-cells in the islets of Langerhans, mediated by T-cell
activation and islet-specific autoantibody presence (13). The conditions which allow this
autoimmune storm to proceed are still unclear, although a combination of environmental
triggers, such as viral exposure (14), and genetic susceptibility, especially by the presence of
the HLA alleles DR3-DQ2/DR4-DQ8 (15), have been implicated. T1D was historically termed
“juvenile diabetes” as it was thought to strike only those under 30 years of age; it is now
known that persons of any age can develop the disease (16), although it is still most

3

commonly diagnosed in the young. While pharmacological and bioengineering advances
have improved the purity and delivery of the hormone, the current and standard treatment
for T1D is still limited to exogenous insulin therapy. Despite advances, persons with T1D
live, on average, 15 years less than those without the disease (6).
In 2000, a breakthrough procedure coined the “Edmonton Protocol” was introduced, in
which islets of Langerhans were transplanted into patients with diabetes (17,18). This was
an improvement from the only other transplant option – an entire pancreas – available
solely to patients undergoing concurrent kidney transplant (19). Despite the relative success
of islet transplants, it is limited by the need for immune-modulating drugs, as well as the
high number of islets needed for transplant: the endocrine portion equivalent from up to
three pancreata per recipient, derived from cadaveric sources (17). Even considering these
limitations however, the benefits gained to patients seem to outweigh the risks, such as
increased circulating C-peptide levels, decreased HbA1C, and improved micro-vascular
health (20). Indeed, recent refinements in the procedure have allowed most patients insulin
injection independence for >3 years post-transplant (21).

1.2

Pancreas anatomy and function
The head of the pancreas is attached at the initial curve of the duodenum and

stretches across the abdomen where the tail attaches to the spleen. The pancreas has dual
functions: the exocrine (acinar) cells produce digestive enzymes and bicarbonate, which
access the intestine by the highly branched ductal system; and the regulation of blood
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glucose by the endocrine component, the islets of Langerhans, which account for ≤2% of
the organ (22). A schematic illustration of the pancreas anatomy is shown in Figure 1.1 (23).
The islets of Langerhans contain 5 distinct endocrine cell types, each of which
produces its own hormone. Pancreatic α (alpha) cells release glucagon, which raises glucose
by releasing glycogen from the muscle and liver, whereas β (beta) cells release insulin,
which lowers blood glucose concentrations by stimulating glucose uptake in the liver,
muscle and adipose tissues; these two hormones act synergistically to maintain glucose
homeostasis. δ- (delta) cells produce somatostatin (or growth hormone-inhibiting hormone,
GHIH), a

peptide hormone that regulates the endocrine system and affects

neurotransmission, cellular proliferation, and gastric emptying (24,25). ε- (epsilon) cells
produce ghrelin, found also in the stomach, which acts to stimulate appetite (26–28) and is
the counter-regulatory hormone to leptin. γ-cells (also termed PP cells) produce pancreatic
polypeptide, which acts to self-regulate both endocrine and exocrine pancreas secretions
(29,30).
In the rodent pancreas, α-cells are located in the mantle of the islet, and account for
14-20% of islet mass, whereas β-cells are located in the islet core, representing 75-80% of
islet mass (31–33). δ -cells account for 10% of islet cell proportion (31), with γ-cells and ε cells composing the remaining minority compartments. In the human, the proportional
representation and islet architecture is more heterogeneous: the β-cell proportion varies
widely from 28-75% (32,34,35), whereas α-cells represent 10-65% of cells, and δ-cells
account for 1.2-22% (32). Moreover, the cells are not organized in a core-mantle
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Figure 1.1. Anatomical location of the pancreas
The pancreas is located within the abdomen, and serves to accommodate
dual functions: the production of digestive enzymes and bicarbonate by
exocrine (acinar) cells, which access the intestine by the highly branched
ductal system; and the regulation of blood glucose by the endocrine
component, the islets of Langerhans, which account for only 1-2% of the
organ. The islets contain 5 distinct cell types, each of which makes its own
hormone: β (green, insulin), α (red, glucagon), δ (blue, somatostatin), γ
(yellow, pancreatic polypeptide), and ε (purple, ghrelin).

Reproduced from McKinley, M. and O’Loughlin V.D. Human Anatomy, 2nd
Edition, 2003.
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arrangement as found in rodent islets (31,36), which may be due to alterations in their
vasculature arrangement (36).

1.3

Pancreas development
Pancreas development begins in the mouse at embryonic day (e) 8.5 (Figure 1.2

(37)), when the presence of the transcription factor and homeodomain protein Pancreatic
duodenal homeobox-1 (Pdx1/Ipf1) delineates multiple structures, including the pancreas,
stomach, duodenum, and bile duct (38,39), and which is expressed in all pancreatic cell
progenitors (40). Pdx1 is known as the pancreatic master regulator, playing a critical role in
early pancreas development, as well as β-cell differentiation and the maintenance of
mature β-cell function later in development (41). Pdx1-/- mice present with complete
pancreas agenesis and lethality shortly after birth (42), while inactivation of Pdx1 after bud
formation prevents any further islet or acinar differentiation (43–45). By e9.0-9.5, two
pancreatic lobes – dorsal and ventral – arise from the posterior foregut, in a region of prepatterned epithelium (37,46,47), as shown in Figure 1.2.
This early epithelium begins an evagination process into the surrounding
mesenchyme, as epithelial buds form at a bulge of primary pancreatic multipotent
progenitor cells (47) (MPC, red, Figure 1.3A (48)). Each pancreatic bud develops into an
extensively branched ductal tree between e10.5-e12.5, forming two primordial organs, in a
phase termed the primary transition (Figure 1.2). Endocrine cells arise from progenitor cells
present within the e9.5 gut endoderm in the ductal epithelium, while the acini and ducts
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Figure 1.2. Mouse pancreatic development
On embryonic day 8 (e8), patterned epithelium of the primitive foregut
forms dorsal pancreas (DP) and ventral (VP) buds by e9.5. These buds then
develop into branching ducts and undifferentiated epithelium by e12.5,
during the first (developmental) transition. The undifferentiated epithelium
contains scattered single endocrine cells. The buds begin to differentiate
into endocrine and exocrine cellular lineages by e14, with proliferation and
expansion at the second transition. By e15, the two pancreata rotate, fuse,
and form a nearly developed pancreas by e19, containing the endocrine
cells organized into isolated clusters, termed the islets of Langerhans (third
transition). The tertiary transition is characterized by the maturation of
endocrine cells, continues for until weaning at postnatal day 21. The
representative transcription factors expressed during the program of
development are indicated in blue. The approximate embryonic age (in
days) is designated for each stage of development.
Reproduced from Habener JF, Kemp DM, Thomas MK. Minireview:
transcriptional regulation in pancreatic development. Endocrinology.
2005;146(3):1025–34. Permission granted from The Endocrine Society.
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Figure 1.3. Mouse pancreas organogenesis
A: Upper diagram: A region of gut tube epithelium becomes pancreas-specified
around E9, at a bulge of pancreatic multipotent progenitor cells (MPC, red), which
expands to form a bud. At E11, cells within this bud initiate polarization and
constriction, forming multiple microlumens. Coalescence and proliferation at e12.5 of
the lumen produces epithelial tubes by e14.5. Ultimately, these tubes remodel,
forming a ductal tree as part of the mature pancreas. Lower diagram: Epithelium
specialization towards acinar (red), or endocrine/duct lineages (blue/green), which
delineate from cells within the tip or trunk. Tip and trunk compartmentalization occurs
around the time of tube formation (E12). Tip regions are distributed broadly
throughout the epithelium. MPC that form tip regions (red) proliferate and undergo
tip-splitting, causing outgrowth into the mesenchye, and generating additional trunk
epithelium with bipotentiality for endocrine (blue) or duct (green) fates. ‘Mature
pancreas’ shows that acinar cells (red) form the tips of branched ducts. Islets comprise
β-cells (blue) surrounded by other endocrine cell types (yellow). B: Transcription
factors expressed at each stage of pancreas development. Note that the same ductal
epithelial transcription factors are expressed in early development as well as late.
Reproduced from Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to
gland. Dev Dyn. 2011;240(3):530–565. Permission granted from John Wiley and Sons.
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develop by e14.5 (49). These early endocrine cells contain minimal amounts of glucagon; by
e10 – e10.5, they co-express glucagon and insulin, then divide into distinct lineages (37).
Early lineage tracing experiments by Herrera showed that adult α- and β-cells derive from
independent lineages (50); however, recent experiments by the same group have suggested
that α-cells retain the ability to transdifferentiate to β-cells under conditions of extreme βcell loss (51), and by forced Pdx1 expression (52). Conversely, β-cells have been shown to
trans-differentiate to α-cells during T2D diabetes progression (53), further confounding the
loss of β-cell mass, and which was postulated to represent β-cell dedifferentiation, and
failure as a result of stress (54).
By e12.5, these MPCs have proliferated, the epithelium has stratified, and epithelial
tube formation has occurred (Figure 1.3A). Around e14, the pancreatic buds begin to
differentiate into distinct endocrine and exocrine lineages, a phase termed the secondary
transition. Zhou and colleagues found that this differentiation was due to “tip-trunk
segregation” of the epithelium, where the tip cells become acinus, and the trunk cells
remain as uncommitted trunk (duct-endocrine) cells (55) (Figure 1.3A). These bipotent
trunk cells are identified by a signature of transcription factors including Pdx1, SRY (sexdetermining region Y) box9 (Sox9)(56–58), hepatocyte nuclear factor 1 beta (Hnf1β/Tcf2)
(59), and hepatocyte nuclear factor 6 (Hnf6) (60) (Figure 1.3B).
After the bifurcation of the exocrine compartment from duct-endocrine fates, the
expression of the bHLH transcription factor neurogenin3 (Ngn3) represents a lineage switch,
distinguishing cells that become endocrine pancreas from ductal epithelium (61–63) (Figure
1.3B). Ngn3 is expressed only in endocrine progenitors and is promptly down-regulated
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during terminal differentiation (62). Ngn3-/- animals completely lack all pancreatic endocrine
cell types (64).
Around e15, the dorsal and ventral pancreata rotate and fuse, forming a nearly
complete pancreas by e19 as shown in Figure 1.2. Immature β-cells express multiple
transcription factors after fate specification from Ngn3+ precursors, including v-Maf
musculoaponeurotic fibrosarcoma onco- gene homologue A (MafA) and MafB (Figure 1.4
(65)). Between e14-birth, MafA levels increase and MafB levels decrease in β-cells, and
MafB expression becomes restricted to α-cells (65,66).
By e19, the endocrine cells have organized into clusters, the islets of Langerhans.
Mature β-cells express multiple transcription factors, including Neurogenic Differentiation1
(NeuroD/Beta2) (67), Paired box gene4 (Pax4) (68), Pax6 (49,69), Homeobox protein
Nkx_2.2 (Nkx2.2) (70), and Nkx6.1 (71). The transcriptional cascade during islet
development is shown in Figure 1.3B. After e19-e21/P0 (birth), endocrine cells undergo
further maturation during the third developmental transition, which continues for 2-3
weeks after birth (37). It is generally assumed, but not entirely proven, that islet cell
regeneration in the postnatal period, or progenitor cell differentiation in vitro, will proceed
by similar (canonical) pathways.
After bifurcating from the common bipotent trunk progenitor state shared with
endocrine cells, duct cells maintain the expression of some transcription factors (Sox9,
Hnf1β, and Hnf6) but notably lose expression of Pdx1, whilst gaining functional markers
such as carbonic anhydrase II (CAII) (72) and cytokeratin 19 (CK19) (73).
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Figure 1.4. The transcription factors MafA and MafB undergo a
developmental switch during β-cell maturation
In early development (e13.5), β-cells exhibit high expression of MafB and
low levels of MafA; by the secondary transition at e14.5, MafA expression
has increased significantly. By birth, these two transcription factors
demonstrate a developmental switch, with MafA expression overtaking
that of MafB. By postnatal day 28, MafA is expressed in high proportion in
insulin-expressing β-cells, whereas MafA expression is generally restricted
to the glucagon-producing α-cells.
Reproduced from Artner I, Hang Y, Mazur M, Yamamoto T, Guo M, Lindner
J, Magnuson MA, Stein R. MafA and MafB Regulate Genes Critical to Beta
Cells in a Unique Temporal Manner. Diabetes. 2010;59(October):2530–39.
Copyright © 2010 American Diabetes Association, Inc.
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In early postnatal mammalian life, further macro-organization of the endocrine
pancreas occurs. Meier et al showed that neonatal human pancreas displayed significant
small clusters of β-cells, and which organized into proto-typical islet structures during
childhood (74). They, and others (75), found that these clusters of β-cells were more
proliferative than those found within islets in the young human and rodent. The
coordinated expansion of these small clusters, and fission of islet-like clusters contributes to
the fully mature pancreas (75). Consistent with this, the proportion of β-cells present within
clusters declines by adulthood, instead being found in islets (75,76).

1.4

β-cell function
In the β-cell, two other markers of mature function are glucokinase (Gck) and the

glucose transporter-2 (Glut2). Gck is known as the “glucose sensor” (77,78), and is involved
in the first step of glycolysis by phosphorylating glucose (79,80). Glut2 is a trans-membrane
carrier protein which allows the facilitated movement of glucose across cell membranes in
liver, kidney, and pancreatic β-cells, and is stimulated to initiate transport by high glucose
concentrations outside of the cell. In humans, this protein is encoded by the SLC2A2 gene
(81). Glut2 is required for the initial step in glucose-induced insulin secretion by glucose
uptake (82,83). In studying metabolic disease, is important to note that human β-cells use
both GLUT2 and GLUT1 (preferentially GLUT1), whereas in the rodent pancreas, β-cells
exclusively utilize Glut2 (84). Pdx1 is involved in trans-activating Glut2 in addition to its role
in activating the insulin gene (41).
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1.5

Sources of (new) β-cells, islet plasticity, and regeneration
The availability of a renewable pool of insulin-producing cells would alleviate the

need for cadaveric-sourced islet transplants, and much work has focussed on identifying
new or replicable sources of β-cells. The β-cell mass in vivo is maintained by a delicate
balance of cellular growth and regression. In the neonatal period, rodents undergo
significant remodelling of their pancreatic endocrine component, with increased rates of
replication, neogenesis, and apoptosis (85). These processes lead to an increase in β-cell
mass soon after weaning (86); but both replication and apoptosis drop significantly
thereafter. Under normal circumstances, islet neogenesis (the generation of new pancreatic
endocrine cells) in the rodent ceases after birth (87), although examples of endocrine
regeneration after injury are well documented (88).

Central to this debate are two

expansive, yet related, questions: (i) under what circumstance(s) is β-cell regeneration
possible? and, (ii) what is (are) the source(s) of the regenerating cells?
Two broad categories for the generation of any cell are the replication of preexisting cells, and the differentiation from stem/progenitor cells. In the pancreas, these
have been depicted by Bonner-Weir in Figure 1.5 (89) as (i) replication of pre-existing βcells, (ii) differentiation from ductal progenitor cells, (iii) differentiation from
stem/progenitor cells outside of the ductal epithelium, and (iv) acinar transdifferentiation.
The first 3 will be discussed in enhanced detail below.
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Figure1.5. Sources of new β-cells within the pancreas
Four broad categories of cell source within the pancreas are (i) replication
of pre-existing β-cells, (ii) differentiation from progenitors present within
the ductal epithelium, (iii) differentiation from stem/progenitor cells
outside of the ductal compartment, and (iv) transdifferentiation from
acinar cells.
Reproduced from Bonner-Weir S, Weir GC. New sources of pancreatic
beta-cells. Nat Biotech. 2005;23(7):857–61. Permission granted from
Nature Publishing Group.

15

1.5.1

Replication of pre-existing β-cells

1.5.1.1

β-cell turnover with age

In rodents, β-cell proliferation occurs postnatally at a rate of between 0.5% (90) to
~4% daily (85,91,92) between P30 – 100, and is countered by apoptosis rates of
approximately 0.5% (91,92). This rate of proliferation then decreases to <1% per day after 1
year of age, with some estimates of β-cell replication at only ~0.2%/24 hours (93–95),
indicating an increase in β-cell mass during early life (91). Multiple publications have
addressed the issue of tissue turnover and β-cell mass expansion with age, and the
consensus findings have suggested that the β-cell is capable of efficient compensatory
proliferation in young animals, which diminishes with advancing age (88,95,96).
Human β-cell proliferation estimates have shown similarly low rates, with the few
available publications indicating that the highest rate of β-cell replication occurs during the
mid-fetal period (17-32 weeks gestation) at 3.2 ± 0.5% (97,98). By birth, the highest rate of
proliferation was 2.6% in one case (74), and decreased thereafter, with β-cells replicating
only 0.2%/day by early adulthood (74,98). Cnop et al showed that 97% of the human β-cell
population was established by the age of 20 years (99). It was noted that in young humans,
the proliferation was highest in small islets and scattered β-cells, there was wide variability
between samples, and surprisingly, there was no wave of proliferation during adolescence
as hypothesised (74). Furthermore, data from human pancreas studies suggest a mitigated
ability of β-cell mass to proliferate based on physiologic demand when compared to young
rodents (100), and that there was no adaptive response to increased insulin demands by
replication in adult islets (99). Figure 1.6 demonstrates the decline in human β-cell
proliferation rate in the first 20 years of life (74).
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Figure 1.6. β-cell proliferation rate decreases with advancing age
While there is decreasing proliferation frequency with increasing age
overall, intra-sample variability is high.
Reproduced from Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R,
Bhushan A, Rizza RA, Butler PC. Beta Cell Replication is the Primary
Mechanism Subserving the Postnatal Expansion of beta-Cell Mass in
Humans. Diabetes. 2008;57 (June):1584–1594. Copyright © 2008
American Diabetes Association, Inc.
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The mechanisms which control the cell cycle in pancreatic β-cells are still not yet
fully elucidated. Genetically, cell cycle progression requires DNA replication (S phase), and
cell division or mitosis (M phase), which is halted between phases by a number of gaps (G).
It has been shown that control of β-cell proliferation is greatly influenced by the cell cycle
checkpoint at the G1/S phase transition (101,102). Successful transition from the G1/S
checkpoint is accomplished via a family of transcriptional activators and repressors called
the E2F proteins (102). The retinoblastoma protein (pRb), in addition to related pocket
proteins p130 and p107, is regarded as the molecular brake on cell cycle progression,
resulting in G1/S arrest (102). pRb binds preferentially to E2F-1, -2, and -3, which serves to
repress their transcriptional activity (102,103). This process is further regulated by a group
of proteins such as cyclin D1/D2 (104) and their associated cyclin-dependent kinases (CDKs),
specifically CDK4 (105), which act to promote β-cell proliferation. Conversely, proliferation
can be inhibited by up-regulation of such proteins as the INK4 cell cycle inhibitors. One such
negative regulator is p16INK4a, which inhibits the CDK4-cyclinD2 complex in β-cells, and
therefore inhibits cell cycle progression and cell proliferation. Moreover, expression of
p16INK4a increases markedly with advancing age, further restricting the capacity for β-cell
regeneration (96,106). This age-dependent decline in proliferation was recently shown to be
a result of platelet-derived growth factor (PDGF) signalling, which controls the replication
refractory period (107). Furthermore, it was also shown that nearly all G1/S cell cycle control
molecules are located in the cytoplasm and not the nucleus (108), but actively traffic to the
nucleus for proliferation initiation (109). A detailed schematic illustrating the genetic control
of β-cell replication is shown in Figure 1.7 (109). Interestingly however, the age-dependent
decline in β-cell proliferation was demonstrated to be reversible when adult quiescent β18

Figure 1.7. Old and new models for β-cell proliferation and progression
through the G1/S checkpoint
Previous (A) and recent (B) models of β-cells at quiescence, and new models
of successful (C) and unsuccessful (D) transition through the G1/S checkpoint
during β-cell proliferation. The new model indicates a trafficking of cell cycle
inhibitors and associated proteins including Cdk6 and cyclin D3 from the
cytoplasm into the nucleus.
Reproduced from Fiaschi-Taesch NM, Kleinberger JW, Salim FG, Troxell R,
Wills R, Tanwir M, Casinelli G, Cox AE, Takane KK, Srinivas H, Scott DK, Stewart
AF. Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult
human β-cell replication: a revised model of human β-cell G1/S control.
Diabetes. 2013;62(7):2460–70. Reprint available for teaching, copyright ©
2013 American Diabetes Association, Inc.
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cells were transplanted into young mice. This phenomena was postulated to be the result of
a circulating β-cell trophic factor present in early life, and independent of p16INK4a
expression (110). This new data opens up the field to new therapeutic options for targeting
β-cell replication and regeneration.
In a now-seminal publication, Dor and colleagues from the Melton group proposed
that all (postnatally formed) adult β-cells arise from pre-existing β-cells, and not from stem
cell differentiation (111). The group performed a pulse-chase experiment using the
transgenic mouse model RIPCreER;Z/AP, which constitutively tags a subset of β-cells with a
human placental alkaline phosphatase (HPAP) reporter protein after injection of the
selective estrogen receptor modulater, tamoxifen (TM). The HPAP-tagged β-cells were then
followed over the course of a year. They found that the ratio of tagged: untagged β-cells
remained constant, indicating that no new β-cells arose from non- β-cell source, or that the
contribution from stem cells was negligible. This was similarly concluded by the Kushner lab
using sequential thymidine labelling of β-cells (112). However, there are caveats to this
restrictive conclusion, including the lineage-tracing system utilized, which relies on
interpretation of the frequency changes in labelling rates from a small percentage of tagged
cells, with some inherent leakiness of the Cre transgene, as well as assessment on a small
sample number (113).
The low rate of β-cell replication combined with the lack of definitive evidence for a
β-cell stem/progenitor population would then suggest that the endocrine pancreas has a
limited ability for growth in the postnatal setting; however, there are physiological instances
documented where significant β-cell expansion is possible, such as during pregnancy (114–
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116), or in response to obesity (34,117,118). Saisho and colleagues reported that in
humans, a 50% increase in β-cell mass was found in (non-diabetic) obese patients (119). βcell proliferation is also affected by various physiological stimuli, including glucose
metabolism: sustained exposure to hyperglycemia has been shown to induce a modest
increase in β-cell mass (120), and genetic defects in Gck show reduced β-cell proliferation,
whereas activation of the enzyme increased proliferation (121). Related to these
phenomena, insulin resistance in patients with T2D has been shown to promote an increase
in β-cell proliferation (122–124). This has been suggested to be the result of a secreted
protein termed “betatrophin” from liver and adipose cells, which selectively, and strikingly,
increased β-cell proliferation in both mice and humans (125). The potential therapeutic
opportunity provided by this new hormone is staggering in its scope for human disease
modulation, predominantly for patients with T2D. However, recent evidence has somewhat
tempered the supposition of this hormone to be the “magic bullet” for curing the disease
alone, as the effects seen in mice were not replicated in human islet transplant experiments
(126).
Combining both aging and disease, studies have examined islet/endocrine function
from patients with long standing T1D. Recent reports have challenged the presumption that
β-cell destruction is a one-time, static process, instead showing evidence for β-cell
regeneration attempts in patients with long-term T1D (16,127). The Medalist Study
examined histological sections from 9 pancreata donated post mortem of patients with >50year duration of T1D (128). Of 4 pancreata selected based on positive antibody titres, two
showed evidence of insulin+ TUNEL+ (apoptotic) cells, and one pancreas exhibited insulin+
Ki67+ (proliferative) cells, indicating active tissue turnover (128).
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What is evident from these reports is that the rate of β-cell apoptosis outstrips the
rate of β-cell regeneration/proliferation. However, reversal of T1D may be accomplished by
mitigating the auto-immune destruction of the β-cell and allowing endogenous
regeneration to occur. This could be provided by autologous hematopoietic stem cell
transplant, which has shown to be effective in other autoimmune diseases including
multiple sclerosis (129), or by immuno-modulatory therapy (130). However, the etiology
and progression of T1D, with substantial loss of β-cell mass prior to overt symptoms, may
limit full endogenous regeneration from occurring even if the autoimmune destruction can
be controlled. Immuno-modulatory therapy may therefore be of use only for patients
previously identified as at-risk for diabetes development, and not necessarily those with
established disease present.

1.5.1.2

Models of β-cell injury and regeneration

Multiple injury models have been shown to induce endocrine regeneration, such as
partial pancreatectomy (Px) (111,131,132), pancreatic duct ligation (PDL) (133–136), the
injection of the β-cell toxin streptozotocin (STZ) or its related drug, alloxan, and recently, by
genetically-based methods of specific β-cell ablation.

Partial pancreatectomy
Partial pancreatectomy involves the surgical resection of up to 90% of the pancreas
in rodent models, and Bonner-Weir and colleagues have performed multiple studies
demonstrating both endocrine and exocrine regeneration capacity in the weeks following
surgery (131,132,137–139). Dor and colleagues also performed Px in parallel to the aging
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model so as to ascertain if there was a difference in developmental origin of newly formed
β-cells formed during regeneration. They concluded that after Px, similar to aging, β-cells
from adult mice primarily arose from pre-existing β-cells, and not progenitor cell source
(111).

Pancreas duct ligation
Pancreas duct ligation involves surgically obstructing the pancreatic duct, causing
digestive enzymes to be shunted, and hence accumulate, in the ligated portion of the organ.
This initiates severe inflammation and acinar apoptosis, similar to pancreatitis in humans
(140). This model has been used extensively for islet regeneration (141–144), with new βcells putatively arising from the ductal compartment (135). However, recent evidence has
indicated that these results have been confounded by extensive (global) pancreatic damage
and that endocrine regeneration does not occur (145).

STZ
STZ and alloxan are glucose mimetics and as such, access the β-cell via Glut2
(146,147); a structural comparison between the two compounds is shown in Figure 1.8
(146).

STZ (2-deoxymethyl-nitrosurea-glycopyranose) destroys the rodent β-cell by

transferring a methyl group to DNA, leading to DNA fragmentation. Attempts to repair DNA
by stimulation of poly (ADP-ribose) polymerase leads to cellular depletion of NAD + and ATP
stores (148,149), and necrosis of the β-cell ultimately causes hyperglycemia within days of
administration (147,150–152). However, due to its use of Glut2 as a mode of entry, other
cell types which utilize this transporter are also damaged after drug administration (e.g.
23

Figure 1.8. Schematic illustration showing the structural similarities of
the β-cell toxin streptozotocin (STZ) to glucose

In rodents, both STZ and glucose enter the pancreatic β-cell via the glucose
transporter Glut2.
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liver, kidney), and care must be taken to avoid damage to distal organs which can confound
interpretation of the diabetogenic effect of the drug (147). Moreover, human β-cells, which
predominantly utilize GLUT1, are less susceptible to these effects than rodent β-cells (153).
In rodents, STZ has also been shown to induce inflammation and peri-islet lymphocyte
infiltration, suggesting that it not only causes β-cell apoptosis and hyperglycaemia, but also
closely models TID disease development. However, this response is more classically seen
after multiple low-dose STZ treatment, and not after a single bolus (154,155).
Interestingly, the regenerative capacity after administration of STZ is temporally
defined: rodents given STZ during the neonatal time period can partially regenerate their
endocrine pancreas (96,150,156–162), whereas the regenerative response is mitigated
when the drug is administered in adulthood (96,146). The regenerative capacity also
depends partly on the timing of STZ administration: a single bolus of 100 mg/kg of the toxin
at P0 showed glucose normalization and β-cell mass re-establishment by 3 weeks of age
(150), whereas STZ given after P5 showed a less-robust regenerative capacity (146),
although it was still seen in mice up to 6 weeks of age as compared to adults (96). The
mechanism(s) behind this temporal regeneration capacity have not been determined.

β-cell ablation by genetic manipulation
A new mode of β-cell damage is the Insulin-rtTA;TET-DTA model, combining a
transgenic mouse strain that expresses the reverse tetracycline-dependent transactivator in
pancreatic β-cells (Insulin-rtTA) with a mouse strain that expresses the diphtheria toxin A
(DTA) subunit under a rtTA-responsive promoter (TET-DTA) (163). In the presence of
doxycycline, rtTA induces the expression of DTA, causing β cell apoptosis (164). The benefit
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of this model is that it specifically targets only the β-cell, and avoids confounding issues of
inflammation, or effects on other organs that are observed in other injury models.
Nir and colleagues found that after giving doxycycline (Dx), 70-80% of β-cells were
destroyed and overt hyperglycemia and diabetes was noted. Interestingly, upon withdrawal
of Dx, insulin expression normalized, islets regained their architecture to 90%, and there
was a remission of hyperglycemia, although full glucose tolerance was only complete after 8
months. These results were consistent regardless of the age at which the mouse β-cells
were ablated. The authors then lineage traced the β-cells during this process, and found
that the labelling indices of both regenerating and non-regenerating mice (injured and noninjured, respectively) were the same, and that proliferation rates were the same between
the two groups, leading to the conclusion that β-cell regeneration is possible, but the cell
source was exclusively pre-existing β-cells (164).
A separate publication from the same group then knocked out Pdx1-expressing
pancreatic progenitor cells at multiple time points, using a similar diphtheria-toxin
expressing strain (165). Here, the Pdx1tTA mouse was crossed with a tetODTA mouse: addition
of tetracycline maintained the normal developmental program, while cessation of
tetracycline induced Pdx1+-cell ablation. When tetracycline was administered throughout
pregnancy or after e9.5, the progeny developed normally. However, if tetracycline was
withdrawn entirely, or after e11.5, the resultant pups had near complete pancreatic
agenesis. These results suggested that there are no stem cells in the embryonic or adult
pancreas, and that final pancreas size (and by default, regenerative ability), is restricted by
the number of progenitor cells present between e8.5-e12.5. Knocking out these progenitor
cells before e12.5 completely abrogated the formation of Pdx1 + pancreatic progenitor cells
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with the ability to rescue normal pancreas development. The authors stated, “...our studies
show that compensatory growth during pancreas development is either quite limited or
does not occur at all. Thus, embryonic progenitor cells represent a critical and limiting
determinant of pancreas size” (165).
Another study proposed that the restriction of β-cell proliferation in aged mice was a
result of the injury model used (such as STZ, high fat diet, or partial pancreatectomy), and
instead subjected their mice to β-cell damage by DTA using the transgenic approach as
described previously (166). Addition of Dx to very old (25 month old) insulin-rtTA;TET-DTA
mice caused a disruption in both normoglycemia and islet architecture; removal of the toxin
resulted in a 3-fold increase of replication from basal rates. Addition of a glucokinase
inhibitor, which enhanced glycolysis rates, had a similar effect (166). These results indicate
that under multiple circumstances, β-cells are generated postnatally from pre-existing βcells.

1.5.1.3

Generation of insulin-expressing cells in vitro

As has been shown, the majority of β-cells are formed by replication of pre-existing
β-cells in vivo, which normally exhibit a low rate of cellular proliferation after birth. Since
islets are in such high demand for use in transplant, then alternative sources of insulinexpressing cells are required, and expansion of (pre-existing) β-cells in vitro is an attractive
option. Efforts to alter β-cell proliferation rate directly have generally failed, but
differentiation techniques have been relatively more successful in vitro (167,168). Cellular
identity is broadly determined by the interplay of genetic (and epigenetic) and
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environmental factors which control gene expression in a cellular system (169). Therefore,
instructive changes to either/both the environment and/or the genes present may effect a
change in cell fate. Since all pancreatic cell types arise from a common progenitor cell type,
in vitro differentiation is a conceivable approach. Dedifferentiation can be defined as the
loss of mature, defining and functional characteristics from a partially or terminally
differentiated cell type (169), whereas transdifferentiation is broadly defined as a change
from one differentiated phenotype to another, involving morphological and functional
phenotypic markers (170). These operational terminologies are utilized to describe the
differentiation, dedifferentiation, or transdifferentiation of pancreatic cells towards or away
from the genetic, morphological, and functional properties of mature β-cell. Importantly,
cellular transdifferentiation can be induced by a multitude of factors, such as direct
reprogramming induced by transcription factor over-expression, or alternatively by
modified progression through dedifferentiation to a multipotent progenitor-like stage, and
subsequent redifferentiation. These cellular fate (re)specifications are depicted by Puri et al
in Figure 1.9

(169), and show that terminal cellular differentiation in the endocrine

pancreas is not as unidirectional as previously supposed.
One group published multiple reports over a number of years on the culture of
human fetal pancreas cells, and demonstrated that these cells could be induced to expand
and express insulin (171–177). They and others induced islet expansion and/or
differentiation by the use of in vitro techniques, such as extracellular matrix selection
(175,178,179), or specific combinations of growth factors such as hepatocyte growth factor
(HGF) (180), fibroblast growth factor-2 (FGF-2), keratinocyte growth factor (KGF/FGF-7) and
insulin-like growth factor – II (IGF-II) (177,181), activin, betacellulin, exendin-4, and HGF
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Figure 1.9. Transition states as a result of environmental/genetic
manipulation or stress, and relationship to pancreatic disease.
Illustration of differentiation potential of cells, resulting from either
stress/disease, or by genetic and/or environmental manipulation. Note that
“transdifferentiation” can occur by direct means from “normal” (1), or by
prior “dedifferentiation” (2). Regeneration is hypothesized to occur by a
return to “ normal” from the “dedifferentiated” state.
Reproduced from Puri S, Folias AE, Hebrok M. Plasticity and
Dedifferentiation within the Pancreas: Development, Homeostasis, and
Disease. Cell Stem Cell. 2014:1–14.
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(182), basic FGF (bFGF) and leukemia inhibitory factor (LIF) (183), epidermal growth factor
(EGF) and cholera toxin (179,184), or insulin/ transferring/selenium (ITS) (185), and
generally, the use of serum-free media.
Many groups contended that the resultant cells, with extensive proliferation of
fibroblast-like cells, had arisen from β-cells, due to the re-expression of insulin (186,187).
However, the insulin generated from in vitro culture was much lower than would be found
in vivo. Epithelial-to-mesenchymal transition (EMT) and its subsequent reversal (MET) have
been proposed as a requirement for differentiation (188), but there is now substantial
evidence that it is not causally related (182,183).
The advent of lineage tracing technology allowed β-cell fate to be followed during in
vitro culture conditions, and demonstrated that the majority of mouse β-cells were, in fact,
eliminated from culture (167,168,182,183,185). A few studies were able to dedifferentiate
a small subset (<5%) of adult mouse β-cells (167,168) or adult human β-cells (189) to noninsulin-expressing states, showing some β-cell dedifferentiation potential.

Why some

protocols have resulted in successful β-cell differentiation and survival, while others did not,
has yet to be determined. Moreover, it also remains to be determined why some β-cells are
capable of differentiation whereas the majority of them are not. Interestingly, it emerged
that human β-cells potentially retain a higher plasticity potential than do mouse β-cells
(167,190), which was postulated as due to β-cell “chromatin memory” (167), although the
mechanisms behind this have not been elucidated.
Collectively, these data would suggest that replication of pre-existing β-cells
accounts for the de novo generation of the majority of postnatal β-cells. Indeed, replication
of existing β-cells may be the default mode of endocrine mass maintenance; however, the
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contribution from putative progenitors, or the situations in which they are required, has not
been thoroughly examined to exclude them entirely.

1.5.2

Differentiation of stem/progenitor cells to β-cells
An alternate mechanism for the generation of insulin-producing cells is through

directed stem/progenitor cell differentiation (Figure 1.5 (89)).

The use or role of

stem/progenitor cells in medicine and tissue repair, especially in the field of diabetes, has
been hotly debated and anticipated. Multiple examples of endocrine regeneration have
prompted investigation into the role of stem cells. A widely accepted definition of any stem
cell is based on functional properties, exhibiting an unlimited capacity for self-renewal and
retaining the ability to generate multiple cell types (or, multi-potentiality), which may or
may not be in response to injury. A progenitor cell, on the other hand, is a proliferative cell
with a limited capability for self-renewal and which is most often uni-potent (191,192). The
distinction between these two cell states is often fluid and vaguely indeterminate in the
literature, but may yield important and definitive outcomes for medicine. Similarly,
subdivisions in definition exist for the somatic, or tissue-specific, stem cells vs. embryonic
stem cells, namely that the latter demonstrates the capacity to generate progeny across all
primary germ layers. However, precedents exist to suggest that this is not always rigidly
adhered to, as has been demonstrated by haematopoietic and neural stem cells forming
tissues from germ layers other than mesoderm- and ectoderm-lineage, respectively (193–
196).
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Endogenous stem cell repair mechanisms have been demonstrated following
hyperglycemia and during endocrine regeneration. Transplants of mesenchymal stem cells
(MSCs) after injury aided in the endogenous regeneration of tissue, instead of direct
differentiation from stem cells to β-cells (197).

In some cases composite cells from

MSCs/endothelial cells were detected (198), which assisted in revascularization of islets or
counteracted innate immunity response after transplant (199). This action was replicated
by endogenous hematopoietic stem cells homing to injury site and enhancing β-cell mass
regeneration through endothelial interaction (161,200). That the stem cells did not directly
differentiate into new tissue either in vivo or after injecting ex vivo was perhaps surprising,
implying instead that regeneration occurred through differentiation of tissue-specific
stem/progenitor cells, and/or replication of surviving cells, rather than activation of
haematopoietic stem cell differentiation.
Bone-marrow-derived progenitor cells purified based on aldehyde deydrogenase
(ALDH) activity, a conserved characteristic of multipotent progenitor lineages, were shown
to correct hyperglycemia in mouse models of diabetes. When uncultured ALDH hi cells were
transplanted to STZ-treated recipients, islet-specific proliferation and pro-angiogenic
programs were induced. If the ALDHhi cells were instead cultured prior to transplant, an
increase in small islet clusters was noted, and which were associated with the ductal
epithelium (201). This indicated that the subtype(s) of stem/progenitor cells presented to
injured pancreas modulated distinct endogenous repair mechanisms. Moreover, if these
ALDHhi cells were transplanted directly into the pancreas instead of injected intravenously,
there was a significantly higher β-cell regeneration capacity. Furthermore, these cells could
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be obtained from umbilical cord blood rather than bone marrow, representing an easily
obtainable stem cell source (202).
Alternatively, a few groups have created insulin-producing cells directly from
differentiation of human embryonic stem (hES) cells (203–205), although these cells had
overall limited function. In the past decade, insulin-producing cells have been successfully
generated from hES cells in a system that could be reproducibly, and potentially safely
applied for future clinical use (206–209). The approach was to use a 5-stage, stepwise
protocol which recapitulates endocrine pancreas development, in conjunction with the use
of large scale cell production and cell differentiation cassettes for transplants that reduce
opportunities for autoimmune destruction (210). The differentiation of hES cells to extraembryonic and definitive endoderm was shown to be regulated by SOX7 and SOX17,
respectively, and importantly, a stable population of endoderm progenitor cells could be
generated by the constitutive expression of these transcription factors in hES cells (211).
The Melton group has also successfully generated insulin-producing β-cells from hESCs,
which were shown to be closer in phenotype to human fetal β-cells than adult β-cells, with
poor glucose responsiveness and an immature β-cell transcriptome (212). Importantly,
these results provide a novel toolbox of transcription factors where research efforts can be
concentrated for future study. However, despite these advances, these “beta-like” cells
often require in vivo transplantation to be fully glucose-responsive (213),

and the

associated risks of uncontrolled cell growth and teratoma formation are not to be
underestimated, and therefore currently infeasible for human clinical application.
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1.5.3 Differentiation of β-progenitor cells found within the ductal epithelium
Besides extraneous sources of stem cells, the search for intra-pancreatic progenitor
cells is an attractive option. Significant data has historically suggested that the ductal
compartment contains the predominant source of pancreas-derived β-cell progenitors
(73,91,134,138,214–218).
Developmentally, pancreatic endocrine cells are derived from cells within the ductal
epithelium which share a common pathway via a bipotent progenitor with duct cells (55). As
noted earlier, pancreatic duct ligation (PDL) has been shown to be an important mode of
endocrine pancreas regeneration. Wang et al performed PDL and found a replacement of
acinar cells for ductal complexes and significant growth of islet tissue (134). There was a
doubling of the β-cell population, an increase in small islets and islet clusters, and an
increase in cell proliferation in the ligated portion of the organ, indicating islet neogenesis
from cells resident within the duct.
An in vitro model of expanded human ductal tissue was used by Bonner-Weir et al
to effect differentiation to islet structures with the use of FGF-7, nicotinamide, and ITS (73).
The authors found that after cellular expansion and transfer to Matrigel (a basement
membrane compound containing primarily laminin, entactin, and collagen), small cyst-like
structures were formed which expressed insulin as detected by immunohistochemistry, and
exhibited a 2.3-fold increase in insulin secretion after glucose exposure as compared to
basal levels (73). Similar results were recently demonstrated by Kim and colleagues (219)
and by Corritore et al (220) The appeal of this approach is that the ductal compartment
accounts for ~10% pancreas mass (140), and is entirely discarded after human islet
isolation. If ducts indeed contain endocrine progenitors or can differentiate directly into β34

cells themselves, the shortage of available cells for diabetes treatment would be effectively
solved.
Indeed, while extensive data has proposed the contribution of cells from the ductal
compartment to β-cell mass, the only way to definitively test that new β-cells conclusively
arise from ductal epithelium is to perform lineage tracing experiments. However, the major
hurdle for determining pancreatic cellular origins is that early ductal cells lack a definitive
progenitor marker; while Pdx1 or Ngn3 can be used to assess newly-formed β-cells, and a
series of transcription factors, such as NeuroD/Beta2, Nkx6.1, Nkx2.2, Pax4, Pax6, MafA,
and MafB, or mature islet markers such as insulin, Glut2, or Gck can be examined, duct cells
express the same markers early in development as well as late. Therefore, while transgenic
technology has revolutionized the field of developmental biology to assess cellular origins,
the use of mature duct-cell markers is a shortcoming in the absence of a more progenitorspecific marker.
In one study, the mature duct cell marker carbonic anhydrase II (CAII) was used to
assess cell state during pancreas organogenesis from e14.5 to adulthood in the mouse and
human (136). It was found that all duct cells in the adult pancreas of both species expressed
CAII, as well as some α-cells in the mouse (72). CAII was notably absent in the β-cells. CAII
was expressed in embryonic duct cells as early as e18.5 (72). CAII was subsequently used to
lineage trace duct cells using the CAII-Cre or CAII-CreER transgenic mice crossed with
ROSA26 (R26R) mice, which adds a LacZ reporter (expressing β-galactosidase (β-gal)) to any
cell expressing CAII after induction with tamoxifen (136). Using longitudinal assessment and
modelling of β-cell mass, the authors estimated that up to 30% of new β-cells in the 31 day
old mouse did not arise from replication of pre-existing β-cells (85). When pancreata of
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CAII-Cre;R26R mice were examined at P0 and at P28, LacZ expression was found in ducts, in
patches of acinar cells, and in some islets (marking both α- and β-cells), which increased
with age, indicating that formation of new islets and acini from ductal progenitors occurred
in the neonatal time period (136). The authors then used the inducible (CAII-CreER) strain
combined with a duct ligation regeneration model to assess the role of CAII during pancreas
remodelling, and found a significant increase in LacZ expression in the ligated portion of the
pancreas (136), indicating a role for duct cells during endocrine regeneration.
Xu et al (135) sought to address the contribution of pancreatic progenitor cells’
contribution to β-cell mass after injury, and used a recombinant lentivirus encoding two
Ngn3-specific short hairpin (sh) interfering RNA molecules to tag Ngn3-expressing (Ngn3+)
cells with an eGFP reporter protein immediately prior to PDL. The shRNA knocked down the
majority of regeneration in the PDL pancreas, indicating that Ngn3 is required for β-cell
regeneration. The authors then used the Ngn3-nLacZ mouse, which adds a β-gal reporter to
any cell expressing Ngn3 at the time of tagging. It was found that 15% of all β-gal+ cells were
present in the ductal lining 7 days after PDL, and co-expressed cytokeratin (CK). They also
found that one third of all β-gal+ cells expressed hormones, including insulin. The authors
further showed that this was due to Ngn3+ progenitor cell differentiation to hormone+ cells,
and not mature (hormone+) cell dedifferentiation, by using InsCre;R26R mice to trace
mature insulin+ cells during injury. They found after PDL, all LacZ+ cells were Ngn3-,
indicating that this was indeed progenitor cell differentiation.
Criscimanna and colleagues similarly found that duct cells were capable of both
endocrine and acinar cell regeneration using either PdxCre;R26 DTR or ElacreERT2;R26DTR
transgenic lines; interestingly, they also found that the mode of regeneration, either
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recapitulation of the developmental program, or direct differentiation of duct to acinar
cells, was directly associated with the severity of damage (221).
These studies are countered by articles which examined the role of insulin + cells
present in the ducts during aging and after injury. One study lineage traced the early ductal
transcription factor Hnf1β using an Hnf1β-CreER;R26R mouse model (59), and found, similar
to other reports, that Hnf1β+ cells are precursors for all pancreatic- epithelial cell types
(acinar, duct, and endocrine) during early gestation, which exclude acinar cell fates by midgestation (59). However, it was reported that the Hnf1β+ cells do not contribute to
endocrine cell fate after birth, at 6 months of age follow-up, or following two separate
models of endocrine injury using PDL and alloxan treatment. The authors tried to reconcile
their findings with the significant data that propose that duct cells are the progenitors for
islets, and suggested instead that ducts share a “tissue milieu” that favors the formation of
new endocrine cells. They further proposed that while some endocrine cells may reside in
the ductal epithelium and expand after regenerative stimulus (such as injury), these cells
were not ultimately derived from duct cells postnatally (59).
Another paper sought to determine the origins of insulin + cells found in the ductal
epithelium after injury, and found that insulin+ cells indeed arise from ductal epithelial cells
during development, but not after birth (222). Using a model of ductal hyperplasia induced
by transforming growth factor-α (TGFα), they lineage traced pancreatic cells and showed
that the ducts had arisen in some limited cases from acinar cell trans-differentiation, but
not from insulin+ cells. The authors further reported that the majority of insulin+ cells
present within the ductal epithelium had arisen from pre-existing β-cells and not duct or
acinar cells (222). However, the authors conceded that up to 5% of these insulin+ cells
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contained the lineage marker from acinar cells, but concluded that this was due to
either/both transgene “leakiness” (and not proof of acinar – or duct - to-endocrine
transdifferentiation) or an insignificant contribution from those compartments. This has
been independently shown using a mucin1 (Muc1)-lineage tracing mouse model (223).
Overall, many of these reports provide evidence in support of current dogma, that
β-cells primarily arise from pre-existing β-cells in the in vivo adult pancreas (111), during
aging and after injury and consequent regeneration, indicating that the potential for
contribution from ductal cells and/or ductal progenitors in the postnatal time period is
limited. However, to dismiss the substantive data amassed previously would be imprudent,
and differential interpretations of phenomena may be required.

1.5.4 Differentiation of stem/progenitor cells within the endocrine pancreas
The search for stem/progenitor cells present within the endocrine pancreas itself
has yielded frustratingly little information, as proto-typical “stem” cells have not been
readily identified within the pancreas as can be found in other organs, such as the intestine
(192). However, recent paradigm shifts have changed the focus to looking within the
endocrine pancreas itself as the source of regeneration. Szabat et al traced human and
mouse β-cells with a dual reporter system, using a lentivirus which differentially labelled
Pdx1 and insulin. The authors reported that a subpopulation of adult β-cells from both
species exhibited negative/low expression of insulin while maintaining expression of Pdx1
(Pdx1+Inslowcells) in relatively high proportion (15-25%), which could differentiate into
Pdx1+Ins+ cells without cell division, implying differentiation (224). Furthermore, these
Pdx1+Ins- cells displayed a progenitor phenotype, lacking expression of Glut2, Gck, and
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MafA, whilst being proliferative. Interestingly, these Pdx1+Ins- cells could be sub-divided into
two groups: those that matured into insulin-expressing cells, and those that maintained a
progenitor phenotype (224).
A separate study examined the role of nutritional insult in early life with regard to βcell regeneration potential (159).The authors found that there was no effect on Pdx1+Inscell number when mice were protein-restricted during gestation, or treated with STZ
independently. However, the cells were present in higher proportion in pancreas exposed
to STZ and low protein simultaneously, suggesting that the ability of progenitor cells to
mature and differentiate to functioning β-cells was mitigated as a result of the in utero
insults (159).
Data from Liu and colleagues directly contradicted work by Dor et al (111), in that
lineage tracing of the β-cell, using the same RIPCreER;Z/AP+/+ transgenic mouse model,
resulted in an increase in HPAP+ (reporter) β-cell labelling with age, as well as the presence
of HPAP+ insulin- cells after aging and STZ-mediated injury (225). They found that HPAP+Inscells demonstrated an immature phenotype, with expression of Pdx1 and MafB, and the
lack of Nkx6.1 and Glut2. Furthermore, HPAP+ Ins- cells were proliferative after STZ as
demonstrated by expression of Ki67, and were 2-fold smaller than typical β-cells. The
relative proportion of HPAP+Ins- cells after injury was found to be 0.1% of all insulin + (β-)
cells. Liu and colleagues concluded that these cells represented β-cell progenitors which, by
default of expressing the β-cell reporter, must have exhibited active insulin expression at
the time of Cre induction. Only after injury or aging, and hence after differentiation to
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proto-typical mature β-cells, was insulin expressed, which accounted for the increase in
HPAP+ labelled Ins+ cells with increased age (225).
Seaberg et al found that rare cells within mouse islets and ductal preparations could
form clonal spheres with the capacity to generate neural and pancreatic exocrine and
endocrine lineages (226); these cells could then be further differentiated into functional βcells which demonstrated glucose-sensitive insulin release. The group determined that
these cells were not derived from embryonic stem cell origin, nor from neural crest, nor
from mesoderm-lineage, but instead from “multipotent precursor” (progenitor) cells found
within the pancreas (226).

A subsequent study from the same group replicated

experiments by Dor et al (111), and found that HPAP+ cells tagged non-β-cells after a long
chase period including endocrine and non-endocrine cells, indicating that cell fate may not
be as immutable as was previously stated (227). Moreover, after replicating the clonal
sphere assay (226), it was revealed that these multipotent cells had derived from insulinexpressing cells. However, the multipotent cells were found to represent a unique subset of
β-cells in that they demonstrated decreased levels of Nkx6.1 and Pdx1, increased levels of
Ngn3, and importantly, lacked Glut2. These cells were present within adult mouse and
human islets in a proportion of <1/5,000, and could be differentiated in vitro to multiple
endocrine lineages (including α, β, δ, and γ cells), exocrine cells, and neural lineage cells
including neurons, (neuro)glia, and oligodendrocytes (227). Moreover, after differentiation
to β-cells, these were fully capable of ameliorating hyperglycemia after transplant,
demonstrating their utility as functional endocrine cells (227).
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Based on these reports, there is emerging evidence that β-cell progenitors are
present within adult pancreas, although the relative contribution of these cells to normal
physiology has not been determined, nor is it known whether they represent a therapeutic
target for diabetes.

1.6

Rationale
Clearly, there are multiple routes to generating β-cells, notwithstanding of variable

function. As was eloquently stated by AMJ Shapiro, pioneer of the Edmonton protocol,
“…given the enormous clinical burden of diabetes, the search for alternative sources of
regulated insulin-producing cells must continue, since the current supply from deceased
donors cannot meet the demand” (18). Based on the evidence that (i) the generation of
new β-cells occurs almost entirely by replication of pre-existing β-cells postnatally; (ii) the
replication rate of mature β-cells is extremely low, and (iii) β-cells develop from a bipotent
progenitor cell state which shares a common pathway early in development with duct cells,
the differentiation of pre-existing β-cells to a ductal phenotype may allow the β-cell
population the ability to expand in vitro. These cells can then be re-differentiated “back” to
insulin-producing cells for use in human transplants given the appropriate environment.
Furthermore, since young mammals exhibit higher growth potential and more lineage
plasticity than do mature ones, experiments will be conducted using neonatal tissue.
Characterization of the cell type(s) capable of differentiation will be consequently
accomplished.
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1.7

Hypothesis
It is hypothesized that neonatal mouse β-cells demonstrate the ability to

dedifferentiate into alternative cell types, including cells sharing characteristics of ductal
epithelial cells, which can be subsequently redifferentiated into insulin-producing cells
based on in vitro environmental cues. Furthermore, the β-cells which retain the capacity for
differentiation will be involved during regeneration after pancreatic injury.

1.8

Objectives

To determine the regenerative potential and lineage plasticity of mouse β-cells
1. Demonstrate neonatal mouse islet cell plasticity in vitro
a. Dedifferentiate neonatal mouse islets for the reversion to a proliferative
ductal phenotype
b. Establish if the dedifferentiated cells are capable of redifferentiation to
insulin-producing β-cells
c. Optimize in vitro conditions for these processes, and whether the cells are
functional after transplant in vivo
2. Lineage trace the β-cell in vitro using the transgenic mouse model RIPCre;Z/AP to
establish whether cell dedifferentiation involves the β-cell
3. Characterize resultant subpopulations of lineage plastic β-cells
4. Assess the analogous population of β-cells within the human pancreas, and how it
changes with age
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5. Determine why young rodents are capable of endocrine regeneration after STZablation but not in adulthood, using the transgenic mouse model RIPCreER;Z/AP.

1.9
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Dedifferentiation and Redifferentiation Conditions

Christine A. Beamish, Brenda J. Strutt, Edith Arany, Gediminas Cepinskas, David A Hess,
Andrew Pepper, Delfina Siroen, and David J. Hill

63

2.1

Introduction
The de novo generation of insulin-producing cells in the pancreas has been a subject

of great research focus, ultimately for β-cell replacement therapy for patients with diabetes.
The current gold standard treatment is islet transplantation, but is limited by the availability
of cadaveric-sourced tissue. Multiple reports have demonstrated moderate success in the
directed differentiation of human embryonic or induced pluripotent stem cells to β-cells (1–
4). Alternatively, the dedifferentiation, expansion, and subsequent redifferentiation of preexisting β-cells as a source of insulin-producing cells has been suggested (5–7).
Dedifferentiation is the loss of mature, defining and functional characteristics from a
partially or terminally differentiated cell type (8). While transdifferentiation is defined as a
change from one differentiated phenotype to another, involving morphological and
functional phenotypic markers (9), it can be preceded by cellular dedifferentiation (8). One
such protocol involving the use of epidermal growth factor (EGF) and cholera toxin has
indicated that human islets may be dedifferentiated to a proliferative monolayer of cells
positive for markers of ductal epithelium (10–13). Resultant cells were shown to increase
proliferation by 1500%, and demonstrated a precursor-like phenotype. Using a subsequent
“redifferentiation” protocol which includes the ductal mitogen keratinocyte growth factor
(KGF/FGF-7) and insulin-like growth factor- 2 (IGF-II), “islet-like clusters” could be generated
that demonstrated insulin secretion (14–16).
Experiments carried out by Lammert and colleagues showed that explanted e8.5
mouse endoderm grown in vitro formed a structure similar to a gut tube, but did not show
any pancreatic differentiation, lacking both Pdx1 and insulin expression (17). When this
same explanted endoderm was co-cultured with dorsal aortae, both insulin and Pdx1 were
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expressed, and pancreatic buds were visible in ~30% of the structures. Moreover, insulin
was shown adjacent to the endothelium. Follow-up reports by the same authors illustrated
that endothelial cells induce crucial steps in the development of both liver and pancreas
(18,19). It has been shown that microvascular loss is a contributing factor in the initial
apoptosis and dedifferentiation of islets during transplantation (20), and islets cultured with
endothelial cells prior to transplantation demonstrate enhanced survival (21) which can be
attributed to decreased immune rejection and increased revascularization in the recipient
(22). Furthermore, after pancreatic injury, mesenchymal stem cells have been shown to
home to the site of injury and initiate repair, postulated to promote an increase in
angiogenesis (23,24). Therefore, the role of endothelial cells in the revascularization of islets
after isolation may have a major influence on their capacity for differentiation in vitro and in
vivo. Indeed, multiple studies have demonstrated that the formation of new β-cells or other
endocrine cells from embryonic stem cells (25) or human fetal pancreas (26) requires
transplantation in vivo for full maturation and glucose responsiveness.
Using conditions as described by Yuan and colleagues (10) for islet dedifferentiation,
and a combination of factors for redifferentiation including IGF-II, KGF, and Matrigel, we
first sought to explore the capacity of neonatal mouse islets to dedifferentiate to a
proliferative phenotype, and subsequently redifferentiate back towards functional
endocrine cells in vitro. We hypothesized that changes in environment would provide the
inductive signals for insulin re-expression. The redifferentiation potential was also examined
after co-culture with mouse endothelial cells, and after transplantation into immunedeficient mice to assess whether the in vivo environment was more effective than that
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provided in vitro in re-directing the resultant islet-derived cell-aggregates into functional
insulin-producing cells capable of ameliorating hyperglycemia.

2.2

Materials and methods

2.2.1

Islet and duct isolation
Animal experimentation was approved by the Western University Animal Use Ethics

Committee and in accordance with the Canadian Council on Animal Care. Reagents were
obtained from Invitrogen (Carlsbad, CA) unless otherwise specified. Islets were isolated
using a modified protocol as described (27). Briefly, postnatal day 7 (P7) C57Bl/6 mice
(Charles River Laboratories, Wilmington MA) were euthanized by decapitation and their
pancreata excised, starting at the tail of the spleen, and placed in a Petri dish. One millilitre
(1 mL) of digestion buffer, consisting of 1 mg/mL collagenase type V (Sigma Chemical, St.
Louis, MO) in Hank’s Buffered Salt Solution (HBSS), was perfused through each pancreas
using a 23 G needle until it expanded, and collected in an additional 1 mL digestion buffer
per pancreas. Pancreata were placed in a shaking water bath at 37°C for 20-30 min and
additionally shaken by hand gently for 1 min. Digested tissue was passed through a 14 G
needle and washed in HBSS + 5% (v/v) fetal bovine serum (FBS). Intact islets were separated
from acinar and duct cells using sequential Dextran (MP Biomedical, Solon, OH) gradients at
27, 23 and 11% (v/v), and centrifuged for 25 min at 610 x G. Islets were collected from the
27-23% interface using a 14 G syringe and washed in HBSS + 5% FBS, then placed in a Petri
dish with HBSS + 5% FBS and handpicked using an inverted microscope.
Intact ducts were isolated similarly to islets, but the digestion time was decreased
to prevent the loss of intact structures, and hand-shaking was omitted. The pancreatic cell
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mixture was passed through 2 mesh basins containing filters, one 30 μm and the other 70
μm; large ducts being collected between these two, while intact islets collected at the
bottom. The ducts were then handpicked.

2.2.2

Islet dedifferentiation
Isolated islets were cultured in media as described (10), similar in composition to

that used for the culture of generalized epithelial cells, including mammary (28), prostate
(29), and cornea (30). Such media commonly contain EGF, a corticosteroid, serum, insulin,
and cholera toxin, which acts as a cAMP-elevating agent (28). Specifically, the formulation
used for pancreatic ductal epithelial culture was composed of DMEM/F-12 (Gibco, Grand
Island, New York), 10% FBS, 100 mM Penicillin/Streptomycin (Gibco), 10 mM Fungizone
(Gibco), 1 μg/mL insulin (Sigma), 100 ng/mL cholera toxin (Cedarlane Labs, Burlington ON),
1 μM dexamethasone (Sigma), 0.1 mg/mL soybean trypsin inhibitor (Gibco), and 10 ng/mL
EGF (ID Labs, London, ON). Islets were cultured on type I (rat-tail) collagen as a basement
membrane (10).

2.2.3

Redifferentiation of islet-derived cells
After 1-4 weeks in ductal dedifferentiation culture, collagen was digested using

Collagenase XI (Sigma), and the cell monolayer dispersed into a single cell suspension using
Dispase and Accutase (BD Biosciences, Mississauga ON) as per manufacturer’s instructions.
Cells were cultured for endocrine redifferentiation on 0.5 mL Matrigel (BD Biosciences)
diluted 1:1 with DMEM/F12, and supplemented with media composed of DMEM/F12, 10%
FBS, 100 mM Penicillin/Streptomycin, 10 mM Fungizone (Gibco), 100 ng/mL IGF-II (ID Labs)
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and 50 ng/mL KGF (FGF-7) (ID Labs). Alternatively, dispersed and dedifferentiated cells were
cultured in media previously shown to promote endocrine maturation as described by Russ
et al (31), and similar to Seaberg et al (32) consisting of 25 mmol/L D-glucose, 1% bovine
serum albumin (BSA), ITS (Sigma), N2 and B27 supplements (Gibco), 10 mmol/L
nicotinamide (Sigma), 8 nm exendin-4 (Bachem Chemical, Bubendorf Switzerland), and 8
nm activin-A (Cedarlane Labs, Burlington, ON), in 6-well plates coated with Matrigel (1:25
dilution).

2.2.4

RNA isolation and qualitative Reverse Transcription-Polymerase Chain Reaction
For analysis of cells at various stages of development or differentiation, RNA was

assessed. Isolated cells were stored in RNAprotect (Qiagen, Venlo, Netherlands), and total
RNA extracted using RNeasy Plus Mini/Micro kits where appropriate (Qiagen). One
nanogram (1 ng) total RNA was reverse transcribed to cDNA using Superscript II, Oligo(dT) 1218

and 10 mM dNTPs. Four microlitres of RT (cDNA) was amplified for specific genes of

interest using 20 μM forward and reverse primers (Sigma) as described in Table 2.1, with 1
U (0.2 μL) Taq DNA Polymerase (UBI Life Sciences Inc, Saskatoon, SK). Annealing
temperatures were determined using Fast-PCR software (PrimerDigital Ltd, Helsinki
Finland). RT-PCR was performed for islet markers insulin (Ins), glucokinase (Gck), and
glucose transporter 2 (Glut2); transcription factors Pancreatic Duodenal Homeobox-1
(Pdx1), Neurogenin3 (Ngn3), Neurogenic Differentiation1 (NeuroD), Paired box gene4
(Pax4), Pax6, Homeobox protein Nkx_2.2 (Nkx2.2), Nkx6.1, v-Maf musculoaponeurotic
fibrosarcoma onco- gene homologue A (MafA) and MafB; the mesenchymal marker
vimentin (Vim); ductal (precursor) transcription factors SRY (sex-determining region Y) box 9
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Table 2.1. Primer sequences designed for the amplification of mouse cDNA
Gene
Insulin
Pdx1
Gck
Glut2
NeuroD
Ngn3
Pax4
Pax6
Nkx2.2
Nkx6.1
MafA
MafB
CK19
Sox9
Hnf6
Hnf1β
CAII
β-tub
FSP-1
Vim

Sense primer (5’-3’)
ccctgctggccctgctctt
tgtaggcagtacgggtcctc
gcagatcctggcagagttcca
caagatcaccggaaccttgg
cttggccaagaactacatctgg
ggcgcctcatcccttggatg
gtgagcaagatcctaggacgc
aaacaaacgccctagctctcc
ctcttctccaaagcgcagac
ttctctggacagcaaatcttcg
tcactctgcccaccatcac
ggtataaacgcgtccagcag
gtgccaccattgacaactcc
ttcatgaagatgaccgacga
cgcggtgactcagctacaga
atctgtgaccaccattgcag
agattggacctgcctcaccaa
tcactgtgcctgaacttacc
atggcaagacccttggagga
aatgcttctctggcacgtct

Antisense Primer (5’-3’)
aggtctgaaggtcacctgct
ccaccccagtttacaagctc
ggaaggagaaggtgaagccca
attccgcccactgcaaagct
ggagtagggatgcaccgggaa
cagtcacccacttctgcttcg
cggggagaagatagtccgatt
ccgcccttggttaaagtcctc
aacaaccgtggtaaggatcg
ctgagtgattttctcgtcgtca
tgacctcctccttgctgaag
cgagtttctcgcacttgacc
aatccacctccacactgacc
gtccagtcgtagcccttcag
atctgtgaccaccattgcag
tgcggtgactcagctacaga
ttacttaaaggacgctttga
ggaacatagccgtaaactgc
cattgcacatcatggcaatg
tcttccatctcacgcatctg

Band Size
214
326
408
313
230
161
379
118
515
298
198
138
289
242
103
178
220
319
263
414

Pdx1: pancreatic duodenal homeodomain box 1; Glut2: glucose transporter 2; Gck,
glucokinase; Ngn3: neurogenin3; β-tub: β-tubulin; Ck19: cytokeratin 19; Sox9 : SRY
(sex determining region-Y) box-9; Hnf6: hepatocyte nuclear factor 6; Hnfβ:
Hepatocyte nuclear factor-β; MafA : V-maf musculoaponeurotic fibrosarcoma
oncogene homolog A, Nkx2.2: homeobox protein Nkx_2.2; Pax 4: paired box gene
4; NeuroD: neurogenic differentiation 1; CAII: Carbonic Anhydrase II; Vim:
vimentin; FSP-1: fibroblast-specific protein 1
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(Sox9), Hepatocyte nuclear factor 6 (Hnf6), Hnf1β, mature duct markers, carbonic anhydrase
II (CAII), and cytokeratin 19 (CK19), and β-tubulin used as control. PCR conditions were
established to ensure linear amplification of PCR products using varying cycle numbers (2640 cycles). Amplified cDNA was run on a 2% agarose gel and visualized under UV-light,
counterstained with ethidium bromide.

2.2.5

Immunofluorescent cytochemistry
For imaging of cells grown in vitro, collagen was digested using collagenase XI

(Sigma) and Accutase (BD Biosciences, Mississauga ON), and Matrigel digested using
Dispase (BD Biosciences), and washed in PBS to remove serum. Dispersed cells in PBS were
then added to glass-bottomed Mattek dishes (Mattek Corp, Ashland, USA) adsorbed with
diluted Cell-Tak (BD Biosciences) for 15 min. Adherent cells were fixed with 4% (v/v)
paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA) for 15 min. Whole
mount tissues such as intact islets or cell clusters were alternately handpicked and placed
on Cell-tak-coated Mattek dishes for 30 min and fixed for 30 min in 4% PFA. Fixed cells
adherent on Mattek dishes were stored in PBS at 4°C until immunocytochemistry was
performed. Isolated cells were permeabilized with 0.3% (v/v) triton-X-100/PBS for 30 min
before blocking with Background Sniper (Biocare Medical, Concord CA) for 8 min. Primary
antibodies were incubated in Antibody Diluting Solution overnight at 4°C and secondary
antibodies for 2 h at room temperature. A list of antibodies and dilutions is provided in
Table 2.2. Cell proliferation was determined by the addition of 0.05% (v/v) EdU (5-ethynyl2´-deoxyuridine)/PBS to the media for 6 h prior to fixation. Cells were stained with EdU
Click-It Reaction kit. Nuclei were visualized by counterstaining with 4’, 6-diamidino-270

Table 2.2. Antibodies used for immunofluorescent histochemistry
Protein
Insulin
Insulin
Pdx1
CK19
CK19
E-cadherin
Ki67
Ki67
Ngn3
Vimentin

Animal
mouse
rabbit
rabbit
rabbit
mouse
mouse
rabbit
mouse
mouse
rabbit

Company
Sigma Chemical (St Louis, MO)
Santa Cruz (Santa Cruz, CA)
Abcam Inc (Toronto ON)
Abcam
Dako (Glostrup, Denmark)
Abcam
Neomarkers (Freemont CA)
BD Biosciences (Mississauga ON)
DSHB *
Santa Cruz

Dilution
1:2000
1:200
1:1000
1:100
1:100
1:100
1:200
1:50
1:40
1:100

*DSHB, Developmental Studies Hybridoma Bank, University of Iowa,
Department of Biology, Iowa City, Iowa

71

phenlindole (DAPI, blue), Sytox Green, or ToPro Red. Cells/sections were imaged on a Zeiss
Laser Scanning Confocal Microscope (LSCM) (Zeiss, Oberkochen, Germany), and counted
manually using the Zeiss LSM Image Browser. The EdU staining kit utilized a far-red
fluorophore (647 nm). A beam splitter was placed on the LSCM at 560 nm, allowing a red
fluorophore (543 nm/ 555 nm) to be used simultaneously with a far-red fluorophore (647
nm).

2.2.6

Transplantation experiments
NOD/scid IL-2rγ-/- mice were utilized as transplant recipients, as these animals are

deficient in T cells, B cells, all lymphocytes, and natural killer (NK) cells, and have been used
previously in islet transplant experiments (33). Transplant recipient mice (n = 6) were
maintained in barrier cages with free access to (sterilized) food and water at St. Joseph
Animal Care Facility. Five hundred freshly isolated mouse islets and 1000 clusters from
female C57Bl6 mice were transplanted to individual sites under the left kidney capsule of
eight-week old NOD/scid IL-2rγ-/- male mice. Sex-mismatched transplants were chosen to
distinguish donor from host cells if necessary using a gender-specific biomarker (Star*FISH,
Cambio Ltd, Cambridge UK). Mice were anaesthetized using isofluorane, and post-surgical
ketoprofen was administered as anaesthetic. Mice were monitored daily after surgery.
Intraperitoneal glucose tolerance tests (IPGTT) were performed 1 month posttransplant to assess functionality. Animals were fasted 4 h prior to injection with 2 g/kg Dglucose. Blood glucose measurements were taken at 0, 5, 15, 30, 60, and 90 min, and 50 μL
blood samples were taken at 0, 15, and 90 min. Serum insulin values were assessed using
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Ultrasensitive Insulin radioimmunoassay (RIA) (range 0.02-1 ng/mL) (St. Joseph Health Care,
London ON).
Mice were euthanized following IPGTT by CO2. Kidneys and pancreas were dissected
and fixed in 4% PFA for 24 h, then washed in PBS for 24 h prior to incubation in 30% (v/v)
sucrose overnight, embedded in OCT, and cryosectioned for immunofluorescence analysis.
Sections were immunostained for insulin, glucagon, Pdx1, and Ngn3 to determine the
degree of maturation of transplanted cells, and proliferation frequency assessed using Ki67
antigen.

2.2.7

Media / Basement membrane recombination
To assess the contribution of basement membrane proteins vs. media compositions

to differentiation state, islets were cultured in various combinations: (1) dedifferentiation
media + type 1 collagen; (2) redifferentiation media + type 1 collagen; (3) dedifferentiation
media + Matrigel; and (4) redifferentiation media + Matrigel. After 4 weeks in these
conditions, cells were dispersed into single cell suspension and subsequently cultured for
“redifferentiation” on Matrigel with redifferentiation media containing IGF-II and KGF as
described.

2.2.8

Mouse pancreatic endothelial cell co-culture
Mouse pancreatic endothelial cells (ECs) were isolated from C57Bl/6 mice at P10.

Briefly, pancreata were isolated and placed in 0.25 mg/mL type XI collagenase at 37ºC for
15 min. Cells were washed in HBSS + 5% FBS twice, then added to 3 mL DMEM/F-12+ 10%
FBS. Cells were then aspirated through a 3 mL syringe, followed by sequential aspiration
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through 18 G, 20 G, and 22 G needles. The slurry was filtered through a sterile 100 μm nylon
mesh into single cell suspension. EC cell selection was accomplished using PECAM-1
antibody (1:50, CD31) (Hycult, Plymouth Meeting, PA) coated magnetic beads (Dynabeads)
and a rotary magnet according to manufacturer’s instructions. The isolated ECs were
cultured on 0.1% (v/v) Fibronectin (Sigma) cultured with EBM-2 media, with all supplements
(Clonetics, Lonza Group Inc, Basel Switzerland). ECs were passaged a maximum of 3 times,
splitting the cells 1:5, and media changed twice per week.
Eight thousand ECs were mixed with 500 μl DMEM/F-12, then diluted 1:1 with
Matrigel and plated in a 6-well tissue culture dish. ECs formed branching structures within
the Matrigel after 7 days and were supplied with EBM-2 media. Alternately, ECs were laid
on top of the Matrigel, rather than embedding within it. Differentiated islet-derived cells
were then cultured on top of this.

2.2.9

Statistical analysis
Data are presented as percent (%) mean ± SEM, with statistics performed using a

one-way ANOVA and Tukey’s post-test, or student’s t-tests as indicated, and with an
acceptable level of significance of p < 0.05. Statistics were analyzed using GraphPad Prism 5
software (La Jolla, CA).

2.3

Results

2.3.1

Changes in islet cell morphology
Islets plated in dedifferentiation conditions (Figure 2.1A) lost all morphological

characteristics of functional endocrine cells (Figure 2.1B), forming a heterogeneous,
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Figure 2.1. Neonatal mouse islets cultured in dedifferentiation and
redifferentiation conditions. Neonatal (P7) mouse islets plated on collagen
under dedifferentiation culture conditions, shortly after plating (A), after 4 days
once monolayer formation had commenced (B), and after 4 weeks (C). Cells
cultured in dedifferentiation media and harvested after 4 weeks were re-plated
onto Matrigel under redifferentiation culture conditions. The cells formed
cellular aggregates which suspended in the media, sometimes exhibiting long,
duct-like morphologies (D) or alternatively, small spherical aggregates (E). Size
bar denotes 50 μm, n > 10 experiments.
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proliferative epithelial-like monolayer within 4 weeks (Figure 2.1C), consistent with data
shown by others (10,34). This monolayer could be passaged multiple times without further
change in morphology (not shown). Similar morphologies were found after culture of
isolated mouse pancreatic ducts.
When subsequently plated in “redifferentiation” conditions containing IGF-II and
KGF, the dispersed islet-derived and duct-derived cell monolayers re-organized within the
Matrigel, forming floating cell aggregates. These cell clusters adopted variable
morphologies, often forming long, branched tube-like structures which resembled ducts
(Figure 2.1D), or alternatively forming small spherical clusters (Figure 2.1E). These cell
clusters could be continuously formed for months after plating.

2.3.2

Changes in islet cell gene expression
Intact islets demonstrated markers of mature islet function, including Ins, Pdx1, and

MafA as shown on a composite gel (Figure 2.2A). When cultured in dedifferentiation
medium these mature markers diminished, instead showing an up-regulation of markers for
ductal epithelium such as CK19 and CAII (Figure 2.2B), as well as ductal transcription factors
Sox9, Hnf6, and Hnf1β (Figure 2.2B). MafB expression was maintained while MafA was lost.
After culture in redifferentiation conditions on Matrigel in media containing IGF-II
and KGF, the cell aggregates maintained ductal epithelial gene markers (Sox9, Hnf6, Hnf1β,
CK19, CAII), but exhibited limited re-expression of some endocrine pancreas markers, such
as Pdx1 and Nkx6.1 (Figure 2.2C). MafB expression was maintained after cell-cluster
formation (Figure 2.2C), but Vim expression was lost (not shown). Ins, MafA, and Ngn3 were
not re-expressed.
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InsI Pdx1 Gck Glut2 NeuroD Ngn3 Pax4 Pax6 Nk2.2 Nk6.1 MafA MafB CK19 Sox9 Hnf6 Hnf1b CAII β-tub

A

B

C
Figure 2.2. Gene expression profile of cells obtained after culture of mouse
islets. Expression of cDNA on a composite gel from isolated islets (row A), after
four weeks on collagen with dedifferentiation media (row B), and from cellular
clusters after subsequent culture in redifferentiation media (row C). Isletspecific markers are surrounded by blue and duct-specific markers in red bar; n
> 10.
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2.3.3

Changes in islet cell protein presence
Assessment of protein presence using whole islet confocal microscopy revealed that

isolated islets displayed immunostaining for insulin (Figure 2.3A, green), and Pdx1 (Figure
2.3B, red), but not CK19 (Figure 2.3C, red). The dispersed dedifferentiated monolayer
showed a loss of insulin immunostaining (Figure 2.3D, green), and an increase in
immunostaining for CK19 (Figure 2.3D, red), as well as positive staining for e-cadherin
(Figure 2.3E, green). After redifferentiation culture, intact cell clusters showed that both
small spherical and elongated cluster morphologies were cyst-like, demonstrating a hollow
core (Figure 2.3F, blue, DAPI). These cyst-like cell clusters maintained positive
immunostaining for CK19 (Figure 2.3G, green), and e-cadherin (Figure 2.3H, green). Rarely,
the small, spherical clusters demonstrated limited immunostaining for Pdx1 (Figure 2.3J,
red), which was never seen in the elongated, branching cell clusters (Figure 2.3I). There was
extremely low cell replication rates as calculated by EdU incorportion within the clusters
(<0.1%, not shown). Efforts to promote redifferentiation by addition of other growth factors
to redifferentiation media such as EGF, nicotinamide, betacellulin, and gastrin were
unsuccessful, in that expression of key markers of redifferentiation were unchanged (not
shown). However, when dedifferentiated islet-derived epithelial cells were cultured in
established redifferentiation conditions shown to promote endocrine maturation (31,32),
rare cells (<1:1000) demonstrated insulin expression by immunostaining (Figure 2.3K, red).

2.3.4

Transplantation of islet-derived cells
Donor islets and islet-derived cell clusters within grafts survived after

transplantation beneath the kidney capsule of normoglycemic NOD/scid IL-2rγ-/- mice
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Figure 2.3. Immunofluorescent images of cells obtained after
dedifferentiation and redifferentiation culture of mouse islets. Isolated islets
were immunostained for insulin (A, green), Pdx1 (red, B) and CK19 (C, green).
After dedifferentiation culture to ductal epithelium, there was a significant
increase in the proportion of cells positive for ductal markers including CK19 (D,
red) and e-cadherin (E, green). Redifferentiation procedures in the presence of
IGF-II and KGF yielded cyst-like structures which resembled ducts (F), and which
maintained expression of CK19 (G, green) and e-cadherin (H, green) and which
was negative for Pdx1 (I, red). Alternative redifferentiation culture in media
yielded restricted re-expression of Pdx1 and insulin in the small spherical
clusters only (J, and K, red). Size bars represent 50 μm, n > 10 experiments.

79

(Figures 2.4A-G). Transplantation of isolated islets demonstrated no loss of expression of
insulin (Figure 2.4A, green) or Pdx1 (Figure 2.4B, red). Transplantation of IGF-II + KGF media
redifferentiated cell clusters revealed cells containing immunoreactive Pdx1 after 4 weeks in
vivo (Figure 2.4D, red), as well as cell proliferation shown by staining for Ki67 antigen
expression (Figure 2.4F, red, not quantified). However, insulin, MafA, and Ngn3 were not reexpressed in any of these grafts. Ductal markers were maintained in the redifferentiated cell
grafts, with positive immunostaining for e-cadherin (Figure 2.4G, green, arrows). A glucose
tolerance test showing normal glycemia after transplant is provided in Figure 2.4H,
demonstrating that the metabolism of the host mice was not altered following surgery.

2.3.5

Co-culture of dedifferentiated cells with pancreatic endothelial cells
Mouse pancreatic ECs could be isolated and grown on fibronectin-coated culture

dishes (Supplemental Figure S2.1A), and which could be passaged (Figure S2.1B). These
cells grew substantially within the first 7 d of culture when isolated and mixed with Matrigel
supplemented with EBM-2 medium (Figure S2.1C). After 7 d, ECs had formed branching
structures (Figure S2.1D). When dedifferentiated islet cells were overlaid on top of Matrigel
containing EC isolated from mouse pancreas, the dedifferentiated cells grew well in the
presence of ECs, although this was not quantified (3 days, Figure 2.5A; +7 days, Figure 2.5B;
+3 weeks, Figure 2.5C). The dedifferentiated cell morphology was slightly more disorganized
when ECs were cultured on top of Matrigel with dedifferentiated cells overlaying these
(Figure 2.5D). In both culture conditions however, there was no re-expression of insulin,
ngn3, or other β-cell specific markers (not shown).
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Figure 2.4. Effect of transplantation on cell differentiation state
Islet grafts transplanted under NOD/scid IL-2rγ-/- mouse kidney capsules
showing insulin (green, A) and Pdx1 (red, B) immunostaining.
Redifferentiated cell cluster grafts (C-F) under the kidney capsule (blue, DAPI,
C, E) demonstrated the presence of Pdx1 (D, red) and ki67 (F, red) but
retained their ductal phenotype as shown by e-cadherin immunostaining (G,
green). A glucose tolerance test of transplant recipient mice is shown in H.
Size bar denotes 50 μm, n = 6 mice.
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Figure 2.5. Co-culture of islet-derived cells with mouse pancreatic
endothelial cells After plating dedifferentiated cells on top of pancreasderived mouse endothelial cells (ECs), there was significant growth (+3
days, A, +7 days B, + 3 weeks, C). Morphology was less uniform when ECs
were plated on top of Matrigel with dedifferentiated cells overlaying
these (D). Scale bars represent 50 μm, n = 4.
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2.3.6

Matrix/media combinations
To determine the effects of matrix and medium on islet dedifferentiation, isolated

islets were cultured in either type I collagen or Matrigel with dedifferentiation medium or
redifferentiation medium. Islets plated on collagen with dedifferentiation media
(combination 1) produced a proliferative, heterogeneous epithelial monolayer (Figure 2.1AC) and islet morphology was lost within the first week in culture, as described above. Islets
cultured on collagen with redifferentiation media (combination 2) retained the original islet
structure, with an increase in fibroblasts; this was also found when islets were cultured in
dedifferentiation media with Matrigel (combination 3), and when islets were grown in
redifferentiation media on Matrigel (combination 4) (Figure 2.6A). Islets cultured in
redifferentiation media with Matrigel became highly disorganized around the original islet
structure with areas of epithelial as well as fibroblast growth. After dispersing and culturing
all cells for redifferentiation in Matrigel, combination (1) cells formed ductal-like cell
clusters which resembled cysts, and which were positive for ductal epithelial markers, as
previously described. Cells grown in combinations (2) and (3) both reformed cellular
clumps, which were positive for fibroblast markers such as vimentin and fibroblast-specific
protein 1 (FSP1), and which maintained expression of insulin and glucagon (not shown).
Interestingly, islets grown in redifferentiation conditions from the outset maintained
expression of islet markers such as insulin and glucagon, increased expression of fibroblastic
markers, and also formed what appeared to be lipid droplets (Figure 2.6B) although further
validation is required. Islets cultured in dedifferentiation media without cholera toxin did
not form an epithelial monolayer and maintained the original islet structure. Overall, these

83

A

B

Figure 2.6. Variable cell types arise after culture of mouse islets in altered
matrix/media combinations.
Changing the combination of media
(dedifferentiation or redifferentiation) and matrix (type I collagen and
Matrigel) showed that only islets plated on collagen and supplemented
with dedifferentiation media caused the islet structure to disappear and a
dramatic increase in ductal epithelial markers; all other combinations
maintained the original islet structure (A). Cells with adipocyte-like
morphology were noted as shown by the appearance of lipid-like droplets
when isolated mouse islets were grown in Matrigel with redifferentiation
media, then dispersed and re-plated under the same conditions (B). Scale
bars represent 50 μm, n = 4.
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data suggest that the media and matrix combination of type 1 collagen with EGF and
cholera toxin promotes the most robust change in islet-derived cellular morphology.

2.4

Discussion
Following islet dedifferentiation to ductal epithelial cells on collagen in the presence

of EGF and cholera toxin, a highly proliferative epithelial monolayer of cells was generated.
Subsequent culturing of these cells on Matrigel using IGF-II and KGF yielded cell aggregates
that maintained ductal genetic markers formed during dedifferentiation, with ductal/cystlike morphology. Dedifferentiated cells were also plated for redifferentiation in co-culture
with mouse endothelial cells, or transplanted under the kidney capsule of immune deficient
mice, to promote further cell maturation. These manipulations did not further result in the
generation of insulin-producing cells. However, alternative use of redifferentiation medium
reported by Russ and colleagues (31) did generate rare insulin-producing cells. It remains to
be determined which experimental approach (dedifferentiation vs redifferentiation) is the
limiting step for the generation of sufficient insulin-producing cells for transplant.
Determination of the lineage origin of cells generated in the culture process would provide
answers to these questions.
Developmentally, islets are derived from cells within the pancreatic epithelium
which share a bipotent progenitor cell state with duct cells (35). Extensive work has
centered around the neogenesis of islets or insulin-producing cells from ducts, with
compelling evidence suggesting the ductal compartment contains islet progenitor cells
(16,36–42). Early lineage-tracing studies using CAII indicated that cells within the ductal
epithelium were involved in endocrine regeneration (43), and some Ngn3+ lineage-tagged
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cells co-localized with duct cells after injury (44). However, recent evidence has indicated
that the endocrine cells present within the ductal epithelial layer were not generated
postnatally (45,46), thus restricting the contribution from ductal progenitors after birth to
endocrine cell replacement.
The media formulation used for the “redifferentiation” protocol is similar in
composition to that used in the formation of “islet-like cell clusters” containing IGF-II, KGF,
and HGF from human fetal pancreas (14,15), and to that used in the trans-differentiation of
ducts to insulin-expressing cells (16). We have previously shown that IGF-II is an islet antiapoptotic factor (47), and KGF has been shown to be a potent ductal epithelial mitogen (48).
Another study dedifferentiated islets to CK19+ cells, and subsequently used nicotinamide,
ITS, and HGF for “redifferentiation” to insulin-producing cells (49). The continued use of
serum in our model may have limited the ability of mature cells to change differentiation
state; however, we found that the cells did not survive long-term culture without the
trophic stimulus provided by the serum. Moreover, in the absence of lineage-tracing
techniques, it is impossible to definitively conclude that the generation of insulin from
ductal preparations did not arise from insulin-producing β-cells present at the outset.
Similarly, a recent study by Kim et al generated insulin-expressing cells from isolated human
ductal cells, using activin-A, exendin-4, and high glucose (50). These same components are
present in media used by Russ and colleagues (31), and were shown to generate rare
insulin+ cells as demonstrated here. However, Kim et al asserted that these cells had derived
exclusively from the ductal fraction, as they pretreated the pancreatic cell preparation with
5mM streptozotocin (STZ) to destroy any residual β-cells retained therein (50). Human βcells have been shown to be generally resistant to the effects of STZ due to the low
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expression of GLUT2 as compared to rodent islets (51), and therefore the possibility that
pre-existing β-cells present in the ductal cell preparation proliferated and generated
functional insulin production has not been thoroughly disproved. In all studies of islet
redifferentiation however, the re-expression of insulin was minimal when compared to βcell secretion in freshly-isolated islets (49,52). Even when directly promoting differentiation
of human fetal pancreas, <5% of “islet-like clusters” exhibited positive insulin-expression in
vitro, although this jumped to ~50% after transplantation (26). This evidence suggests that
these in vitro manipulations do not provide complete re-maturation of β-cells, let alone
islets, thereby questioning the feasibility of this technique for clinical application.
The formation of cysts during islet cell redifferentiation was similarly shown by
Bonner-Weir and colleagues during the trans-differentiation of ductal cells (16). While that
study reported the generation of considerably more insulin-producing cells, our
experiments utilized specific growth factors and serum which created a more mature ductlike phenotype of long, branched structures. Interestingly, a study was performed using
embryonic (e11.5) mouse pancreas epithelium to determine the effect of endocrine
differentiation on basement membrane selection and mesenchyme inclusion (53). The
authors cultured early epithelium in varying culture environments, including collagen I gels,
Matrigel, or by transplantation under the kidney capsule of mice, thereby providing a milieu
of vascular and dynamic temporal changes by the in vivo environment. They found that
these early epithelial cells transplanted under the kidney capsule formed islets, whereas the
cells grown in Matrigel formed almost exclusively ducts. The cells grown in collagen did not
differentiate, and there was no expression of endocrine marker genes. They also concluded
that the mesenchyme was only required for acinar cell differentiation (53). Within the
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context of the present study, these data indicate that the Matrigel itself preferentially
promoted ductal cyst formation. However, since we also performed transplant experiments
and co-culture experiments with endothelial cells, and neither generated functional islets
nor endocrine hormone-expressing cells, it would suggest that the lineage (re-)specification
of intact, P7 islets or insulin-expressing β-cells was greatly determined by previous
dedifferentiation on collagen, and that further manipulation of the cell culture environment
during “redifferentiation” would have only modest effects.
In addition to ductal-epithelium and fibroblastic cells, islets grown in Matrigel with
redifferentiation media were shown to form adipocytes. Culturing pre-adipocytes in the
presence of insulin, FBS, a glucocorticoid, and a cAMP-elevating agent has been shown to
promote robust adipocyte differentiation (54), but which did not occur when culturing
islets. However, when these islet cells were instead grown in Matrigel with media
containing IGF-II and KGF, cells with an adipocyte-like appearance were generated. This
could be attributed to the presence of laminin in the Matrigel, a strong pro-adipocyte
differentiation factor (55), as opposed to the presence of EGF and type I collagen in the
dedifferentiation media, which independently exert negative effects on adipocyte growth
(55). Clearly, the interactions between media and basement membrane components
influence the fate of the cells in question.
The origin of the ductal-derived cell monolayer remains unknown, and there remains
the possibility that one or more cell types were capable of ductal differentiation. The α-cell
is one candidate cell type shown to exhibit a high level of plasticity (56,57), and may
represent a future avenue for exploration. However, as β-cells compose ~80% of the islet
compartment by mass, lineage tracing of the β-cell is a top priority for determining the cell
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type(s) of origin in the culture conditions purporting to effect dedifferentiation and
redifferentiation. Barring significant contributions from δ (somatostatin-expressing), PP
(pancreatic polypeptide-expressing) cells, or contaminating duct cells, the present data
suggest that the cells obtained after islet growth in epithelial-promoting conditions must
have derived from β-cells, or from an unidentified progenitor cell type resident within the
islet which could rapidly and reproducibly proliferate. Therefore, determining the
contribution of β-cell lineage to the ductal epithelial monolayer will be subsequently
undertaken.
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CHAPTER 3

Lineage tracing of the β-cell during Dedifferentiation and Redifferentiation
In Vitro from Neonatal Mouse Pancreas

A version of this chapter has been previously submitted for publication.

Christine A. Beamish, Brenda J. Strutt, Sofia Mehta, Edith J. Arany, and David J. Hill
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3.1

Introduction
It has been proposed that all β-cells in the postnatal pancreas arise from pre-existing

β-cells, both during aging and under regenerative circumstances (1,2). However, the
contribution of “facultative” progenitor cells, which may require a stimulus of injury or
depend on the maturation status of cells, has not been excluded (3). It has been shown that
β-cell generation in diabetic mice can be induced by the presence of bone marrow-derived
cells (4) and that cells with a functional β-cell phenotype can be generated from embryonic
stem cells (5), and multiple groups have demonstrated the generation of β-cells de novo
from multiple pancreatic cell types (6–8). Since β-cells develop from bipotent trunk cells in
the pancreatic epithelium which share a common precursor population with duct cells, we
hypothesized that a plasticity of β-cells would exist in early life that would allow for their
controlled dedifferentiation to a duct-like phenotype, subsequent population expansion,
and finally redifferentiation to a β-cell phenotype. It was previously shown that mouse and
human β-cells can be expanded or dedifferentiated in vitro (9,10), with dedifferentiation
defined here as the loss of mature and functional characteristics from a partially or
terminally differentiated cell type. In some cases, this may occur prior to
transdifferentiation, defined as the change from one differentiated phenotype to another
involving morphological and functional phenotypic markers (11,12).

However, lineage

tracing of the de- or transdifferentiated cells from those experiments indicated that the
proliferation rate of resulting cells was low, insulin expression diminished after culture, and
the progeny derived from mouse β-cells were ultimately eliminated from in vitro
techniques. We adapted a tissue culture protocol to promote dedifferentiation of isolated
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mouse islets to ductal epithelium (13,14), and utilized neonatal mice (postnatal day 7, P7)
in the expectation that at this age β-cells possess a degree of lineage plasticity. Using a
lineage tracing technique where RIPCre;Z/AP+/+ transgenic mice (15,16) are genetically
tagged with a human placental alkaline phosphatase (HPAP) reporter in the majority of βcells, we sought to identify the fate of β-cells and their progeny during the dedifferentiation
process. Our results indicate that a sub-population of insulin-expressing cells exists within
the neonatal mouse pancreas which retains a capacity for multi-lineage plasticity.

3.2

Materials and methods

3.2.1 Animal experimentation
All animal experimentation was approved by the Western University Animal Use
Ethics Committee, in accordance with the Canadian Council on Animal Care. The transgenic
mouse RIPCre+/+ (15) was crossed with a LacZ/HPAP reporter strain (16) (Jackson
Laboratories, Bar Harbor, ME). Genotyping of RIPCre;Z/AP+/+ mice was accomplished by PCR
amplification using primers for the RIPCre

(FW – gcggtctggcagtaaaaactatc and RV –

gtgaaacagcattgctgtcactt, 100 bp) and LacZ/HPAP transgenes (FW - ccgcttcccatatgtggctct
and RV- gcatgagctcagtgcggttc, 548 bp) from P5 pups. LacZ/HPAP- littermates were used as
controls. Details of genotyping procedures are shown in supplemental methods.

97

3.2.2

Islet dedifferentiation
Reagents were obtained from Invitrogen (Carlsbad, CA) unless otherwise specified.

Islets were isolated from P7 mice as described (17) (Chapter 2). Whole islets were plated
25/ well in a 6-well plate coated with 1 mL type I (rat tail) collagen, with media as described
(13) (Chapter 2). All cell culture media contained 100 mmol/L penicillin/streptomycin and
10 mmol/L fungizone.

3.2.3

Fluorescent immunohistochemistry
Cell monolayers derived after dedifferentiation on collagen were prepared as

described in Chapter 2. Mice were injected with 2 μl 10 mmol/L EdU /g body weight 24 h
prior to dissection, or, for in vitro incubation, 0.05% (v/v) was added to culture media for 6 h
prior to fixation. To assess pancreatic cells ex vivo, mice were euthanized on P7 by
decapitation and at later ages by CO2 asphyxiation, and pancreata were excised and
immediately fixed in cold 4% paraformaldehyde (PFA) (Electron Biosciences, Hatfield, PA)
for 24 h, washed in PBS for 24 h, incubated in 30% sucrose/PBS for 24 h, then embedded in
OCT and snap frozen prior to cryosectioning at 8 nm. The Ki67 antibody required antigen
retrieval using 0.1 M Tris-EDTA at 95°C for 30 min. Sections and cells on Mattek dishes were
permeabilized with 0.3% triton-X-100 /PBS for 10 min before blocking with Background
SNIPER (Biocare Medical, Concord, CA) for 8 min. The HPAP antibody made in mouse
(Sigma-Aldrich, St Louis, MO) required the use of a mouse-on-mouse (MOM) staining kit
(Vector Labs, Burlingame, CA) to block endogenous immunoglobulins. Other antibodies
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utilized are described in Table 3.1. Antibodies were diluted in Antibody Diluting Solution
and sections/ cells on Mattek dishes incubated overnight at 4°C. Fluorescent secondary
antibodies were conjugated to 488/555/647 fluorophores (1/500) appropriately matched to
the primary antibody, and sections incubated for 2 h at room temperature in the dark.
Rates of cell proliferation were determined by EdU incorporation using the EdU Click-It
reaction kit. Cells were counterstained with DAPI for quantification. Slides and Mattek
dishes were imaged on a Zeiss LSM 510 Duo Vario (Carl Zeiss Ltd, Oberkochen, Germany)
confocal microscope at the Biotron, Western University using Zen software, and cells
counted manually using the Zeiss LSM Image Browser (version 4.2).

3.2.4

Quantification of cells
HPAP+ cells were quantified by co-staining with insulin in P7 pancreas sections (> 200

insulin+ cells /section). Isolated islets from each mouse were cultured separately. At least 5
replicate cultures were performed, with >2000 cells counted per time point/replicate. Due
to low reporter protein presence after culturing, all HPAP + cells were counted per Mattek
dish. At least 20 fields of view (FOV) were captured and total cell numbers counted (>50
cells /FOV). The proportion of HPAP+ /total cells was calculated by extrapolating the average
number of cells /FOV, then projecting this number to total FOV / Mattek dish.
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Table 3.1. Antibodies used for immunofluorescent histochemistry
Protein
Insulin
Insulin
Insulin
Glut2
Glut2
Glucagon
Somatostatin
CK19
CK19
Ki67
HPAP
HPAP
GPm6a
GFAP
β-III tubulin
Amylase

Species
mouse
rabbit
guinea pig
goat
rabbit
rabbit
mouse
mouse
rabbit
mouse
mouse
rabbit
mouse
rabbit
mouse
mouse

Company
Dilution
Sigma Chemical (St Louis, MO) 1:2000
Santa Cruz (Santa Cruz, CA )
1:200
Abcam Inc (Toronto ON)
1:300
Santa Cruz
1:100
Millipore EMD (Billerica, MA)
1:500
Santa Cruz
1:200
Santa Cruz
1:200
Dako (Glostrup, Denmark)
1:100
Abcam
1:100
BD Biosciences (Mississauga ON) 1:50
Sigma
1:500
Abcam
1:200
MBL International (Woburn, MA) 1:100
Millipore
1:200
Sigma
1:500
Abcam
1:50

Glut2: glucose transporter 2; CK19: cytokeratin-19; HPAP: human placental
alkaline phosphatase; GPm6a: glycoprotein m6a; GFAP: glial fibrillary acidic
protein.
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3.2.5

Redifferentiation of islet-derived cells
Dedifferentiated cells were cultured in redifferentiation media as described by Russ

et al (18) (Chapter 2). Cells were cultured in 6-well plates coated with 1:25 Matrigel (BD
Biosciences, Mississauga, ON) and maintained for up to 60 d. Matrigel was dissolved using
Dispase (BD Biosciences) prior to downstream cellular analysis.

3.2.6

Fluorescent-activated cell sorting
Excised pancreata were perfused with 2 mL digestion buffer (1.0 mg/mL collagenase

V, 0.2 mg/mL BSA, 0.1 mg/mL soybean trypsin inhibitor, in HBSS) and incubated at 37°C,
shaking, for 30 min. Cells were further dissociated with 0.25% trypsin/EDTA, shaken in a
37°C water bath for 5 min, then drawn twice through 14 G, 18 G, 20 G, and 22 G needles.
Enzymes were inactivated by the addition of 5 mL HBSS + 10% FBS + 0.1 mg/mL DNase I.
After washing, the resulting cells were re-suspended in 1 mL Red Blood Cell Lysis Buffer for
1 min, then inactivated by adding 5 mL HBSS + 10% FBS + 0.1 mg/mL DNase I. The slurry was
strained through a 40 µm nylon mesh (BD Biosciences). Viability count was taken using 20 µl
trypan blue + 20 µl cell mixture. Dispersed cells were immunostained for surface markers
using antibodies for Glut2 and GPm6a (19) (Table 3.1), with primary and secondary
antibodies incubated sequentially for 60 min each. 7-Aminoactinomycin D (7-AAD) was
added as a viability marker. Gating strategy is provided in Figure S3.1. Live
GPm6a+Glut2HI/MID/LO cells were sorted into separate fractions on a Becton Dickinson
FACSAria III cell sorter running FACSDiVa software (v. 6.1.2) at the London Regional Flow
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Cytometry Facility at the Robarts Research Institute and the University of Western Ontario.
Cells were recovered for in vitro culture.

3.2.7

Glucose-stimulated insulin secretion (GSIS)
Cells recovered from flow cytometric sorting were cultured overnight in DMEM/F-12

+ 10% FBS, or dedifferentiated and redifferentiated in vitro, and stimulated as described for
static GSIS assays in (20) using 2.8 and 16.7 mmol/L D-glucose. Insulin release was
determined using an Ultrasensitive Insulin RIA (range 0.02-1 ng/mL) (St. Joseph Health Care,
London ON).

3.2.8

Neural-lineage differentiation
Ins+(GPm6a+)Glut2HI/LO cells recovered from FACS were cultured in Neurocult Neural

Stem Cell (NSC) Basal Media with Proliferation Supplement (Stemcell Technologies Inc,
Vancouver, Canada) plus EGF and bFGF as per manufacturer’s instructions on low
attachment plates for 7-14 d. Intact neurospheres were transferred to Matrigel-coated
(1:25) Mattek dishes, and cultured with NSC Basal Media with Differentiation Supplement
for 7-14 d. Cells were fixed and immunostained for neural-lineage markers β-III tubulin and
glial fibrillary associated protein (GFAP) (Table 3.1).
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3.2.9

Statistical analysis
Data are expressed as mean ± SEM, and comparisons between groups analyzed

using a student’s t-test or one-way ANOVA where indicated unless otherwise stated, and
with a minimum acceptable level of significance of p < 0.05. Statistical analysis was
performed using Graphpad Prism software (v. 5.01, San Diego CA).

3.3

Results

3.3.1

Loss of islet phenotype after culture
Freshly isolated islets were cultured as described in Chapter 2 (Figure 2.1 (A-C)).

Immunostaining for the acinar cell marker amylase was seen in pancreas sections outside of
the islet (Supplemental Figure S3.2A), and was absent after 1 week in the dedifferentiated
cell monolayer, as was insulin immunostaining (Figure S3.2B).

3.3.2

Significant increase in CK19 expression during islet culture
Islets

within

pancreas

sections

contained

insulin

as

demonstrated

by

immunofluorescence (IF), and did not express CK19. After islet isolation and 1 week in
dedifferentiation medium, 75.9 ± 4.5% of all cells expressed CK19 (p < 0.001), and this was
maintained throughout the remaining culture period. Cell proliferation was examined by
the localization of EdU-positive cells, and within all islet cells was 3.1 ± 0.5%. After
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dedifferentiation culture for 1 week, the incidence of cell proliferation was 33.1 ± 8.2% (p <
0.01); and thereafter remained at 6.3 ± 0.4%.

3.3.3

Lineage tracing illustrates rare β-cell dedifferentiation
We sought to determine the extent to which Ins+ cells contributed to islet cell

dedifferentiation in vitro using the HPAP lineage tracer localized by immunohistochemistry
using RIPCre; Z/AP+/+ mice. The HPAP reporter protein (Figure 3.1B, red) identified insulinexpressing β-cells (Figure 3.1A, green) within the islet (Figure 3.1C, merged) with an
efficiency of 85.3 ± 1.2% (Figure 3.1F). The staining frequency of HPAP (Figure 3.1E) in extraislet β-cell aggregates (BCA) containing <5 β-cells was significantly lower at 39.0 ± 6.9% (p <
0.01) (Figure 3.1D, insulin, arrows; Figure 3.1F). These BCA were not included in the whole
islet analysis as they were not cultured due to the physical limitations of handpicking islets.
RIPCre;Z/AP-/- littermates did not exhibit HPAP immunostaining within pancreas sections
(Figure 3.1H). CK19-positive cells were identified around ducts (Figure 3.1G, red) but not
within HPAP+ islets (Figure 3.1G, green) in P7 pancreas sections. In this system, β-cells
constituted 78.9 ± 4.4% of total islet cells; thus 67.3 ± 3.9% of total islet cells expressed
HPAP initially.
After islet isolation and 1 week in vitro, the dedifferentiated monolayer displayed a
total loss of insulin immunostaining (Figure 3.2A, red), and the frequency of HPAP
expression dropped significantly to <0.1% of remaining cells (Figure 3.2B, green, arrow, 67.3
± 3.9% vs 0.04 ± 0.01% HPAP+ cells/total cells, p < 0.0001, islet vs 1 week), representing 14-
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Figure 3.1. Specificity of HPAP to the β-cell using RIPCre;Z/AP+/+ mice
(A) RIPCre;Z/AP+/+ transgenic mouse model showing insulin+ β-cells (green, A)
tracked by the reporter protein HPAP (red, B, and merged, C), and quantified
in (F). The HPAP expression in β-cell clusters containing fewer than 5 β-cells
(D, E) was significantly reduced (F). HPAP+ β-cells in pancreas sections (G,
green) did not co-express CK19 (G, red). RIPCre;Z/AP-/- mouse beta cells (H,
green, insulin) did not exhibit HPAP immunostaining (H, red). Scale bar
denotes 50 μm, n > 5. Data are represented as % Mean ± SEM, **p < 0.01.
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Figure 3.2. Lineage tracing of the β-cell during in vitro islet dedifferentiation.
After islets were cultured in dedifferentiation media for 7 d, all insulin
expression was lost (A, red), and only rare cells retained HPAP expression (A,
green). CK19 (B, green) expression increased drastically, and the rare
remaining HPAP+ cells also adopted CK19 expression (C, green, arrows). After
replating the resultant epithelial-like monolayer of cells in redifferentiation
media, the majority of the rare remaining HPAP+ cells (D, E, green) reexpressed insulin (D, red). Scale bar denotes 50 μm, n > 5 replicates.
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95 HPAP+ immunostained cells retained per dish (n > 6), and equivalent to ~1/2,000 cells
deriving from β-cells after 1 week in vitro. However, of the surviving HPAP+ cells (Figure
3.2C, green), 87.5 ± 3.9% expressed CK19 (Figure 3.2C, red) after 1 week in culture (islet vs
all other time points, p < 0.0001). Proliferation of the remaining HPAP+ cells increased
significantly at 1 week in culture, from 2.7 ± 0.9% to 25.6 ± 1.8% (p < 0.001) by EdU
immunostaining, then decreased thereafter.
To confirm that this represented loss of β-cells and not simply loss of insulin
immunostaining, we examined β-cells early in culture. We found that insulin expression had
diminished consistently with time, such that after 3 days, 48.1 ± 1.2% of cells present were
insulin+, and by day 5, only 18.4 ± 2.1% of the cells were insulin+, and that HPAP tracked
these cells at 85% consistently (Figure S3.3).
The dedifferentiated cells were subsequently cultured in media shown to promote
endocrine redifferentiation (18), and greater than 90% of rare remaining HPAP+ (Figure 3.2E
& F, green) cells re-expressed insulin (Figure 3.2E, red, arrow) over 4 weeks of culture.

3.3.4

Classification of β-cell subpopulations by Glut2 and GPm6a expression
We examined if the β-cells retained after dedifferentiation (i.e., CK19+HPAP+ cells)

had a distinct phenotype. Seaberg et al reported that rare, pancreas-derived multi-potential
progenitor (PMP) cells exist within mouse islets which can generate progeny in both
pancreatic and neural lineages (21). It was subsequently reported by Smukler and
colleagues that these PMPs expressed insulin, albeit at reduced proportions as compared to
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proto-typical β-cells. Furthermore, these cells displayed a progenitor character, with
decreased expression of Nkx6.1 and Pdx1, increased expression of Ngn3, and a lack of Glut2
(22). We hypothesized that HPAP+CK19+ β-cell progeny in dedifferentiated cultures may
have derived from such insulin+ PMPs. As the proportion of these progenitor cells in islets
was reported to be only 1-5/10,000 (22), flow cytometric sorting of β-cells from whole
pancreas from RIPCre;Z/AP+/+ mice was initially used to optimize yield. Cells were selected
using antibodies for GPm6a (19), a cell surface marker shown to identify the β-cell, and
Glut2. GPM6a (red) immunostained insulin-expressing β-cells (green) as shown in Figure
S3.4. Figure 3.3A illustrates GPm6aHIGlut2HI cells (red, phenotypically mature β-cells) and
GPm6a+Glut2MID/LO cells (green); these cells were split into GPm6a+Glut2MID and
GPm6a+Glut2LO groups and collected separately.

Insulin immunostaining was more

prominent in the GPm6a+Glut2HI cells than in the other populations (Figure 3.3C, red).
GPm6a+Glut2HI β-cells were immunopositive for Glut2 (Figure 3.3C, green, top panel), but
this was greatly diminished in the GPm6a+Glut2MID cells (middle panel), and absent in the
GPm6a+Glut2LO cells (lower panel). Measurement of insulin secretion demonstrated that
GPm6a+Glut2HI cells secreted 18.6 ± 1.8 ng insulin when stimulated with 16 mmol/L Dglucose, whereas secreted insulin from GPm6a+Glut2LO cells was below the threshold for
detection (n = 3, 6000 cells/experiment).
When cultured in ductal dedifferentiation conditions, the majority of GPm6aHIGlut2HI
cells did not survive; the few resilient cells being non-proliferative, and failing to stain for
CK19. Conversely, GPm6a+Glut2MID/LO cells dedifferentiated in vitro and immunostained for
CK19 (red) and HPAP (green) (Figure 3.4A, arrows and circle). The GPm6a+Glut2LO cells
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Figure 3.3. Pancreatic β-cells flow-cytometrically sorted by Glut2 and GPM6a.
Whole pancreas (A) and isolated islets (B) were dispersed and flow-cytometrically
sorted into distinct populations of insulin+ (GPM6a+) cells according to differential
Glut2 expression: GPM6a+Glut2+ (red) and GPM6a+ Glut2MID/LO (green), further split
into GPM6a+Glut2LO (A, green, lower, and B, left population) and GPm6a+Glut2MID
(A, darker green, upper). FAC-sorted GPm6a+Glut2LO cells isolated from neonatal
islets (B) represented only 0.3 ± 0.07% of total insulin+ cells. GPm6a+Glut2MID cells
were not recovered from isolated islets (B). Cells recovered after sorting were
immunostained for Glut2 (green) and insulin (red); insulin staining (C, red) was
more prominent in typical β-cells (GPm6a+Glut2HI, top panel) as compared to
GPm6a+Glut2MID/LO cells; furthermore, Glut2 immunostaining (green) was
diminished in the GPm6a+Glut2MIDcells (middle), and was absent in the
GPm6a+Glut2LO cells (green, bottom). Scale bars denote 50 μm, n = 5.
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Figure 3.4. Dedifferentiation and redifferentiation of pancreatic GPM6a+
Glut2LO β-cells. After flow sorting and 1 week in dedifferentiation culture, the
majority of Ins+Glut2LO cells co-expressed CK19 (red) and HPAP (green) (A,
arrows and circle). (B) Redifferentiation of dedifferentiated ductal-like cells
after 4 weeks of culture, showing the β-cell lineage reporter HPAP (green) colocalizing with insulin (red) (arrow). Scale bar denotes 50 μm, n = 5.
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exhibited ~2-fold higher proportion of CK19+ cells after 4 weeks dedifferentiation than did
the GPm6a+Glut2MID cells (72.4 ± 7.7% of Glut2LO vs 42.7 ± 8.9% of Glut2MID cells, p < 0.01, n
= 5).
When subsequently cultured for redifferentiation, HPAP + cells (Figure 3.4B, green)
demonstrated insulin expression (Figure 3.4B, red); however, the redifferentiated β-cells
were functionally immature and did not demonstrate robust insulin secretion at low or high
glucose concentrations (14.1 ± 0.4 pg vs 18.9 ± 0.4 pg insulin, respectively, n = 3, 5 x 104
cells/experiment). These results are consistent with human stem cell differentiation to βcells (23), which demonstrated an immature phenotype in vitro.
Flow cytometric sorting was performed on β-cells recovered from isolated islets
(Figure 3.3B), but GPm6a+Glut2MID cells were not recovered in contrast to their presence
within whole pancreas (Figure 3.3A). GPm6a+Glut2LO cells in isolated islets represented only
0.3 ± 0.1% of total cells by flow cytometry, indicating that the majority of GPm6a +Glut2LO
cells exist outside of the islet (Figure 3.3B).

3.3.5

Ins+Glut2- cells are primarily found outside of islets
To identify the anatomical location of the insulin-positive but Glut2-negative cells,

pancreas sections were immunostained for insulin, Glut2, and EdU. The majority of these
cells were found to reside outside of islets; a representative Ins+Glut2-EdU+ cell being shown
in Figure 3.5A. As a convention, we use the nomenclature “Glut2LO” to represent isolated βcells identified by FACs, and “Glut2-“ to denote β-cells identified by IF analysis within
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Figure 3.5. Location and proliferation of neonatal mouse Ins+Glut2- β-cells
(A) Immunofluorescent images of a mouse P7 pancreas section
immunostained for insulin (i, red), Glut2 (ii, green), EdU (iii, yellow), and
merged images (iv), located in an extra-islet β-cell aggregate (iv, BCA),
demonstrating an Ins+Glut2-EdU+ cell (arrow). (B) Ins+Glut2- cells were primarily
located in BCA as compared to islets (B, ***p < 0.001 total vs <5 β-cells, ****p
< 0.0001 >5 β-cells vs <5 β-cells). (C) The proliferation rate of Ins+ cells was
higher in BCA than in islets (**p < 0.01, Mann-Whitney test). (D)
Ins+EdU+Glut2- cells can be found in high proportion in both BCA and islets (D,
*p < 0.05). Scale bar denotes 50 μm, n > 5. Data are represented as % mean ±
SEM.
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pancreas sections. Ins+Glut2- cells represented 3.5 ± 0.2% of all insulin-expressing cells in
the P7 pancreas by fluorescent immunocytochemical staining (Figure 3.5B, 1,935 cells, n = 5
pancreata). When separated for quantification into β-cells found within islets (>5 β-cells) or
within extra-islet β-cell aggregates (<5 β-cells, BCA), Ins+Glut2- cells represented 1.2 ± 0.3%
of insulin+ cells within islets, and 20.5 ± 3.6% of insulin+ cells within BCA (Figure 3.5B,
23/1703 cells and 45/232 cells, respectively). The proliferation rate of Ins + cells was higher
in BCA than in islets at P7 (12.6 ± 0.7% vs 2.8 ± 0.2% respectively, Figure 3.5C). These
proliferating insulin+ cells were examined further, and showed that 12.8 ± 4.1% of Ins+EdU+
cells lacked Glut2 within islets, and 20.1 ± 5.6% within BCA (Figure 3.5D), illustrating that at
P7 Ins+Glut2- cells are proliferative both within and outside of the islet as compared to
Ins+Glut2+ β-cells.

3.3.6

HPAP+ cells tag non-insulin-expressing-cells after extended time in vivo
In the young RIPCre/Z/AP+/+ mouse (<14 d), HPAP+ cells that immunostained for

proteins other than insulin were extremely rare (Figure 3.6C and D, white bars). However,
when older (>1 yr) RIPCre;Z/AP+/+ mice were examined, the proportion of HPAP+ cells
(green) labelling non-insulin expressing cells increased, including glucagon (Figure 3.6A, red)
and somatostatin (Figure 3.6B, red), Quantification of these events is presented in Figure
3.6C and D (black bars).
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Figure 3.6. Alternate cell fates of HPAP+ cells in vivo.
Images from RIPCre;Z/AP+/+ mice demonstrating that some HPAP-tagged cells
(A, B, green) express non-β-cell markers after a long time period (>1 yr, n = 3
mice), including glucagon (A, red) and somatostatin (B, red) as compared to
young mice (<14 d, n = 5). Arrows indicate dual stained cells. These were
quantified into marker+/HPAP+ cells (C) or HPAP+/marker+ cells (D). Scale
bar denotes 50 μm. Data are represented as % mean ± SEM, C and D, >1 yr vs
<14 d, t-test, * p < 0.05.
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3.3.7

Ins+Glut2- cells generate neurospheres and neural-lineage cells in vitro
To assess the capacity for cellular plasticity, insulin-expressing cells detected using

GPm6a were recovered after FACS and cultured in neural differentiation conditions. A
subset (~1/200) of these GPm6a+Glut2LO cells proliferated and formed neurospheres (Figure
3.7A); Ins+Glut2HI cells did not proliferate (Figure 3.7B). Once plated for neural
differentiation, the Ins+Glut2LO-derived neurospheres formed cells with neuronal-like
processes (Figure 3.7C, D). These cells demonstrated immunostaining for the neuronal
marker β-III tubulin (Figure 3.7E, G, green) and the astrocyte marker glial fibrillary acidic
protein (GFAP) (Figure 3.7F, H, red). Both of these resulting cell phenotypes expressed the
β-cell reporter HPAP (Figure 3.7F, G, red, and Figure 3.7 G, H, green), demonstrating the
lineage plasticity of Ins+Glut2LO cells. Furthermore, all neurospheres generated both
neuronal and astrocyte cell types.

3.4

Discussion
Islet dedifferentiation, expansion, and subsequent redifferentiation have long been

proposed as a source of insulin-producing cells to facilitate transplantation for the reversal
of diabetes. Based on a model which postulated “islet trans-differentiation” to a hormonenegative phenotype with similarities to ductal-epithelium (13), we hypothesized that the
resultant cell monolayer was derived, in part, from β-cells that could be tracked using a
lineage tracing technique utilizing HPAP expression. We found that the majority of β-cells
from isolated islets did not survive in vitro; however, ~1/2,000 of the cells present had
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Figure 3.7. Pancreatic Ins+Glut2LO β-cells are multi-potential and can
differentiate into neural cell lineages.
Insulin+ cells recovered from whole mouse pancreas after FAC-sorting based
on Glut2 expression were placed in neural proliferation conditions.
Neurospheres (A) were generated from GPM6a+Glut2LO cells, compared to
GPM6a+Glut2HI cells (B). After replating in neural differentiation conditions,
the neurospheres generated multiple morphologies, including neuron-like
processes (C, D). When immunofluorescently stained, neurons were
visualized by β-III tubulin (E, G green), and astrocytes by GFAP (H,J, red).
These neural cells co-stained with HPAP (red, F, G; green, I, J). Scale bar
denotes 100 μm (A, B), and 50 μm (C-J), n = 5.
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derived from β-cells and dedifferentiated to become CK19+ cells. We subsequently
hypothesized that these HPAP+CK19+ cells represented the progeny of Ins+Glut2- cells,
reported to denote a pancreatic multipotent progenitor cell pool (22). We have shown that
these PMPs can be isolated from neonatal mouse pancreas, and which are capable of
differentiation to a variety of cell types in vitro. Importantly, while Ins+Glut2- cells can
indeed be found in intact islets as reported (22), a higher proportion are located in
scattered β-cells outside of islets, and which have a significantly greater proliferative
capacity at P7 than the Ins+Glut2+ cells.
More than one cell type populated the islet-derived dedifferentiation cultures, with
only a minority derived from β-cells. Other groups have demonstrated similar results by
lineage tracing experiments, with 1.4% and 0.5% mouse β-cells dedifferentiating in vitro,
respectively (9,10), and <5% of β-cells dedifferentiating from human islets using similar
culture conditions (24). These findings indicated higher rates of dedifferentiation than
found by us; however, those groups did not further characterize the rare β-cells capable of
dedifferentiation. As our initial cellular preparation contained multiple cell types, it is
conceivable that some of the CK19-expressing cells generated during dedifferentiation
culture were derived from adherent ductal cells present at the time of islet isolation and
which subsequently expanded in vitro, diluting the cellular contribution from β-cells.
The concept that progenitor cells may paradoxically express mature markers, such as
insulin, could explain why such cells in the pancreas have remained elusive. Interestingly, it
does satisfy the evidence that postnatal β-cells arise from pre-existing β-cells (1), but, as
shown here, not all insulin-expressing cells are of equivalent phenotype. Other precedents
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for mature marker presence in stem cell populations exist, such as neural stem cells
expressing the astrocyte marker GFAP (25). We have shown that Ins+Glut2- cells represent
1.2% of β-cells in the neonatal islet by immunostaining, but only a subset of these cells are
capable of differentiation to pancreatic islet and ductal phenotypes; the proportion of
plastic cells being similar to that found by Smukler et al (22). However, a striking 3.5% of
insulin-expressing cells within whole pancreas at P7 lacked Glut2, with up to 20% of these
cells being found within BCA. This suggests that the highest source of β-cells capable of
demonstrating lineage plasticity is found outside of the islet, and these extra-islet BCAs are
most abundant in the neonatal period and thereafter decline with advancing age (26). The
absence of Glut2 expression is likely not the sole identifier of a β-cell progenitor however,
since the co-expression of other markers such as Ngn3 and Nkx6.1 has been proposed by
others (22,27). Reports have demonstrated the presence of putative β-cell progenitors
during adulthood, with or without diabetes, and showed that these cells exhibited higher
expression levels of Pdx1and MafB, and low/absent expression levels of genes indicative of
mature gene function, including Nkx6.1 and Glut2 (6,28). Furthermore, these β-cells could
be subdivided into those with the ability to transition to mature β-cells in culture, and those
that maintained a progenitor phenotype throughout, illustrating β-cell heterogeneity and
differing states of functional maturation (28). Mouse β-cells in the immediate postnatal
period are immature, with poor GSIS and lower expression of Glut2 compared to adult βcells (29–31). It was recently reported that neonatal β-cells require a glucose threshold for
maturation, and that β-cells within BCA of young mice are functionally different than those
in islets (20). Furthermore, infant human β-cells demonstrate some plasticity in insulin
secretory machinery as compared to adult β-cells (32). Our data suggests that a lack of
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Glut2 expression may reflect not only β-cells with decreased function, but also a subset of
progenitor cells. Interestingly, Stolovich-Rain et al (33) showed that after β-cell ablation,
surviving β-cells in the mouse pancreas displayed significantly decreased levels of Glut2,
purportedly due to glucose toxicity. While injury models were not examined in the present
study, it must be assessed whether a decrease in Glut2 expression is a necessary
mechanism during regeneration, a direct result of environmental toxicity, or whether the
surviving cells exhibited Glut2 expression at all. As we have shown an increased
proliferation in the Ins+Glut2- cells, it is conceivable that these could clonally expand to
replace β-cells after injury, with subsequent maturation to functional β-cells exhibiting high
Glut2 expression.
Russ et al (9) showed that human β-cells were able to dedifferentiate much more
readily than mouse β-cells in vitro. Despite distinctions between human and rodent islets
with respect to architecture (34) and higher prevalence of GLUT1 utilization over GLUT2
(35–39), Smukler et al (22) demonstrated that Ins+Glut2LO cells from adult human islets had
a similar phenotype, occurrence, and lineage plasticity to those found in mice. Moreover,
GLUT2 has been recently implicated in human neonatal diabetes (40) and its importance for
glucose transport into human β-cells has been demonstrated (41). If Ins+GLUT2- cells are as
abundant in the BCA of human pancreas from young donors as we have shown here in
mice, the inclusion of these cells may enhance the effectiveness and longevity of human
islet transplantation.
Dor et al showed that β-cells in adult mice within the small extra-islet clusters had a
similar labelling index with a genetic lineage tag as did those in larger islets, and concluded
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that these simply represented small islets, or islets with β-cells undergoing apoptosis, rather
than reflecting a new source of β-cells derived from a progenitor population (1). Our
experiments differ in that; 1) we used a non-inducible transgenic model which results in the
labelling of a much higher percentage of β-cells allowing for greater discrimination in subpopulation changes, and 2) we studied neonatal as opposed to adult mice. Within this
paradigm, we have shown that there is significantly lower lineage labelling with HPAP in βcells located within the BCA than in anatomically mature islets in P7 mice (39% vs 85%),
which is likely to reflect the generation of new β-cells from progenitors within the BCA
during early postnatal life. While the number of extra-islet BCA decreases with age in
rodents, they are still found in adulthood (26). Chintinne et al (42) found that the majority
of β-cells in young rats were present in small aggregates (<50 μm diameter, including single
cells) which formed postnatally, and concluded that the neogenesis and clustering of these
aggregates is a key process to attaining β-cell mass in adulthood. Our data would suggest
that such β-cells in mice represent, in part, a population that has recently differentiated
from insulin- progenitors, which consequently did not tag with HPAP.
As indicated by Murtaugh (43), the study by Smukler et al (22) used the inducible
RIPCreER;Z/EG model to tag β-cells and follow them in vivo, a model in which only a subset
of β-cells are tagged, and which has been recently suggested to inappropriately label a
fraction of acinar cells over an extended chase, raising concern over RIPCreER transgene
stringency (44). The present study used the non-inducible strain RIPCre to tag a high
proportion of β-cells with HPAP before islet isolation and in vitro culture. As the amount of
lineage-tagged β-cells retained was only ~0.05% after 1 week in vitro, we propose that this
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number does not over-represent the surviving β-cell population. Furthermore, while the
lineage-label eGFP was used for sorting β-cells in that study (22), the non-fluorescent HPAP
reporter in our model required us to employ a proxy β-cell surface marker, GPm6A (19). We
have shown that Ins+Glut2- cells can be detected and collected using different techniques
(FACS and immunofluorescence), various markers for β-cells (insulin, GPm6A, and HPAP),
and two separate antibodies for Glut2, indicating that these findings are unlikely to
represent artefact. That a sub-population of Ins+ cells can reproducibly create CK19+ duct
cells, subsequently re-express insulin, or can alternatively differentiate into neural-lineage
cells indicates a substantial plasticity potential. It has also been questioned whether <0.1%
of β-cell progenitors within islets could reasonably account for β-cell mass renewal (43). We
have shown that the majority of Ins+Glut2- cells are found in the scattered BCA of the
pancreas, which have received little experimental attention. These Ins +Glut2- cells are
proliferative, and as speculated by Smukler et al, could represent the rare, proliferative βcell “clones” described previously (45); findings contrary to studies which indicated that all
β-cells exhibit an equal proliferative potential (2,46). However, given the scarcity of the
Ins+Glut2- cells within adult islets, they could have been overlooked. Of note, it was recently
reported that after pancreatic duct ligation of 8 week old mice, the highest proliferation of
insulin-expressing cells had occurred in small islets of <20 β-cells, which were found to
regenerate the pancreas, and which had derived from Ngn3 + cells within small β-cell
clusters (47).
This work builds on evidence that the mouse and human pancreas contain Ins +
multipotent pancreatic progenitor cells, which can be identified by the absence of Glut2
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(21,22). Determining the fate of these progenitors during maturation, and the age at which
their numbers cease to be a feasible source of renewable insulin-producing cells, may
elucidate the extent of postnatal β-cell plasticity.

3.5
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4.1

Introduction
A replacement of insulin-producing β-cells is required for the reversal of diabetes,

and may be theoretically obtained by utilizing endogenous pancreatic β-cell progenitors.
However, the presence of these β-cell progenitors is controversial, with as many
publications supporting their existence (1–4) as those that reject it (5–7). The debate may
not be as polarized as appears, since the presence of facultative stem cells (8), age (9–11),
pregnancy (12–14), obesity (15–17), release from cell-cycle regulators (18), altered glucose
metabolism (19), and the type of pancreatic injury (20,21) may each contribute to the
milieu of factors putatively capable of effecting regeneration of the endocrine pancreas.
This debate is further complicated by evidence that rare pancreatic progenitor cells present
in human and mouse islets are capable of multi-potential differentiation and express insulin
(22), usually considered to be a marker of a mature β-cell. Importantly, while these cells
expressed insulin, they lacked Glucose-transporter 2 (Glut2), another feature of mature βcells, and furthermore displayed progenitor characteristics, with increased expression of
early β-cell transcription factors.

Recently, we (Chapter 3) demonstrated that these

Ins+Glut2- cells were present within neonatal (postnatal) P7 mouse islets which
demonstrated multi-lineage plasticity, and displayed a loss of glucose responsiveness,
indicating that these β-cells are atypical. Importantly, there was a higher proportional
presence of these in the small pancreatic β-cell aggregates of cells (BCA, <5 β-cells) than in
islets. BCA have been presumed to be of little physiological importance. The relative
abundance of the cells capable of multi-lineage differentiation ranged from 1/2000 β-cells
within P7 mouse islets as found by us, to 1/10, 000 in the adult human and mouse islet as
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found by Smukler et al (22). It was established by immunohistochemistry that up to 1% of
all β-cells present in the P7 mouse pancreas – the majority of them extra-islet β-cells expressed insulin but not Glut2, but that only 1/200 were capable of differentiation; the
bulk then possibly representing immature and/or glucose-unresponsive β-cells. The present
study therefore sought to explore two main avenues of interest: first, to identify whether
Ins+GLUT2- cells were also present in human samples, especially within BCA; and second, to
determine how the location and abundance of these Ins+GLUT2- cells changed with age in
both mouse and human pancreas.

4.2

Materials and methods

4.2.1

Human and mouse pancreas sample collection
Twenty-five human pancreas samples were assessed, obtained as formalin-fixed and

paraffin-embedded tissue sections from the Department of Pathology at the University of
Western Ontario, Schulich School of Medicine (London ON), and the University of Chicago
(Illinois), with approval from the University of Western Ontario Research Ethics Board
#103167, and Lawson approval number R-12-501. Inclusion criteria were that pancreas
samples be selected from cadaveric tissues, taken from donors with no known metabolic
disease, and body weight within established healthy BMI standards (18-25 kg/m2). Tissues
utilized were representative of diverse ethnic backgrounds, and evenly split between male
and female samples (48% female, 12/25 samples). Paraffin blocks were chosen from midpancreas whenever possible.
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All animal procedures were approved by the Western University Animal Use Ethics
Committee, in accordance with the Canadian Council on Animal Care. Mouse pancreas
samples were collected from wild-type littermates and retired breeders from our existing
transgenic colonies present at the Lawson Health Research Institute, St Joseph Health Care,
London ON, and with a C57Bl/6 background. Mouse pancreata were fixed in 4%
paraformaldehyde (PFA, Electron Microscopy Sciences (Hatfield PA)) for 24 h, washed in PBS
for 24 h, incubated in 30% sucrose for 24 h, and frozen in OCT at -80°C prior to sectioning at
8 nm.
Tissues from various ages were chosen to illustrate major developmental stages,
including early endocrine pancreas development, infancy, childhood, adolescence/sexual
maturation, adulthood, and late life; human samples are shown in Table 4.1, and a
schematic of life stages for both species are shown in Figure 4.1. Tissue samples were agematched within each life stage and were collected from both sexes.

4.2.2

Fluorescent immunohistochemistry
Fluorescent immunohistochemistry was performed using antibodies for insulin

(human anti-mouse, Sigma-Aldrich (St Louis MO), 1/2000, and rabbit anti-human, Santa
Cruz Biotechnologies (Santa Cruz, CA) 1/200), Glut2 (goat anti-human, Santa Cruz, 1/200,
and rabbit anti-human, Millipore (Billerica, MA) 1/500), and Ki67 antigen (mouse antihuman, BD Biosciences (Mississauga, ON), 1/50). Secondary antibodies were matched to the
species of the primary antibodies, and conjugated to 488/555/647 fluorophores (Life
Technologies Inc (Carlsbad CA) 1/500). DAPI (Life Technologies, 1/1000) was used to
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Table 4.1. Human Pancreas Samples
Case No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
22
24
25

Sex
F
F
F
M
F
M
F
M
M
F
F
M
M
F
M
F
M
F
M
F
M
M
M
F
M
M

Age
22 weeks G
30 weeks G
30 weeks G
2 days
11 days
14 days
5 years
6 years
6 years
6 years
9 years
10 years
11 years
14 years
19 years
20 years
36 years
41 years
50 years
52 years
54 years
56 years
65 years
72 years
72 years
79 years

Developmental Stage
Fetal
Fetal
Fetal
Infant
Infant
Infant
Child
Child
Child
Child
Child
Adolescent
Adolescent
Adolescent
Young Adult
Young Adult
Young Adult
Young Adult
Adult
Adult
Adult
Adult
Late Adult
Late Adult
Late Adult
Late Adult
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A

Adulthood
Gestation Infancy Childhood Puberty

Time
40 wks 0 -1 2-9
(years)

B

21d

0

18-40

41-64

65+

Sexual Adulthood
Wean Maturity

Gestation Birth

Time

10-17

7d

14d 21d 28d

3mo

6mo

12mo

18mo

Figure 4.1. Lifespan of the mouse and human. The entire lifespan was
examined in human (A) and mouse (B), with ages selected to illustrate
major developmental stages, including early development, infancy,
childhood/weaning, puberty/sexual maturation, and adulthood, as
represented by each red star. When possible, developmental points were
matched. A significant proportion of mouse islet development occurs
postnatally, such that 20 weeks gestation in humans is analogous to
postnatal d8 in mice. n ≥ 4 mice, and ≥ 3 humans/star.
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counterstain nuclei of all tissues. GLUT2 immunostaining in human pancreas samples
required the use of tyramide signal amplification (23) using a kit (Perkin Elmer, Waltham,
MA) conjugated to a Cy3 fluorophore. Ki67 signal visualization required antigen retrieval at
95°C in Tris-EDTA buffer for 30 min. All tissues were permeabilized for 10 min with 0.3%
triton-X-100 and blocked with Background SNIPER (Biocare Medical, Concord CA) for 8 min.
Tissues were imaged by confocal microscope using a Zeiss LSM 510 Duo Vario (Carl
Zeiss Ltd, Oberkochen, Germany) at the Biotron Facility, Western University, and counted
manually using Zen software. Minimum cell counts were >250 insulin + β-cells/section for
mice (≥2 sections per pancreas), and >1500 insulin+ β-cells/section in human pancreas (1
section per pancreas from 1 block). Controls were determined by cutting replicate sections
from the same block (>100 μm apart), and variance around the mean was below 9%.

4.2.3

Statistical analysis
There were at least quadruplicate samples per cohort per life stage for mouse

samples and triplicate pancreata analyzed for human samples (Table 4.1).

Data are

presented as percent (%) mean ± SEM of insulin+ β-cells, with statistics performed using a
one-way ANOVA and Tukey’s post-test, or student’s t-tests as indicated, and with an
acceptable level of significance of p < 0.05.

Statistical analysis was performed using

Graphpad Prism software (v. 5.01, San Diego CA).
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4.3

Results

4.3.1

β- cell Aggregate (BCA) proportion decreases with age in mouse and human

pancreas
Pan & Wright (24) showed that mice display significant postnatal endocrine
development, such that P8 mouse endocrine pancreas is analogous to 22 week gestation
fetal pancreas in humans; thus, we used these time points to begin our analysis. At 7d, 16.1
± 0.8% of mouse β-cells were located in BCA (Figure 4.2A, white bar). This proportion
decreased by 18 months of age to only 2.1 ± 0.7%; the majority instead being present in
proto-typical islets (Figure 4.2A, black bar, 18 mo vs 7d, p < 0.005).
In contrast to mice, 41.6 ± 3.3% of human β-cells were located in BCA during the
fetal period (G22-30w) (Figure 4.2B, white bar, and Figure 4.2C, immunostaining positive for
insulin (green)). This proportion was significantly larger than the equivalent population in
mice during the earliest time point studied (G22-30w vs 7d, p < 0.0005, t- test, not shown).
The proportion of BCA in human pancreas dropped during infancy (0-1 y, hatched bar) and
childhood (2-9 y, hatched bar) to 28.4 ± 2.2% (Figure 4.2B, 0-1 and 2-9 vs G22-30w, p
<0.05), then significantly decreased at puberty to 5.5 ± 1.1% (Figure 4.2B, hatched bar, G2230w vs 10-17, p < 0.0005, and 4.2D). Interestingly, there was an equivalent proportion of
BCA at the time of sexual maturation between mouse and human samples (28d mouse vs
10-17 yr human, t-test, p = 0.68, not shown). The majority of human β-cells were thereafter
maintained throughout adulthood within islets (Figure 4.2B, black bars, and arrows, Figure
4.2D). There was a statistically significant difference in the BCA proportion between human
female and male samples in early adulthood, with 11.0 ± 0.3% vs 4.3 ± 0.7% respectively
134

A

B

**

***
**

C

D

E

Figure 4.2. Beta cell aggregate proportion decreases with age in both mouse
and human pancreas. Similar developmental points were grouped (7d
(mouse) and fetal (human) samples = white bars, pre-weaning and sexual
maturation (14-28d) (mouse) and infancy/childhood/adolescence (human)
samples = hatched bars, and all adult ages = black bars. β-cells were counted
and assigned to either the BCA compartment (<5 β-cells) or islet (>5 β-cells).
(C-E) Representative images from human pancreas immunostained with
insulin (green) illustrate changes during the maturation of islet structures,
from fetal age (C, 30 week gestation female) through puberty (D, 14 year old
female), and late adulthood (E, 72 year female). Graphs are shown as
proportion (%) mean ± SEM of total β-cells counted; 1-way ANOVA * p < 0.05,
** p < 0.005, *** p < 0.0005. Size bar denotes 50 μm, n > 3 .
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(18-41, p <0.05, t-test). By late adulthood, there were very few BCA present within sections
of human pancreas (Figure 4.2E, arrows). Mouse and human pancreata displayed no
difference in BCA proportion during adulthood and late adulthood.

It must be

acknowledged that if islets were sectioned at the periphery, then the size would
theoretically be equivalent to that of the BCA; however, this would be a relatively rare
event. Furthermore, if that were true, then these data would not change with age as seen
here.

4.3.2

Ins+Glut2- cell proportion decreases with age
We examined the population of Ins+Glut2- cells over the lifespan of both human and

mouse. Human pancreas sections demonstrated immunostaining for insulin (green) and
GLUT2 (red) as shown in Figure 4.3. A representative image of human Ins+GLUT2- cells is
shown in Figure 4.3B (arrows) within the BCA compartment. In mice, the proportional
presence of total Ins+Glut2- cells decreased significantly from 3.8 ± 0.8% at 7d to 0.6 ± 0.2%
at 3 mo (Figure 4.4A, 7d vs 28d-12mo, p < 0.05), which was further exaggerated by 18 mo
(Figure 4.4A, p < 0.005). The decrease in this population was also significant from preweaning to late adulthood (Figure 4.4A, 14d, 21d vs 18 mo, p < 0.05). There was a similar
trend found in humans, with total Ins+GLUT2- cells decreasing from the fetal time period to
adulthood (Figure 4.4B, G22-30w vs all others, p < 0.0005) , as well as from childhood to
late adulthood (Figure 4.4B, 2-9 vs 65+ p < 0.05). There were twice as many total Ins+GLUT2cells in human pancreas than in mouse at the initial time point studied (7.8 ± 0.9% G22-30w
vs 3.8 ± 0.8% 7d, p < 0.05).
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A

B

Figure 4.3. Insulin and GLUT2 immunostaining in human pancreas.
Representative images of an islet (A) and beta cell aggregate (B) stained for
insulin (green) and GLUT2 (red) in human pancreas. Ins+GLUT2- cells are
shown in B (arrows). Size bar represents 50 μm.
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Figure 4.4. Ins+Glut2- cell proportion decreases with age.
Ins+Glut2- cell proportion from total β-cells (A, B), islets (C, D), and BCA (E,F) as
found in mouse (A, C, E) and human (B, D, F) pancreas samples. Graphs are
shown as proportion (%) mean ± SEM of total β-cells counted; 1-way ANOVA
with tukey’s post-test or student’s t-test, §,* p < 0.05; §§ p < 0.005; §§§, ***
p < 0.0005.
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The anatomical location of Ins+Glut2- cells was then examined. Figure 4.4C shows
that 1.6 ± 0.4% of mouse β-cells lack Glut2 at 7d within the islet (white bar), which is
consistent with previous findings (Chapter 3). As hypothesized, this proportion significantly
decreased by early adulthood (range 0.2 ± 0.1% – 0.4 ± 0.1%, 7d vs 3 mo, p < 0.05).
In humans, 1.1 ± 0.2% of the β-cells within the islet lacked GLUT2 during fetal life,
which decreased significantly by childhood, and further thereafter (Figure 4.4D, G22-30w vs
10-17, p < 0.005). There were few Ins+GLUT2- cells present in islets by late adulthood in
human pancreas (Figure 4.4D, 1.1 ± 0.2 vs 0.07±0.01%, G22-30w vs 65+, p < 0.0005). There
was a trend towards a decrease in Ins+GLUT2- cells within the islets in early adulthood, and a
subsequent increase in the population during mid-adulthood (Figure 4.4C and D, black bars;
0.6 ± 0.1% vs 0.07±0.01%, 41-64 vs 65+, p <0.05).
The proportion of Ins+Glut2- cells within the BCA compartment was markedly
different than that within the islet, with 16.1 ± 2.6% of all mouse insulin-expressing cells
lacking Glut2 within BCA at 7d (Figure 4.4E). This proportion increased at the immediate
postnatal time period (14d, 21d), but decreased thereafter at 3 mo and 18 mo (Figure 4.4E,
16.1± 2.6% vs 9.2 ± 2.7%, 7d vs 18 mo, p <0.05).
In the human pancreas, a similar proportion of Ins+GLUT2- cells were found in BCA
in the fetal time period as in the 7d mouse (17.0 ± 1.7% vs 16.1 ± 2.6%, G22-30w vs 7d, ns).
Ins+GLUT2- cell proportional presence in the BCA was maintained throughout most of life,
with a significant decrease in Ins+GLUT2- cells in BCA only in late adulthood (Figure 4.4F,
19.1 ± 1.7% vs 7.1 ± 1.6%, 41-64 vs 65+, p < 0.05).
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4.3.3

β-cell proliferation decreases with age
The proliferation index of total insulin+ β-cells was examined in mouse by Ki67

immunostaining, and was found to be highest at 7d compared to all other time points
(Figure 4.5A, 3.3 ± 0.1% vs 0.7 ± 0.1%, 7d vs 3mo, p <0.0005). Beta-cell proliferation had
decreased by weaning (2.0 ± 0.2% at 14d and 1.6 ± 0.2% at 21d), and thereafter
proliferation was maintained at ~0.6% (Figure 4.5A, black squares). In the human pancreas,
a similar trend was noted, with the highest total β-cell proliferation found in fetal life, which
dropped thereafter (Figure 4.5B, 1.4 ± 0.5% vs 0.2 ± 0.1%, G22-30w vs 65+, p <0.05). There
was significant variability in the pre- and perinatal samples, ranging from 0.9 – 2.3% and 0.2
– 0.9%, respectively (Figure 4.5B).
Proliferation of β-cells within islets followed similar patterns as was found in total βcell proliferation, with rates of replicating β-cells highest in mice at 7d, and which decreased
significantly by early adulthood (Figure 4.5C, 2.8 ± 0.2% vs 0.6±0.1%, 7d vs 6mo, p < 0.005).
In the human, a similar trend was noted as in mice, with proliferation of β-cells being
highest during the fetal time period, and decreasing thereafter (Figure 4.5D, 1.3 ± 0.5% vs
0.2 ± 0.03%, G22-30w vs 65+, p < 0.05). There was considerable variability in the β-cell
proliferation rate within the islet in the fetal and infant samples, ranging from 0. 6-2.2% and
0.1-1.2%, respectively. After adolescence, β-cell proliferation within the islet was
maintained <0.5% (Figure 4.5D).
Within BCA, β-cell proliferation dropped significantly in mice from 7d to 28d and at
3mo (Figure 4.5E, 7.7 ± 1.0% vs 1.5 ± 0.03%, 7d vs 28d, p < 0.05). A similar trend occurred in
the human BCA compartment, with a significant decrease in proliferation from midgestation to adolescence (Figure 4.5F, 1.4±0.3% vs 0.0 ± 0.0%, G22-30w vs 10-17, p < 0.05).
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Figure 4.5. Frequency of β-cell proliferation decreases with age.
Proliferation of insulin+ β-cells by Ki67 presence is shown in total β-cells (A,
B), islets (C, D), and BCA (E,F) within mouse (A, C, E) and human (B, D, F)
pancreas samples. Scatter graphs show the spread of data points between
individual pancreata, and % mean of β-cells counted is indicated by 1-way
ANOVA; * p < 0.05, ** p < 0.005, *** p < 0.0005.
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We have previously shown that Ins+Glut2- cells displayed increased proliferation in
the mouse at P7, with 12.8 ± 4.1% of Ins+EdU+ cells lacking Glut2 in the islet, and 20.1 ± 5.6%
of those cells lacking Glut2 in the BCA (Chapter 3). We examined this same population of
Ins+Glut2-Ki67+ cells throughout the lifespan of mice and humans. Consistent with our
previous findings, 11.9 ± 5.0% of proliferating β-cells lacked Glut2 in the islet, and 23.2 ±
4.7% in the BCA at 7d in the mouse. At the equivalent age in humans (G22-30 w), only 1/3
of pancreas samples exhibited Ins+GLUT2-Ki67+ immunostaining. The total proportion of
proliferating β-cells which lacked GLUT2 increased at infancy to 14.4 ± 9.9% (0-1 yr, 2/3
samples), and during childhood to 10.4 ± 6.2% (2-9 yrs, 2/4 samples); in all cases, the cells
being predominantly found in BCA. After 7d in the mouse and childhood in the human, the
proportion of Ins+GLUT2-Ki67+ cells diminished greatly, with only rare cells found at all
subsequent ages in BCA, and none in islets.

4.4

Discussion
Over the mammalian lifespan, the endocrine pancreas undergoes significant changes

in terms of cellular maturity, function, replication ability, and cell macro-organization (25).
Previous studies have shown that a population of Ins+Glut2-, lineage-plastic putative
progenitor cells can be identified in adult human and mouse islets (22), and which are
proportionally increased in the small, extra-islet clusters of β-cells of neonatal mice
(Chapter 3). Hence, we sought to determine if this population was also present in BCA in the
human pancreas, as well as to assess how this cell population changes with age. We have
found that human pancreas also contains a significant proportion of Ins +GLUT2- cells both
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within and outside of the islet, and this population decreases with advancing age in both
species.
Some novel insights may be gleaned from this ontological study of human pancreas,
specifically regarding pancreas maturation and remodelling at key developmental time
periods, namely birth and adolescence. First, a significant proportion of endocrine cell mass
is present in the young human pancreas outside of proto-typical islet structures, with nearly
45% of β-cells present in small clusters of cells (<5 β-cells) during mid-gestation, ~30%
during infancy, and ~20% during childhood. This trend has been shown previously (26),
however it was not quantified per se. Indeed, there is a lack of consistency in nomenclature
and size metrics when quantifying these small β-cell aggregates or clusters, with an “islet”
being identified as 4 (insulin+) β-cells together (26,27), as compared to “β-cell clusters”
constituting <10 β-cells (5), or <20 β-cells (3) when quantified by cell number, or
alternatively <50 μm (28,29) or <60 μm(30) when determined by β-cell area grouping size.
Within the confines of our model, the proportion of β-cells present as single cells/small
clusters (i.e., BCA, <5 β-cells) outside of the islet only drops substantially around puberty,
and is thereafter maintained in the adult at ~5%. This dramatic decrease was not seen in
mouse, which showed a more gradual decline after weaning. However, in both species, βcell proliferation in the BCA compartment was extremely low (mouse)/ absent (human) at
this developmental stage, which may indicate a shift in cell plasticity. The low rate of β-cell
proliferation during adolescence has been noted previously (26), although not specifically in
reference to β-cells outside of islets. It is of interest to note that the incidence of type 1
diabetes in humans peaks between 10-14 years (i.e., puberty/adolescence) (31), which
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coincides with the developmental shift to larger islets and fewer β-cell aggregates as
demonstrated here. We propose that in addition to the hormonal demands and somatic
growth necessary at this age (26), adolescence may be an especially vulnerable window for
diabetes if this reserve pool of β-cells is not available for endocrine tissue remodelling. It is
currently unknown if the Ins+GLUT2- β-cells are equally susceptible to autoimmune
destruction as mature β-cells. It is speculative to hypothesize that these cells may represent
the small clusters of β-cells retained in the pancreata of older “Medalist” donor tissues (32).
Second, it has been shown that human pancreas contain a higher proportion of
small islets relative to large islets than is found in mice (30). Interestingly, there is evidence
that small islets are functionally superior to large ones following transplant (33,34). While
the physiological relevance of extra-islet β-cells in human pancreas remains to be
determined, the implications of this data are clear: as only intact islets are isolated for
transplant, a significant proportion of β-cell mass is currently discarded during human islet
transplant preparations, specifically from young donors. It was recently shown that islet
transplants from young donors generate superior results, although islet yields are poorer
compared to those from adults (35). Furthermore, we contend that this population of cells
contains the highest proportion of Ins+GLUT2- β-cell progenitors.
There was a surprisingly high degree of correlation between human and mouse in
the cellular population of interest, given that humans predominantly use GLUT1 (23,36,37)
and to a lesser extent GLUT3 (23) compared with GLUT2 for glucose transport when
compared with mice. Regardless, there is clearly a role for the glucose transporter-2 in
human pancreas. In both species, the population of Ins+Glut2- cells was present in high
proportion within the BCA compartment, decreasing only in late life. This implies that as
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long as there are BCA present, there is a capacity for tissue remodelling, and by extension,
tissue regeneration potential. Within the context of the complete BCA data however, the
Ins+Glut2- cell population does decrease in absolute terms as the total population of BCA
decreases with advancing age.
Evidence for β-cell proliferation in the human has, until recently, been limited to few
publications. Kassem et al demonstrated a low rate of proliferation, even in prenatal life
between 17-32 weeks gestation, the rate of human β-cell replication being only 3.2%, and
dropping further to 0.1% after 6 months of age (38). Detailed analyses by Meier et al
showed similar rates of human β-cell proliferation at birth of 2.5% (26,39). Interestingly,
that group also found higher rates of proliferation in small islets and β-cells found scattered
throughout the pancreas, and which decreased with advancing age. This same trend was
also shown by Jo et al, who concluded that large islets were created both from proliferation
as well as the coalescence of small clusters (27), and this cluster aggregation decreased with
age (40). By adulthood, there is the consensus that β-cell proliferation is extremely low, at
~0.2-0.5% (26,41–45). Rates of β-cell proliferation in rodents have been shown to be
similar to those in humans, with 1-3% β-cells replicating in the young rat (46), and only
~0.2% by adulthood (45,47). Our results are consistent with the reported rates of human βcell proliferation, as well as the observed variability between young human pancreata.
However, we have demonstrated the mouse β-cell proliferation rate to be higher than has
been reported by others.
A limitation to this study was availability of human tissue of specific ages. Mouse
pancreas showed some subtle, but potentially important, differences in the Ins+Glut2- cell
population within the BCA compartment during the immediate postnatal time period and
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up to weaning at 21d. However, the human samples we were able to analyze at a similar
developmental stage were limited to the month around birth only. Assessing human
pancreata around the time of weaning could potentially yield more information, although
given the variability in human genetics, lifestyle, and diet which is not found in laboratory
mice, this is conjecture. Direct comparison between human and mouse developmental
time-points contains inherent limitations, but even despite these restraints, the data
demonstrated high correlation. Due to constraints of sample size, we were not able to fully
analyze gender-specific differences in human pancreas.

Moreover, we did not have

information regarding whether the human female subjects we studied had ever been
pregnant. We did not find, however, any differences in any parameter studied (BCA
proportion, Ins+Glut2- cell population, or proliferation rate) between nulliparous and
multiparous female mice (48).
A key goal is to determine the physiological function of the Ins+Glut2- cells.. We have
demonstrated that these cells are present in substantial number during early postnatal life,
and that they decline with age. We postulate that this represents a reserve pool of cells
available for use in times of metabolic need and during endocrine pancreas maturation.
However, it is theoretically conceivable that β-cells instead undergo a normal cycle of
developmental transition in glucose-responsiveness, expressing Glut2 in high and low
proportion, although this phenomena would not likely change with age as shown here. Our
data would suggest that some of these Ins+Glut2- cells mature into Ins+Glut2+ cells, similar to
data proposed by Szabat et al (49), which showed that β-cells can transition between
Pdx1+Inslocells to Pdx1+Ins+ cells.
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The regenerative capacity of the endocrine pancreas decreases with advancing age.
This coincides with the decline in both Ins+Glut2- (putative progenitor) cells, and the
location in which they are predominantly found. Determining the role of these cells during
pathological circumstance or in times of metabolic demand will further elucidate a potential
role for this cell population in human health and pancreas development.

4.5
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CHAPTER 5

Ins+Glut2- β-cell Progenitors Contribute to Endocrine Pancreas Regeneration
after STZ Ablation in the Neonatal Mouse

Christine A. Beamish, Sofia Mehta, Brandon Cheuk, Brenda J. Strutt, and David J. Hill
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5.1

Introduction

The replication of pre-existing β-cells has been shown to be the prominent source of
cell turnover with age (1,2). However, the contribution of progenitor cells to β-cell mass
postnally is less understood, especially within the context of induced regeneration, such as
following pancreatic duct ligation (PDL) (3,4), or administration of the β-cell toxin
Streptozotocin (STZ) in the young rodent.
The glucose-transporter 2 (Glut2) is a transmembrane carrier protein that enables
glucose movement across cell membranes in liver, kidney, and pancreatic β-cells (5). The
existence of insulin-positive, Glut2-negative (Ins+Glut2-) cells was identified within the
pancreas over two decades ago (6), but a potential role for these cells was only recently
elucidated, with their characterization as pancreatic multi-potential progenitor cells in both
adult mouse and human islets and ducts (7). We have recently shown a significantly higher
number of these Ins+Glut2- cells in neonatal (postnatal day 7, D7) mice, within islets and
especially in extra-islet β-cell aggregates (BCA, <5 β-cells) (Chapter 3). These cells are
proliferative in vivo and in vitro, and a subset retain the capacity to differentiate into
pancreatic endocrine and ductal lineages. Moreover, these Ins+Glut2- cells are present in the
highest proportion during the neonatal time period and decrease with age in both mouse
and human pancreas (Chapter 4).
We (8–12) and others (13–15) have shown that young rodents retain the capacity to
partially regenerate β-cell mass after STZ ablation, but this regenerative potential is
mitigated in adulthood (15–17). As a glucose mimetic, STZ accesses the β-cell via Glut2 (18–
20) and causes β-cell necrosis within 24 h of administration by DNA alkylation and
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fragmentation (21); Glut2-/- mice then are resistant to the effects of STZ (20). Given the
numerous Ins+Glut2- progenitor cells present in BCA, and because the number of BCA are
highest in the neonatal time period and decrease with age (22) (Chapter 4), it is
hypothesized that neonatal rodents are able to regenerate their β-cell mass after STZ
administration in part from Ins+Glut2- cells spared exposure to the toxin. These Ins+Glut2cells then contribute to the regeneration of the endocrine pancreas. Using a pulse-chase
experiment in which a proportion of insulin+ cells are tagged with a human placental
alkaline phosphatase (HPAP) reporter followed by STZ administration and EdU
incorporation, we sought to lineage trace the fate of β-cells after ablation and during
regeneration, and to determine the contribution of Ins+Glut2- cells to this process.

5.2

Materials and methods

5.2.1

Animal experiments
All animal experimentation was performed with the approval of the animal use

ethics committee of Western University, London, ON and in accordance with guidelines of
the Canadian Council on Animal Care. Mice were maintained at the Animal Care Facility at
Lawson Health Research Institute, St Joseph Health Care, with free access to food and
water. (Ins2-cre/ERT)1Dam/J (RIPCreER) (23) mice was crossed with a LacZ reporter strain,
tagged with the human placental alkaline phosphatase (HPAP) gene (24) as a lineage tracing
technique to follow the β-cell. LacZ/HPAP+/- and RIPCreER+/- mice were purchased from
Jackson Laboratories (Bar Harbor, Maine). Mice were genotyped using ear/tail tissue
samples on D4.

Identification of double-positive mice was accomplished by PCR
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amplification using primers (Sigma Chemical, St Louis, MO) for the transgenes RIPCreER
(FW- aacctggatagtgaaacaggggc, RV- ttccatggagcgaacgacgagacc, 410 bp), and LacZ/HPAP
(FW- ccgcttcccatatgtggctctgtcc; RV- gcatgagctcagtgcggttccacac, 548bp). Transgenic control
experiments are shown in Supplemental Material and Figures S5.1 and S5.2, and details of
transgenic mouse strain development is described by Dor et al (23).
To induce β-cell tagging with the HPAP reporter, RIPCreER;Z/AP+/+ pups were
injected on D4 and D5 with 0.1 mg/g body weight tamoxifen (Sigma), from 20 mg/ml stock
prepared in corn oil (Sigma). Detail of the dosing strategy for neonatal mice is described in
Supplemental Material and Figure S5.3.

5.2.2

Induction of hyperglycemia by STZ
Streptozotocin (Sigma) was injected on D7 (100 μg/g body weight, in 0.1 M citrate

buffer). Transgene-negative litter mates were used as controls, and injected with corn oil
and 0.1 M citrate buffer (sham). Both STZ-treated and control mice were pulse labelled with
EdU on D8 (Invitrogen, Carlsbad, CA) (2 μl/g body weight of 10 mM stock) to assess β-cell
proliferation immediately following STZ and the transmission of the retained DNA label in
subsequent progeny. Glucose measurements were taken prior to sacrifice by tail vein blood
samples using a One Touch Ultra glucometer (Lifescan Inc, Milpitas, CA). An experimental
schematic is shown in Figure 5.1A, and the lineage-tracing paradigm in Figure 5.1B.
Mice were euthanized on D9, 14, 21, or 28. Pancreata were excised and prepared for
cryosectioning as described in Chapter 3.
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3
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Figure 5.1. Experimental schematic and lineage tracing paradigm.
(A) Transgenic RIPCreER;Z/AP+/+ mice were induced to express the reporter
protein HPAP after 2 injections of tamoxifen (TM) on postnatal days (D)4 and 5.
Streptozotocin was injected 2 days later (D7) to knock down a proportion of
insulin-expressing β-cells. EdU was injected on D8 to track the cells which
proliferated immediately following injury. Starting on D9 and up to 3 weeks later,
pancreata were dissected and analyzed for endocrine regeneration by the
presence and location of cells expressing of insulin, Glut2, HPAP, EdU, and Ki67.
(B) Lineage tracing paradigm using a pulse-chase method. Squares represent
islets, and circles represent unlabelled (white) and labelled (HPAP, black) β-cells.
After induction of HPAP by TM, β-cells were tracked during aging or following
injury. A decrease in the labelling index of HPAP indicates that β-cells form from
cells not expressing insulin initially, i.e., stem cell source (option 1). Conversely,
maintenance of the labelling index of HPAP indicates that β-cells form by selfduplication exclusively (option 2).
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5.2.3

Immunofluorescent histochemistry
Pancreas sections on slides were subjected to antigen retrieval using 95°C in 0.1 M

Tris-EDTA buffer for 30 min. Sections were permeabilized with 0.3% triton-X-100/PBS for 10
min before blocking with Background SNIPER (Biocare Medical, Concord, CA) for 8 min.
HPAP+ cells were identified using a mouse anti-HPAP antibody (Sigma, 1/500) or with a
rabbit anti-HPAP antibody (1/200, Abcam, Cambridge, UK); the mouse antibody required
the use of a mouse-on-mouse (MOM) staining kit (Vector Labs, Burlingame, CA) to block
endogenous immunoglobulins. Other antibodies utilized include mouse anti-human insulin
(Sigma, 1/2000), rabbit anti-human insulin (Santa Cruz Biotechnology, Santa Cruz CA,
1/200), and goat anti-human Glut2 (Santa Cruz, 1/100). Antibodies were diluted in Antibody
Diluting Solution (Life Technologies Inc, Carlsbad CA) and sections incubated overnight at
4°C. Fluorescent secondary antibodies were conjugated to 488/555/647 fluorophores (Life
Technologies, 1/500) appropriately matched to the primary antibody, and sections
incubated for 2 h at room temperature in the dark. Rates of cell proliferation were
determined by EdU incorporation using the EdU Click-It reaction kit (Life Technologies), and
by Ki67 immunostaining using a mouse anti-human Ki67 (BD Biosciences, Mississauga,
Canada, 1/50). Cells were counterstained with DAPI for quantification. Slides were imaged
on a Zeiss LSM 510 Duo Vario (Carl Zeiss Ltd, Oberkochen, Germany) confocal microscope at
the Biotron Institute, Western University using Zen software, and cells were counted
manually using the Zeiss LSM Image Browser.
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5.2.4

Beta cell morphometry
Two pancreas sections per mouse were immunostained with insulin as described

previously (10), and imaged and analyzed using Northern Eclipse software (v7.0; Empix
Imaging, Mississauga, ON, Canada). Total pancreas area was traced at 2.5x magnification,
and β-cell area traced at 40x magnification by insulin immunoreactivity. β-cell mass was
calculated by multiplying the fractional β-cell area by the weight of the pancreas (mg).

5.2.5

Statistical analysis
Data are expressed as percentage of insulin+ β-cells (% mean ± SEM). Changes

between means were determined using Student’s t-test or one- or two-way ANOVA,
followed by Tukey’s post-test where appropriate, and with an acceptable level of
significance of p < 0.05. Statistical analysis was performed using Graphpad Prism software
(v. 5.01, San Diego CA).

5.3

Results

5.3.1

Hyperglycemia and β-cell mass moderately regenerate after neonatal STZ

exposure
Hyperglycemia was noted 2 days after neonatal STZ treatment (i.e., D9), but blood
glucose recovered by D28 (Figure 5.2A, STZ vs control, p < 0.05). The presence of
hyperglycemia correlated with the extent of β-cell mass loss (Figure 5.2B), being greatest at
D14 and moderately recovering by D28 (Figure 5.2B, Control vs STZ, D14 and D21, p < 0.05).
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Figure 5.2. Induction of diabetes by STZ.
Glycemia (A, mmol/L) and β-cell mass (B) were measured in control (white
bars) and streptozotocin (STZ)-treated (black bars) mice over the first 4
weeks of life. Data were analyzed using 1-way ANOVA and Tukey’ s post-test
or student’s t-test. Data shown represent % Mean ± SEM. *, § p < 0.05, n > 5.
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5.3.2

Changes in the proportional presence of Ins+ cells after STZ
In control mice we previously showed that the proportional presence of Ins+ cells

within BCA (<5 β-cells) scattered throughout the pancreas significantly decreased with
advancing age (Chapter 4). Consistent with those results, the proportion of BCA decreased
in this model from D9-28 (Figure 5.3A, white bars, p < 0.05, D9 vs D14, 21, and 28). In small
islets (5-15 β-cells, Figure 5.3B) and large islets (>15 β-cells, Figure 5.3C) there was no
significant proportional change in the distribution of Ins+ cells with age over this range.
After STZ administration, the relative proportion of Ins+ cells present within small
islets significantly increased at D14 (Figure 5.3B, black bars, p < 0.05, D14 vs all other ages,
and p < 0.001, D14 C vs STZ). This correlated with a corresponding decrease in the
proportion of Ins+ cells present within large islet at D14 (Figure 5.3C, black bars, p < 0.05,
D14 vs D21). Unlike controls, there was no decrease in the proportional presence of Ins +
cells in BCA following STZ treatment after D9, and instead there was an increase in the
proportional presence of Ins+ cells in both BCA (Figure 5.3A, p < 0.05 D9 and D14 vs D28
black bars and D28 STZ vs Control) and small islet proportion at D28 (Figure 5.3B, p < 0.05,
D28 STZ vs Control). Thus, while the maximal destruction of β-cells seen at D14 following
STZ administration is likely to have caused the proportional shift of Ins+ cells from large to
small islet categories, there was significant regeneration of β-cell mass by D28 occurring in
the BCA and small islet compartments. In addition, the normal age-related decrease in the
proportion of Ins+ cells located in BCA was prevented following STZ treatment, suggesting
that an early expansion of Ins+ cell number occurred in BCA shortly after administration of
STZ.
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Figure 5.3. Proportional β-cell location changes after STZ administration.
Proportional presence of β-cells within β-cell aggregates (BCA, <5 β-cells, A),
small islets (5-15 β-cells, B), and large islets (>15 β-cells, C) in control (white
bars) and streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks
of life. Data shown represent % Mean ± SEM, §,*, ɸ p < 0.05, §§,**p < 0.005,
n > 5.
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5.3.3

β-cell proliferation increases after injury and during regeneration
The presence of β-cell proliferation shortly after STZ administration was measured

by injection of EdU on D8. The labeling of Ins+ cell nuclei with EdU was tracked using
immunohistochemistry over the course of the study on the assumption that the pulse label
of EdU would be detectable in subsequent β-cell progeny at later time points (Figure 5.4A).
In control mice, the percent labeling of β-cells with EdU was greater in BCA and small islets
than in large islets, and a significant peak in the population of EdU-tagged cells was
observed at D21 (Figure 5.4Ai, p < 0.0005, D21 vs other ages, and Figure 5.4Aii, p < 0.005,
D21 vs other ages), before declining at D28. No significant changes in the relative
proportion of EdU-labeled β-cell population were observed in large islets with age (Figure
5.4Aiii).
After treatment with STZ there was a trend towards an increase in the percent EdU
labeling of Ins+ cells in the BCA at D14, a week earlier than was shown to occur in control
pancreata, although this did not reach significance (Figure 5.4Ai, black bars). There was a
significant increase in Ins+EdU+ cells within small islets at D21, which disappeared by D28,
similar to controls (Figure 5.4Aii, black bars, D21 vs D28). A surge in β-cell proliferation
within BCA following STZ treatment might be expected to result in many of the BCA
expanding to be counted as small or large islets at later time points, thus explaining the
apparent paucity of EdU-labeled cells in the BCA fraction at later ages. In support of this
possibility, a significant increase in the proportional presence of EdU-labeled Ins+ cells was
also observed in large islets following treatment with STZ at D28 (Figure 5.4Aiii, black bars,
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Figure 5.4. Beta cells proliferate to regenerate endocrine cell mass following
damage.
Proportional presence of β-cells within β-cell aggregates (BCA, <5 β-cells, i), small
islets (5-15 β-cells, ii) and large islets (>15 β-cells, iii) in control (white bars) and
streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks of life.
(A) EdU. β-cell proliferation immediately following injury was measured by EdU
incorporation, and retained in cells during aging and regeneration (B) KI67. β-cell
proliferation at the time of euthanasia was measured by Ki67 immunostaining
within Ins+ cells. Data were analyzed using 1-way ANOVA and Tukey’s post-test or
student’s t-test. Data expressed as % Mean ± SEM, §,*p < 0.05, **p < 0.005, ***p
< 0.0005.
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D28 vs D9). This suggests that the pulse label of EdU within β-cells could be ‘chased’ into
larger islets with time during the recovery of β-cell number after STZ treatment.
Assessment of β-cell proliferation at the time of euthanasia was measured by Ki67
immunoreactivity within Ins+ cells. In control animals, β-cells within BCA demonstrated a
greater proportional presence of Ki67+ cells than either small or large islets at D9 (Figure
5.4Bi-iii, white bars, p <0.05), and which declined at later ages (Figure 5.4Bi, white bars, p <
0.05 D9 vs D14-28). There was also an increase in Ins+Ki67+ cells within large islets at D28
relative to other ages (Figure 5.4Biii, white bars, p < 0.005), likely due to a remodelling of
the endocrine pancreas following weaning.
One week after STZ administration (i.e., D14), β-cell proliferation as detected using
Ki67 presence had increased in both small and large islets by 2.6- and 2.1-fold, respectively
relative to controls (Figure 5.4Bii and Figure 5.4Biii, p < 0.05, D14, STZ vs control). In BCA,
Ki67 presence remained in high proportion until after D21, although this was not significant
(Figure 5.4Bi, black bars). Combined with the EdU proliferation data, the increased rate of
β-cell proliferation detected in small and large islets after STZ could have resulted, in part,
from the prior expansion of the β-cell population within at least some BCA. To determine if
this new population of β-cells could also have arisen from a progenitor cell population not
previously expressing insulin within either BCA or islets we next employed lineage-tagging
of β-cells, either with or without STZ treatment.
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5.3.4

The proportion of β-cells genetically tagged with HPAP increases with postnatal

development, and is altered after STZ
In control mice, 22.2 ± 3.2% of β-cells within BCA (Figure 5.5A, horizontal bar)
expressed HPAP at D9 (baseline), compared with 28.5 ± 3.1% of β-cells in small islets (Figure
5.5A, hatched bar) and 31.0 ± 2.8% of β-cells within large islets (Figure 5.5A, vertical bar).
Representative images are shown in Figure 5.5B, with β-cells immunostained for insulin
(green) and HPAP (red). In control mice, the proportion of HPAP-tagged β-cells in all
compartments more than doubled over the early postnatal time period (Figure 5.5C, BCA,
white bars, p < 0.05, D28 vs D9, D14; Figure 5.5D, small islets, p < 0.05, D21 vs D9; Figure
5.5E, large islets, p < 0.05, D21 & D28 vs D9).
Following STZ administration, the proportion of HPAP tagged β-cells in BCA did not
change throughout the study period, and by D28 was significantly lower than in controls
(Figure 5.5C, black bars, p < 0.001 D28 STZ vs C). A similar profile was seen in both small and
large islets (Figure 5.5D and 5.5E) with a reduced presence of HPAP-tagged cells by D21 and
D28 after STZ treatment (Figure 5.5C, p < 0.001 D28 Control vs STZ; Figure 5.5D, p < 0.05,
D21 Control vs STZ; Figure 5.5E, p < 0.05, D28 Control vs STZ). This implies that 3 weeks
after administration of STZ, a greater proportion of β-cells were present in each of the three
cellular compartments that had not derived from pre-existing β-cells, relative to control
animals. This would be consistent with the regeneration of β-cells being derived in part
from non-insulin or low-insulin expressing progenitors within both BCA and islets.
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Figure 5.5. Lineage tracing of the β-cell during postnatal development and
regeneration after STZ.
Tagging proportion of the reporter protein human placental alkaline phosphatase
(HPAP) within β-cells at D9 (A) and over time (C-E) within β-cell aggregates (BCA,
<5 β-cells, A, horizontal bars, and C), small islets (5-15 β-cells, A, hatched bars, and
D) and large islets (>15 β-cells, A, vertical bars, and E). Changes in proportional
presence of HPAP-tagged β-cells within Control (white bars) and Streptozotocin
(STZ)-treated mice (black bars) were noted over the first 4 weeks of life depending
on size compartment (C-E). Representative image of HPAP- tagged (B, green) βcells (insulin, red) in a D28 large islet. Data were analyzed using 1-way ANOVA and
Tukey’s post-test or student’s t-test, and data expressed as % Mean ± SEM. (C)
control **D28 vs D9 and D14, §§§ D28 control vs STZ; (D) control *D9 vs D21, §
D21 control vs STZ; (E) control *D21 and D28 vs D9, § D28 control vs STZ. §,*p <
0.05, **p < 0.005, §§§ p < 0.0005. Size bar denotes 50 μm, n > 3.
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5.3.5

Ins+Glut2- cell proportion increases following STZ treatment
We previously showed that the proportional presence of Ins +Glut2- cells decreased

with age, representing ~3.6% of total β-cells at D7 but <0.7% by 3 months, with the majority
of these cells present in BCA (Chapter 4). In the present model, and consistent with earlier
findings, the proportion of Ins+ cells that did not show the presence of Glut2 was 10-fold
greater in BCA than in islets (Figure 5.6A), and was maintained at this proportion until D28
when there was a significant decline (Figure 5.6A, p < 0.05 D21 vs D28). There was a nonsignificant, gradual decline in this population in large islets over the same range (Figure
5.6C, white bars, D9-28).
Following treatment with STZ the proportional presence of Ins+Glut2- cells within
BCA did not alter, but in small and large islets their presence significantly increased relative
to controls at D14 (Figure 5.6B,C, black bars, p < 0.05 D14 vs D28). Thereafter, the
population disappeared by D28 in small and large islets (Figure 5.6B, C, D28, Control vs STZ)
but was maintained in BCA (Figure 5.6A, D28, Control vs STZ). This implies that the
Ins+Glut2- cells were spared STZ-mediated destruction in all β-cell size compartments, and
contributed to regeneration in islets at D14, presumably by the differentiation into
Ins+Glut2+ β-cells. Within BCA however, the lack of increase in cell proportion may have
been overshadowed by the complex and dynamic changes occurring during both
development and regeneration after injury. These data are consistent with a return to
euglycemia in STZ-treated mice by D28 and a moderate recovery of β-cell mass.
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Figure 5.6. Ins+Glut2- cell proportion increases after STZ administration.
Proportional presence of Ins+Glut2- cells within β-cell aggregates (BCA, <5 β-cells, A),
small islets (5-15 β-cells, B) and large islets (>15 β-cells, C) in control (white bars)
and streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks of life. Data
were analyzed using 1-way Anova and Tukey’s post-test or student’s t-test. Data
expressed as % Mean ± SEM. (A) white bars, *D28 vs D21. (B)(C) black bars, D14 vs
D9; (B)(C) D28 C vs STZ. §,* p< 0.05, n > 3.
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5.4

Discussion
It was demonstrated here that modest endocrine regeneration is possible in the

neonatal rodent pancreas. Consistent with data presented by others, it was shown that
most β-cells indeed arise from pre-existing β-cells after endocrine pancreas damage induced
by STZ. It was further demonstrated that some of the β-cells that recovered during
endocrine cell regeneration arose from a subtype of pancreas progenitor cell. These
progenitor cells express insulin but lack Glut2. The finding that these cells normally diminish
in number with advancing age provides a basis that may explain the enhanced β-cell
regenerative capacity in the young which is not evident in older mice.
For many decades, STZ has been used extensively as a model for type I diabetes
research and has been the agent of choice for the induction of β-cell damage due to its
relative stability during administration (25). While newer damage models such as those
using tetracycline-dependent diphtheria-toxin (26,27) have recently gained favour, we have
learned much information from STZ-administration regarding β-cell death (and its corollary,
regeneration), pancreas development, and diabetes progression. Furthermore, while the
diphtheria-toxin based ablation method exhibits higher specificity for β-cell death without
confounding effects from inflammation or non-pancreatic organ damage, diabetes itself
presents as an inflammatory condition at the time of onset, and in this way STZ
administration in mice mimics disease progression in humans more closely than other
methods. A limitation of the use of STZ as a means of effecting diabetes is that due to
differences in human pancreatic glucose transporter utilization of GLUT1/3 over GLUT2, STZ

169

administration in rodents cannot identically parallel diabetes progression in humans, as
human endocrine pancreata are less susceptible to the effects of the drug (28,29).
The ability to recover β-cell mass after STZ is age-related, with moderate
regeneration after subtotal ablation in young, but not old, rodents. We (Chapter 4) and
others (22,30) have shown that the proportion of β-cells present in single cells and small
clusters decrease with advancing age, concomitant with islet maturation and coalescence
into large islets. This coincides with a transition in the proportion of Ins +Glut2- β-cells during
neonatal life, a time of significant endocrine pancreas remodelling (31–33). Indeed, the
finding that there was an increase in BCA and small islet proportion after STZ demonstrates
the validity of the diabetes model: these cells were spared STZ-mediated death, with the
majority of β-cells instead dying from within islets [where mature β-cells reside (34)]. As
others have also illustrated, rodents exposed to STZ during neonatal life consequently
(re)develop hyperglycemia in adulthood (10,17). This is perhaps explained by the loss of the
putative “reserve β-cell pool” (i.e., the Ins+Glut2- cells, present in early life), which were
recruited to maintain normoglycemia following STZ-mediated injury, and were therefore
unable to contribute to normal tissue turnover thereafter. Conceivably, in humans similar
mechanisms may contribute to misalignment of β-cell supply and demand, as observed in
instances such as obesity, pregnancy, or autoimmunity.
β-cell proliferation is the primary mode of β-cell replacement in the postnatal
pancreas. In this model, Ki67 expression doubled within Ins+ cells present in small and large
islets 7 days following STZ administration. These data are, although slightly lower, broadly
aligned with data shown by others using older mice (15). The difference may be resulting
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from both increased (baseline) proliferation in early life, and some β-cell regeneration from
Ins+Glut2- cell maturation, and not cell proliferation exclusively. Results from the Ki67
analysis were otherwise as expected, but data from EdU incorporation yielded some
interesting insights. First, it was shown that the β-cells present in BCA and small islets which
proliferated early in development peaked at D21 (i.e., weaning), and the population
thereafter declined. This indicates that these cells either died, or were incorporated into
larger, proto-typical islets. After STZ however, and in agreement with the regeneration
model, these EdU+ β-cells peaked at D21 in small islets and thereafter disappeared from this
compartment. Subsequently there was a peak of EdU+ β-cells at D28 in large islets,
indicating that the proliferative cells present in the early postnatal pancreas could be
chased into large islets.
Based on the lineage tracing paradigm established by others (23,35), it was predicted
that if β-cells arose from stem cells, there would be a dilution in lineage tag (HPAP) over the
course of study. The corollary being that if there was no change in lineage tagging
frequency, then β-cells arose from pre-existing β-cells present at the time of induction.
Interestingly, in the present model, HPAP expression increased during early endocrine
development, which may be interpreted as β-cells primarily arising from self-duplication
postnatally. Conversely, after STZ exposure and during recovery, the reporter protein was
maintained at the initial tagging proportion in all β-cell grouping compartments, indicating
that a significant proportion of β-cells arose from cells not tagged initially (i.e. new β-cells).
Differential interpretations of this phenomenon are that (i) the reporter labelling
continues longer than the two-day window between tamoxifen injection and STZ exposure

171

(36); (ii) that β-cells arose from cells that previously did not greatly express insulin at D4-5
and therefore did not label with HPAP, but could still have been an immature β-cell subtype;
(iii) STZ preferentially destroyed HPAP-labelled β-cells; or (iv) that the HPAP-tagged a highly
proliferative sub-population of β-cells present in early postnatal life. We can dismiss
scenario (i), as this would be true only if there was an increase in reporter protein
proportion shortly after tamoxifen administration. Since the reporter protein continued to
increase thereafter in control, but not STZ-treated mice, we can conclude this is not the
cause. Evidence from Reinert et al showed that after high doses of tamoxifen, there was
indeed continued reporter labelling long after the expected window for cell tagging;
however, our dosing regime was similar to the low dose model in that report (37), and
which could be expected to account for only ~5% increase in reporter labelling shortly (<1
week) after administration. In the second and third options, considering that only mature βcells demonstrate active transcription of the insulin promoter, these options are
theoretically conceivable, as there was a difference in labelling index between BCA and
islets at D9, albeit non-significantly. HPAP itself would not (theoretically) render those βcells more susceptible to STZ-mediated damage, but by the fact that mature cells would tag
with HPAP and therefore express high Glut2 presence, these are de facto linked. The fourth
option is also theoretically possible, given the increase in β-cell mass concomitant with
somatic growth during this stage in life, and could be in fact due to the Ins +Glut2- cell
population, although this was not confirmed. As evidenced here, the established lineagetracing paradigm did not originally allow for the possibility that the putative stem cell
source could also express insulin.
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These lineage-labelling trends are partly consistent with aspects of other studies. Liu et
al found that there was a substantial increase in reporter protein frequency with aging, as
was shown here, but also after STZ (35). That study showed an increase in PLAP+ [HPAP] Ins+
cells, which the authors contend arose from β-cell progenitor cells which lacked insulin but
retained the β-cell reporter HPAP.

The authors found that these HPAP+Ins- cells

demonstrated an immature phenotype, with positive expression of Pdx1 and MafB, but
being negative for both Nkx6.1 and Glut2, and which were proliferative after STZ
administration. The relative proportion of these cells remaining after injury was found to be
0.1% of all insulin+ (β-) cells. Taken together, the authors concluded that these cells
represented β-cell progenitors which, by virtue of expressing the β-cell reporter, must have
exhibited active insulin promoters at the time of induction. Only after injury or aging, and
hence after differentiation to proto-typical mature β-cells, was insulin re-expressed, and
which accounted for the increase in HPAP+ labelled Ins+ cells with increased age.
The data presented here also partly align with a study by Dor et al, which demonstrated
no change in lineage reporter expression during normal aging, nor after insult induced by
partial pancreatectomy (23). All three studies used the same mouse strain for analyses, but
demonstrated differences in data trends and interpretation.

We assert that these

differences are directly related to age, as those previous papers are used adult mice, and as
such, the population of β-cells available was largely established and functional. One point of
discrepancy is the difference in function between β-cells located within and outside of
islets. Multiple groups have previously purported differences in function based on location
of β-cells (38–43), but the definitive evidence from lineage-tracing experiments by Dor et al
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demonstrated no differences in β-cell lineage labelling frequency as stratified by location
(23), thus ending the debate. The defining difference in our study is the examination of βcells not just by location, but crucially also at a young age. We have shown that the β-cells
located in small clusters outside of the islet to be substantially different than those located
within it, in terms of proliferation rate, lineage-label tagging frequency, and Glut2
expression.
While multiple papers have sought to determine the role of (unidentified) stem cells to
endocrine regeneration, we questioned specifically the contribution of Ins +Glut2- cells
during this process. As has been shown previously, the β-cells that can be targeted by STZ
must express Glut2 (20), and as previously demonstrated, the population of Ins+Glut2- cells
decrease with age (Chapter 4). We show that under control (non-diabetic) conditions, the
proportion of Ins+Glut2- cells present in both BCA and islets decrease in the first 4 weeks of
life. In agreement with our hypothesis, these cells increased in relative proportion in both
islet compartments in the immediate time-course following STZ exposure indicating that
they were spared destruction. This was followed by a dramatic reduction in the cell
population in islets after weaning, which we speculate to illustrate a maturation of these
cells into functional, glucose-responsive β-cells to compensate for the loss after damage.
However, this assumption requires a conclusive assessment of cells present at the time of
damage versus during regeneration, and thus correlating the HPAP tagged β-cells with the
(lack of) expression of Glut2 would theoretically illustrate this phenomenon. Attempts to
track the Ins+Glut2- cells using HPAP were unsuccessful, as the expected frequency of
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HPAP+Ins+Glut2- cells in control mice at P7 was only ~0.3% of total β-cells in islets and <3%
in BCA; furthermore, the BCA proportion decreases shortly thereafter in control mice.
We sought to answer three questions in this study: first, do Ins +Glut2- cells survive STZ
mediated death?; second, do these cells contribute to endocrine regeneration following
damage?; and third, what is the origin of these Ins+Glut2- cells? However, limitations arose
which made full assessment of all three questions difficult. The first is that the baseline
(control) conditions are in fact, constantly changing. During the first month of life in
rodents, there is significant growth of β-cells concomitant with growth of the pancreas, and
which has demonstrated an even more pronounced change around the time of weaning.
Overlaying this rapidly changing phase with severe insult and subsequent regeneration
yields a considerable number of variables.
The second limitation was that the pharmacological agents used to (independently) tag
and destroy β-cells are likely targeting different populations of cells. We anticipated that the
Ins+Glut2- cells would have a decreased β-cell-tagging frequency and would be selectively
spared ablation by STZ. However, this lineage tracing technique relies on general trends
only and which has made interpretation difficult, especially in the absence of a definitive
lineage label for the Ins+Glut2- cells. It would be useful to examine a cohort of mice weeks
or months after STZ ablation to determine if the Ins+Glut2- cells are replenished in
adulthood, and if so, from which compartment. It would be also informative to determine if
the lineage-label frequency continues to increase after D28.
Despite these limitations however, we show substantial changes in proliferative
subpopulations and in BCA proportion supporting our hypothesis that some β-cells have
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both survived STZ-mediated death, and subsequently matured from Ins+Glut2- cells into
Ins+Glut2+ cells. It was also demonstrated that these Ins+Glut2- cells were primarily located
in BCA, and coalesced from the BCA into islets. Therefore, the temporally-defined nature of
STZ-mediated partial regeneration in the young rodent can be attributed in part to the
presence of Ins+Glut2- β-cells, which normally diminish with age and are therefore unable to
aid in the rescue of the endocrine pancreas if β-cells are ablated after this window of time.
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CHAPTER 6

Summary and Perspectives
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6.1

Summary of findings
Given the improvements in islet transplant procedures, with many patients

experiencing >3 years post-transplant without exogenous insulin injections, a sustained
improvement in glycemia, and a reduction in diabetes-related complications (1), we sought
to find alternate sources of cells, given the paucity of β-cells available from cadaveric
donors. We dedifferentiated isolated islets to duct-like cells based on an established
protocol (2), with the intention of enhancing cell number while in the dedifferentiated
state, then redifferentiating the cells back to an insulin + condition.
Our results were consistent with those found by Yuan et al (2), demonstrating a
substantial increase in the number of cytokeratin-19 (CK19) expressing cells, as well as a
loss in islet morphology, insulin hormone presence, and β-cell and islet-specific
transcription factors (Chapter 2). However, and similar to findings by others, we were
unable to effect significant redifferentiation to insulin+ cells using Matrigel, insulin-like
growth factor –II (IGF-II) and keratinocyte growth factor (KGF), or following the addition of
trophic factors such as gastrin, nicotinamide, epidermal growth factor (EGF), nor with other
established redifferentiation protocols (3,4), co-culture with endothelial cells in vitro, or
after transplantation of the cells into immune-deficient mice. This was surprising, given the
substantial production of ductal cells. As β-cells compose ~80% of mouse islet cell
proportion, we next sought to determine the cell type of origin during in vitro
dedifferentiation and hypothesized that it would involve the β-cell.
Lineage tracing of the β-cell using the non-inducible RIPCre;Z/AP mouse model
revealed that during the dedifferentiation process only a rare minority of β-cells survive
181

culture and adopt a duct-like cell phenotype (Chapter 3), which explained the relative rarity
of insulin-producing β-cells generated after redifferentiation techniques. We sought to
characterize those rare β-cells capable of differentiation, and found evidence in support of a
progenitor cell population present in mouse and human islets which express insulin, albeit
at lower hormone levels than is present in fully mature cells. These cells were previously
described as having decreased expression of key transcription factors such as Nkx6.1 and
Pdx1, increased expression of Ngn3, and, importantly, they can be identified by the lack of
the glucose-transporter 2 (Glut2) (5). We showed that these Ins+Glut2- cells are present in
the neonatal mouse islet and provided evidence that the same cells were responsible for in
vitro differentiation to duct-like cells, and could alternatively be differentiated to neurallineage cells (Chapter 3). Importantly, the relative proportion of these cells is higher in the
neonatal islet than is present within the adult islet, and furthermore, that there is a
significant population of these cells in the β-cell aggregates (<5 β-cells, BCA) that exist
outside of the proto-typical islet (Chapter 3). Not all Ins+Glut2- β-cells were capable of multilineage differentiation however, with many more Ins+Glut2- β-cells present in the neonatal
pancreas than can demonstrate the capacity for altered cell fate. This result provides
further evidence that β-cells exist within a spectrum of functional and developmental
heterogeneity.
We consequently sought to identify whether the population of Ins+GLUT2- cells
could be identified in the human pancreas, specifically within the BCA compartment, and
how the population changed with age in both mouse and human. We showed that
Ins+GLUT2- β-cells were present in very high proportion in human BCA, and that in both

182

human and mouse, these cells decreased with age, concomitant with a decrease in BCA
proportion and proliferation rate (Chapter 4). Our analysis of β-cell proliferation in the
human and mouse pancreas was consistent with data from previous publications, and
showed that the proliferative potential of the Ins+GLUT2- cells declines significantly before
adulthood is reached, further contributing to the loss of regenerative potential with age.
While this immunohistochemical study did not directly illustrate the functional capacity of
the Ins+GLUT2- in terms of multi-potential fate decisions, data from the van der Kooy group
do show that these cells are retained in (at least) islets during adulthood (3,5), and provide
a clear direction for future research.
We finally sought to assess the role of Ins+Glut2- β-cells in the context of a diabetes
model. It has been long known that β-cells can moderately recover their cellular mass after
exposure to the β-cell toxin streptozotocin (STZ) in the neonatal time period, but not as
adults. We theorized that because STZ accesses the β-cell via Glut2, and because there is a
significant proportion of Ins+Glut2- β-cells in the neonate and not in the adult pancreas, that
neonatal endocrine pancreas could regenerate after STZ exposure because a significant
component of β-cell mass is not damaged and can subsequently re-establish
normoglycemia. We therefore examined the changes in β-cell mass, β-cell proliferation, and
proportional changes in Ins+Glut2- cells during the first month of life, with and without STZ,
while lineage tracing the β-cell using the inducible RIPCreER;Z/AP+/+ mouse model.
We found that there was indeed modest β-cell regeneration in the early postnatal
time period after neonatal STZ administration. We also showed that there was retention of
BCA, and an increase in proportion of specifically Ins+Glut2- cells within islets during the
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regenerative phase, which significantly decreased in islets 3 weeks after damage, which is
likely to indicate a maturation of these progenitor cells into glucose-responsive β-cells.
Interestingly, the origin of the β-cells present after 3 weeks in the early postnatal mouse
pancreas indicated self-duplication as their main source in the normal developmental
program, but not during regeneration as indicated by the altered trends in β-cell labelling
with HPAP. Explanations of these opposing trends point to the presence of immature β-cells
contributing to regeneration after β-cell loss, but not during normal postnatal development.
Their contribution to β-cell regeneration seems to be age-related, as these trends only
partially align with similar experiments performed in adult mice (6,7). However, further
analysis at later ages may yield further insights. Overall, this project illustrated the extensive
changes that occur in the endocrine pancreas during the neonatal time period, in terms of
β-cell phenotype, anatomical location, and proliferative capacity.
While we did not generate significant numbers of β-cells as a potential donor source
for use in transplant, we were able to identify a novel subset of progenitor cells in both the
mouse and human pancreas, complementing evidence previously published which has not
been replicated before now. We have contributed knowledge about these progenitor cells
by showing that their predominant location is, in fact, outside of the islet, and their number
significantly decrease with age. These findings may have implications in altering transplant
criteria, and on a broader scale, illustrate a new parameter for study in pancreas
maturation. Moreover, these results identify subpopulations of cells which may be
responsible for adaptive growth during times of increased metabolic need such as
pregnancy or diabetes.
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6.2

Progenitor cell activation versus β-cell replication: the debate revisited
Much evidence has supported hypotheses favouring both progenitor cell

differentiation and pre-existing β-cell replication as the mode for regeneration of endocrine
cell mass during normal development, aging, and after injury. However, the breadth of
convincing data for both arguments suggests that the timing of injury, as well as the manner
and severity of damage play important roles in dictating the degree of endocrine
regeneration, and which mechanism is responsible, i.e. pre-existing β-cell replication versus
progenitor cell recruitment, activation, or cell trans-differentiation. This was illustrated by a
study by Criscimanna and colleagues, which used models to destroy either “all” acinar and
endocrine tissues (but not ductal cells) utilizing PdxCre;R26DTR mice, or the less-severe
damage model created using ElaCre- ERT2;R26DTR mice, which selectively destroys only
acinar tissue (8). The authors found that in the Pdx1-diptheria toxin model, 97% of all
endocrine and acinar cells were destroyed, and both recovered by approximately 60%
within 4 weeks, which was shown to be a result of the recapitulation of the endocrine
developmental program. In contrast, knocking out the acinar compartment alone elicited
trans-differentiation from ductal to acinar cells. That study is complemented by evidence
from Thorel et al, which showed that under extreme β-cell loss, α-cells could transdifferentiate to become insulin-producing cells (9).
These data would indicate that under “normal” circumstances, i.e. aging, pregnancy,
obesity, and even some damage models, β-cell (re)generation occurs through proliferation
of existing cells exclusively. The trigger, or degree of damage, which elicits some other
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mode of tissue regeneration, either from resident progenitor cell activation, or transdifferentiation from other tissue types, remains to be determined in both its scale and
ability to regenerate functional endocrine mass. Indeed, nearly 2 decades ago this concept
was purported (10); however, in the absence of lineage-tracing technology, and under the
current and now-canonical model of exclusive β-cell self-duplication, it was dismissed.
Superimposed on this, of course, is the role of autoimmunity in diabetes; the loss of
β-cell mass and attempts at regeneration, no matter whether β-cells are produced from a
progenitor cell source or by self-duplication, being countered by T-cell-mediated
destruction. This has been likened to a bathtub filling with water: new sources of β-cells,
from replication or progenitor cell source, contribute new water to the tub from the faucet,
while rates of cell death oppose this, and water flows out of the drain. In normal physiology,
these two forces are roughly equal, and the net result is a maintenance of β-cell mass
and/or function, which allows glucose homeostasis to be achieved. However, in the case of
diabetes, the “drain” gets bigger (i.e., increased β-cell death), which far exceeds the
potential of “new water” (insufficient β-cell regeneration and/or extremely slow β-cell
proliferation), and hyperglycemia results (11). Furthermore, even when β-cell regeneration
was shown to occur, anti-rejection drugs commonly used in the transplant setting mitigated
the regenerative process (12).

Whether the Ins+GLUT2- cells are also targeted for

destruction during T1D disease progression has yet to be ascertained, and the data
presented here provides a novel arena for investigation.
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6.3

Progenitor cells and β-cells exist within a spectrum of maturity
The concept that stem/progenitor cells may express mature markers, such as insulin,

opens up the field to semantic arguments regarding what constitutes a stem cell; the
present conclusion hinging on the premise that cell state can be assigned according to a
binary code. Our findings suggest that a more appropriate assessment of cell maturity may
include the concept of a continuum of cell “stem-ness” (or its corollary, maturity). As was
noted by Murtaugh, it also contributes to the long-held debate over stem cell
differentiation versus

replication of pre-existing cell with regards to generation of

postnatally-formed β-cells: it is both, in the same cell; or as Murtaugh states, “yes” [to both
questions] (13). Furthermore, if progenitor cells can express insulin, substantial work by
Melton (7) and Kushner (14), that

β-cells are formed postnatally by self-duplication

exclusively, are reconciled with the evidence of progenitor cell origin (5). In other words, the
contribution from (the Ins+Glut2-) progenitor β-cells is masked because they are (mis)
interpreted to be mature, insulin-expressing β-cells.
The concept of β-cell heterogeneity has recently emerged as a major contender in
understanding the population of cells available for clinical use, either for retention of β-cells
in vivo or for transplant procedures.

It may be a philosophical argument, but is

heterogeneity defined by cell maturity only? Is cell maturity defined exclusively by age?
And, could β-cell anatomical location also dictate its function?
It is well known that mouse β-cells in the immediate postnatal period are immature,
with poor GSIS and lower expression of Glut2 compared to adult β-cells (15–17). It was
recently reported that neonatal β-cells require a glucose threshold for maturation, which
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can be shown by gene expression changes in Urocortin3 (Ucn3) (18). This peptide hormone
has been shown to be expressed in mature mouse β-cells after P7, and acts as a maturation
marker (19). Similarly, human infant β-cells demonstrate some plasticity in insulin secretory
machinery not seen in the adult state (20).
β-cells that reside outside of islets have long been thought to reflect newly
generated, and hence immature, cells (10,21–25). However, none of these publications
utilized lineage tracing, and hence none determined cell origin. The dogmatic publication
by Dor et al then showed that there was no significant difference in lineage labelling index
between β-cells found within and outside of islets during aging or after injury in the adult
pancreas (7), implying that the anatomical location of β-cells was irrelevant to function or
maturity. However, recent work has shown that, indeed, β-cells found in clusters outside of
the islet demonstrate lower levels of Ucn3, especially in the young pancreas (18).
Furthermore, β-cells outside of islets lack the exquisitely intimate contact with both the
vascular network and innervation patterns as found in islets, as well as cell-cell contact with
other β-cells for communication (26). We (Chapter 4) and others (27,28) have shown that
age influences location of endocrine cell mass, concomitant with maturation. Taken
together, it would appear that β-cell function, maturity, and location are intrinsically
conflated.
For completeness this concept requires an investigation into the origin of the Glut2negative β-cells, to test the assumption that “immature” equates to “newly generated”
cells. The abundant evidence in the literature suggests that “all” (if not the majority) of new
β-cells present during aging or after injury are derived from pre-existing β-cells. It is

188

presently unknown if the Ins+Glut2- β-cells act as facultative progenitor cells in vivo.
However, we do know that in the absence of pathologic metabolic challenge, the presence
of multi-potential β-cells is extremely rare in the adult mouse and human pancreas. As
posited in Chapter 5, the Ins+Glut2- cells may represent a reserve pool of β-cells present in
the postnatal pancreas, available for recruitment and/or utilization during remodelling of
the endocrine compartment in early life. This reserve pool theory then implies that there is
a finite number of Ins+Glut2- β-cells, and perhaps, all β-cells, in the postnatal pancreas. Data
from the Melton laboratory supports the idea of a set number of progenitor cells in the
young, and a final β-cell number in the established pancreas (7,29). Our findings suggest
that Ins+Glut2- cells represent a part of this progenitor pool. Differential utilization of “true”
stem cells within this population (the rare, multi-potential cells versus the majority of
Ins+Glut2- β-cells present in the early postnatal pancreas) as a means of changing the
ultimate size of the β-cell pool remains to be examined. We can speculate that the majority
of Ins+Glut2- cells present in the young, mammalian pancreas normally mature directly into
Ins+Glut2+ cells, and the multi-potential cells only undergo lineage expansion under
pathological situations of β-cell loss. The signals required for activation of these stem cells in
the adult context, and whether they can realistically contribute to β-cell regeneration to
rectify hyperglycemia, is currently unknown. It was shown that these Ins+GLUT2- cells
normally ceased to be proliferative in vivo by adulthood (Chapter 4), but in vitro
manipulation of β-cells was shown to select for a population of cells capable of
differentiation towards proliferative “neurospheres”, which after transplantation into
diabetic mice was shown to be effective at combating glycemic excursions (5). We were
also able to replicate these experiments from young mice, generating neurospheres from β189

cells present in neonatal islets and BCA (Chapter 3). Moreover, the evidence that a minority
of β-cells and their progeny have been shown to change cell fate in vivo, by expressing
proteins other than insulin after injury or a long chase (5,6) (Chapter 3), suggests that βcells do demonstrate some plasticity in vivo. However, the minority cell presence or activity
in vivo during diabetes progression or treatment suggests that there are strong mechanisms
within the body to control growth, in addition to known mechanisms within β-cells
themselves which limit proliferation, such as accumulation of p16 INK4a. Indeed, if the
Ins+GLUT2- cells are to have any meaningful role in human diabetes mitigation, they likely
require manipulation in vitro before they can be re-introduced into a mammalian system.
Identification of these progenitor cells is therefore paramount, and the roadmap of
what might define a β-specific progenitor cell is extensive. Putative β-cell progenitors have
been proposed to express higher levels of early endocrine transcription factors such as
Pdx1, Ngn3 and MafB (5,30) and low/absent expression levels of genes indicative of mature
gene function, including Nkx6.1 and Glut2 (6,31). Some β-cells have been shown to be
capable of transitioning into mature β-cells during culture, distinct from those that
maintained a progenitor phenotype regardless of in vitro conditions. As described by Szabat
et al, “together, these findings suggest multiple levels of complexity underlying functional
maturation in adult β-cells, and that maturation state in part underlies functional
heterogeneity” (31).
Other markers have been proposed to represent maturity markers for β-cells,
including Flattop (Fltp) (32), a planar cell polarity gene important for the ordered
arrangement of cells in a plane of tissue. Fltp was recently shown to maintain the rosette-
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like structure of mature β-cells around a blood vessel, and increased in expression up to
80% during postnatal β-cell growth. Furthermore, during pregnancy, proliferation increased
in Fltp- β-cell progenitors more than 6-fold (33). Fltp expression was also shown to correlate
to other markers of maturation, including Ucn3, Glut2, and transcription factors including
Nkx6.1 and MafA (33).
Pax4 is a transcription factor with a well-defined role in β-cell maturation (34,35).
Recent work has shown Pax4 to be present in a subpopulation of β-cells which are capable
of expansion during pregnancy (36). Furthermore, evidence from the Melton laboratory has
shown that certain transcription factors usually present in other [non-pancreatic] tissues
representing the transition from fetal to adult programs were expressed in altered
proportion during human stem cell differentiation to insulin-expressing β-cells, such as
NFIB, PROX1, HHEX, and KLF9 (37).
Overall, these data suggests that β-cell progenitors may be identified by the
combined presence or absence of multiple factors, as depicted in detail in Figure 6.1. We
propose that Ins+Glut2- cells themselves exist within a spectrum of immaturity, and
represent a reservoir of cells present during developmental, ranging from rare early β-cell
progenitors (capable of multi-potential cell fate) to glucose non-responsive β-cells. Indeed,
further sub-categorization of Ins+Glut2- cells will likely be necessary in the future. Moreover,
phenotype identification of these progenitor cells preceding insulin expression would
potentially yield a larger cell pool for manipulation.
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Figure 6.1. Proposed model of Ins+Glut2- progenitor β-cells.
β-cells exist within a spectrum of maturity, especially during early postnatal
development. A subpopulation of β-cells can be identified by the lack of
Glut2, and which have been identified by others as having low expression of
Urocortin 3 (Ucn3), insulin, Flattop (Fltp), MafA, Nkx6.1, and increased
expression of Pdx1 and Ngn3. Within this spectrum of maturity exist rare
multi-potential cells; however, the majority represent immature β-cells which
are not glucose responsive. Most Ins+Glut2- β-cells may be found outside of
the islet, scattered throughout the pancreas in small clusters of cells. As the
endocrine pancreas matures and ages, fewer Ins+Glut2- cells found and which
coincides with a decrease in the proportion of small clusters, as more β- cells
reside within islets. This also coincides with a decrease in endocrine
regeneration potential.
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6.4

Limitations and Uncertainties
6.4.1 Lineage tracing: a necessary evil?
Lineage tracing studies are qualified by the design of the genetic system, and involve

multiple decisions including promoter selection and transgene inducibility, and are effected
by pharmacological intervention. The implications of introducing another drug into a
physiological system, however commonly used, should not be underestimated. Tamoxifen is
widely used to cause transgene induction in a dose-dependent manner as described in
Chapter 5. However, the primary application of this drug is for the prevention of estrogenreceptor- expressing breast cancer recurrence. In humans the standard dose is 20-40
mg/day (38), whereas the dosing regimen in transgenic mice is 3-5 doses of 0.1 mg/g body
weight (i.e, ~3 mg/dose), and in some instances is increased to 4-8 mg/dose (7,39). In mice,
this translates into drug exposure of several-fold higher dose in a much shorter timeframe
than would be given to humans, and which has been shown to be poorly tolerated. While it
was initially established, and widely assumed, that tamoxifen was only active in tissues for
~48 hours after administration (30), it was recently shown that the drug may persist, and
hence continue to label cells, for weeks in vivo, particularly when used at high doses, and
which may confound the interpretation of a pulse-chase experiment (39). While
administration of tamoxifen via oral gavage instead of injection may mediate some of these
discrepancies in absorption, physiological consequences of the drug may influence health
outcomes independent of the disease model, such as the effect of tamoxifen on fertility
(39,40). Due to a limited time frame between tamoxifen dosing and STZ exposure in our
model, it cannot be conclusively determined that the results yielded, showing a doubling of
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lineage-label over the first 4 weeks of life, were due to selective tagging of a highly
proliferative subpopulation, or whether the tamoxifen continued to label β-cells in the
normal developmental program for longer than was expected. Nonetheless, as this trend
was not experimentally demonstrated after STZ exposure, this result points to the
differential utilization of β-cells during regeneration, and implies the existence and
involvement of a progenitor population (Chapter 5).
A similar universal challenge of lineage tracing experiments is that only a subset of
cells are tagged, and after such careful design, we are left to rely on overall trends alone. As
was shown in our inducible animal model in Chapter 5, ~30% of β-cells in islets were tagged
with HPAP after tamoxifen administration, and fewer in BCA. Considering that only ~1% of
β-cells in islets lack Glut2 at P7, and which decreases with age, our assessment of lineagetagged Ins+Glut2- cell proportion at the initiation of the experiment was <0.3% in islets, and
<3% in BCA, making definitive conclusions challenging. Many groups have shown positive
reporter presence in a small population of cells than was expected after lineage-tracing, but
which was consequently dismissed as an artifact of Cre transgene “leakiness” (41,42),
negating the impact of details which can drastically alter interpretation. The assessment of a
rare population of cells using a system that is even minimally imperfect creates an
opportunity for criticism; however, it also highlights that our reliance on lineage tracing
technology has both reformed, and perhaps paradoxically restricted our knowledge of β-cell
biology. The mounting, and seemingly contradictory results provided by multiple groups
trying to answer the same question does lead one to ponder if there is in fact more than
one correct answer. The bold conclusion by the Melton laboratory that β-cells are formed
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exclusively through self-duplication and not stem-cell differentiation may be too restrictive
in the face of years of research showing alternate phenomena. As was testified by BonnerWeir and Sharma in reference to this controversy, there exists “... the difficulty of
definitively proving that something does not happen” (43).
In a similar vein, limitations in lineage tracing technology restricted us from
following Ins+Glut2- cells  Ins+Glut2+ cells directly as there is no specific marker available
for the absence of the glucose transporter. We also do not have the technology to
differentially label β-cells present within BCA versus islets, which could be used to
determine their hypothesized maturation and coalescence. It would be useful if multiple
transgenic lines could be combined to label both insulin and Glut2 with separate reporters,
however as shown in Chapter 5 and above, pharmacological effects and a short window for
transgene induction in young mice would make this system difficult to appropriately study.
As discussed in Chapter 3, the use of the cytoplasmic protein HPAP as a reporter in
our system required us to employ an alternate cell marker for use in fluorescent cytometric
sorting procedures. It was previously demonstrated by the Grompe laboratory that
membrane-bound, non-endocrine, non-hormonal proteins efficiently labelled islet and
acinar cell subpopulations, such as Glycoprotein M6a as a proxy marker for β-cells (44).
Within the pancreas, it can be confidently ascertained that Gpm6a+ cells further defined by
positive expression of Glut2 appropriately selects for the mature β-cell. However, using a
neural marker and the absence of Glut2 as the selection criteria for a progenitor β-cell
population does allow for some degree of uncertainty. Despite insulin immunostaining of
recovered, FAC-sorted fractions and ex vivo tissue sections using the Gpm6a antibody, there
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exists the theoretical possibility that resident neurons could be collected along with β-cells.
Furthermore, while the culture of Ins+Glut2- cells in neural-differentiating conditions
generated neurospheres, and which expressed HPAP, it is theoretically possible that
neurons use insulin as a neurotransmitter (45), and could therefore also retain the reporter
protein, suggesting that this result is not wholly conclusive, however statistically unlikely
this is. Moreover, this has been further complicated by recent evidence from the van der
Kooy laboratory which showed that there are in fact two populations of progenitor cells
within the pancreas: the majority derived from the Pdx1 lineage and which produce the
insulin-expressing cells as described, and a rarer population which is derived from Wnt1
neural crest lineage (46).

6.4.2 Animal models as proxy for human disease
Besides the limitations of interpreting data obtained through lineage tracing, we
must be cautious in extrapolating data provided by studies on rodents directly to the human
context. Knowledge about human β-cell cell biology and proliferation has been obtained
largely through static, post-mortem examination, and which has recently been questioned
as artificially low due to warm ischemia time which influences antibody immunostaining
(47). Relatively few studies have been able to lineage trace human β-cells ex vivo (48,49),
and none in vivo, due to obvious ethical reasons. Data from Chapter 4 showed a surprisingly
high degree of correlation between human and mouse in the progression of Ins +GLUT2- cells
during endocrine pancreas development. However, the numerous species differences
known, with differential utilization of primary glucose transporter subtype, islet macro196

organization with regards to cell-cell contact, vascular arrangement, basement membrane,
and innervation patterns (50–56), timing of endocrine pancreas maturation, widely variable
genetics, and lifestyle factors among others, render paralleling these situations directly as
unsuitable. Furthermore, animal models of diabetes do not directly educate diabetes
disease progression in humans. While it is commonplace to effect hyperglycemia by
pharmacological methods, and much can, and has been learned by the damage and
regeneration models used in mice, STZ-mediated hyperglycemia is not a direct substitute
for the complex physiological changes occurring in patients with type 1 diabetes, such as
continued β-cell damage and lack of C-peptide exposure in the human context.

Indeed,

promising results from animal studies have generally failed in human clinical trial (especially
with regards to autoimmune mitigation), forcing frank reassessment on the appropriateness
of basing diabetes therapy on data gleaned from a 30g rodent. This is, however, nominally
reconciled with the advent of studies involving humanized mice (57,58), as well as a strong
push within the islet biology community to include experiments with human tissue to
ensure that appropriate conclusions are being drawn. It is therefore critically important, and
reassuring, that the results by Smukler et al (5) and by us in Chapter 4 did indeed illustrate
that this population of progenitor cells is present and active within the human pancreas, in
addition to its presence in mice.

6.5

Future Studies
To complete the studies in Chapter 3, quantitative PCR experiments are currently

underway to examine the genetic differences between subsets of P7 RIPCre;Z/AP+/+β-cells,
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flow cytometrically-sorted by the expression of Glut2. Similar to data by Smukler et al (5),
we will assess the relative proportion of β-cell-specific genes (Ins, Glut2, Ngn3, Pdx1,
Nkx6.1).
The model which we have established to stratify β-cells according to function can be
applied to study multiple related endocrine pathologies. We have defined a time-course for
these Ins+GLUT2- cells, a primary location, and that the actions of STZ are (indirectly)
influenced by their presence, at least in mice. To ascertain conclusively if there are
differences in β-cells based on location, experiments will be undertaken to separate these
cells. Islet isolation will be performed as previously described; however, the ~98% of
pancreas-cell content remaining will then be retained and examined. These two
compartments of β-cells – intra- islet vs extra-islet – would be independently separated into
single cell suspension and prepared for flow cytometric sorting for insulin, or its appropriate
cell surface proxy marker, such as GPm6a, as shown in Chapter 3 (44), or by transgenic βcell lineage marker, such as green fluorescent protein present in MIP-GFP mice (5). And, as
shown by us in Chapter 4, these experiments should be undertaken using young (<21 days)
and old (>6 months) mice to characterize the multi-potential population, and if it
concurrently changes with age.
The obvious next step is to interrogate the human pancreas, islets and BCA alike, to
assess whether the Ins+GLUT2- cells also demonstrate a multi-potential lineage capacity,
specifically over different ages. Furthermore, it must be determined whether the added
labour and expense of collecting extra-islet β-cells in addition to intact islets yields
improvements after transplant. With the introduction of new cell-surface markers for
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human β-cells allowing for their isolation by flow cytometry (59), this capability should soon
be within reach.
The multitude of physiological situations requiring enhanced metabolic substrates,
and the situations in which they fail (i.e., diabetes subtypes) could all be examined for the
role of Ins+GLUT2- cells during their progression. As we have successfully identified these
cells in sections of human pancreas, tissue samples from newly diagnosed versus
established type 1 diabetes pancreata could be examined, including those around
adolescence, as speculated in Chapter 4.
Investigation of the role of Ins+Glut2- cells during pregnancy is currently underway,
using RIPCreER;Z/AP mice. β-cells are tagged prior to pregnancy with HPAP, and
proliferation assessed by EdU and Ki67. Pancreata are collected at key points prior to
parturition, with the intent of determining if compensatory β-cell mass increases involve
these putative progenitor cells. We also anticipate a correlation of Ins+Glut2- cells with
Ucn3- (18,19), Fltp- (33) and Pax4+ (36) cells. Examination of human pancreata during
pregnancy and postpartum will also be ideally performed, although the availability of these
samples is limited.
Our study illustrating the progressive decline in Ins+GLUT2- cells with advancing age
was accomplished using lean human individuals alone (Chapter 4); examining this
population in overweight humans, with and without diabetes present could also identify
(pre)clinical parameters for study. Both of these conditions can be mirrored using
appropriate animal models, with the use of non-obese diabetic (NOD) mice to track the role
of immune attack in type 1 diabetes (60), the role of insulin resistance without obesity
199

using β-cell-specific insulin-receptor knock-out mice (IRKO) (61), and the use of C57Bl6 (62)
or liver specific insulin-receptor knockout (LIRKO) mice (63) fed a high fat diet to induce
glucose intolerance and type 2 diabetes with obesity present.

6.6

Conclusions
The work presented here has contributed to the body of knowledge regarding

pancreatic β-cells in three primary ways: first, that a subset of β-cells demonstrates lineage
fate plasticity, which can be stratified into categories of maturity and function based on the
expression of Glut2 in both human and mouse. This has allowed the identification and
retrieval of these cells relatively simply, while integrating succinctly into the current
paradigm of β-cell biology. Second, that this β-cell subtype is temporally defined, with fewer
Ins+Glut2- cells present in mouse and human pancreas with advancing age, which identifies
a window for clinical intervention. And third, that these progenitor β-cells are
predominantly found outside of mature islets, which provides an anatomical location
wherein research efforts can be focussed, and has been heretofore untapped.
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Appendix 1

A

B

C

D

Figure S2.1. Pancreatic endothelial cells. Freshly isolated mouse endothelial
cells (ECs) grown on fibronectin-coated dishes with EBM-2 media (A), and
which could be passaged up to 3 times (B). Alternatively, ECs were harvested
and mixed in Matrigel (C). After 7 days, ECs had formed tubular structures (D).
Scale bars represent 50 μm, n = 4.
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Appendix 2

GPM6a

C

Glut2
Figure S3.1. Strategy for gating neonatal pancreas cells used for flow cytometric
cell sorting by GPM6a and Glut2. Dissociated pancreatic cells were selected by
the ‘Live’ gate based on 7-AAD exclusion (A). Forward scatter (FSC) and side
scatter (SSC) voltages were adjusted to clearly visualize cells as indicated by the
‘Cells’ gate (B). Doublets were excluded based on consecutive gates on FSCHeight vs FSC-Width and SSC-Height vs SSC-Width plots (not shown). Viable
GPM6A (insulin)-expressing cells (B, C) were selected based on differential Glut2
expression (C, red and green) by comparison to cells lacking GPM6a expression
(C, purple). Gates were set based on fluorescence minus one controls and cluster
gating. The FACSAria III cell sorter is equipped with a 30 mW Coherent solid state
405 nm violet laser, a 20 mW Coherent Sapphire solid state 488 nm blue laser, a
50 mW Coherent Compass solid-state diode-pumped 561 nm yellow-green laser,
and a 17 mW JDS Uniphase Helium Neon 633 nm red laser. The blue laser trigon
was configured to detect AlexaFluor 488 from detector B (530/30 bandpass and
502 longpass filter). The yellow-green laser octagon was configured to detect
AlexaFluor 594 from detector D (610/20 bandpass and 600 longpass filter), and 7AAD from detector C (670/14 bandpass and 630 longpass filter). Cells were
sorted at 4oC using a 100 μm nozzle at 20 psi and at a maximum of 6,000
events/second.
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Appendix 2
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Figure S3.2. Neither insulin nor amylase are expressed after
dedifferentiation of neonatal mouse islets to ductal epithelium.
Pancreatic beta cells within P7 islets immunostained for insulin (A,
red), and were negative for amylase (A, green), which immunostained
the acinar compartment. After isolation and culture of islets for 7 d
towards a ductal epithelial phenotype, insulin expression was lost (B,
red), as was amylase expression (B, green). Scale bar represents 50
μm, n = 3.
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Appendix 2

INS

HPAP

HPAP
INS

Figure S3.3. HPAP faithfully tracks the β-cell during dedifferentiation in
vitro.
RIPCre;Z/AP+/+ mouse islet stained for insulin (red) and HPAP (green) after
culturing for 3 days in dedifferentiation conditions. Note that insulin
immunostains only 3/8 cells present, with HPAP immunostaining 2/3 βcells. Scale bar denotes 50 μm, n = 3.
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Appendix 2

INS

GPM6a

Merge

Figure S3.4. Insulin-expressing β-cells immunostained by GPM6a.
Beta cells were immunostained for insulin (green) and the cell
surface marker GPM6a (red) within an islet. Scale bar denotes 50 μm, n = 3.
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Supplemental Methods: Genotyping

At maturity, one RIPCre+/+ and one LacZ/HPAP+/- mouse of the opposite sex were
caged together for mating. Genotyping of resultant P5 mouse pups was accomplished by
ear/tail snips. The DNA extraction buffer consisted of 5 μL 0.5 M NaCl, 2.5 μL each 1 M Tris
pH 8.0 and 20 mg/ml proteinase K (Roche Ltd, Mississauga ON), 0.1 μL 0.5 M EDTA, 0.5 μL
10% SDS, and 39.2 μL DNase-free , RNase-free H20, to a final volume of 50 μL per tissue
sample. Samples were heated at 56°C for >3 h, vortexed, then centrifuged at 600 x G for 15
min at 4°C. Samples were stored at -20°C, and 0.5 μL of DNA within the supernatant was
used in downstream PCR reactions.
The PCR reaction master mix contained 5 μL each 10x buffer and MgSO4 (UBI Life
Sciences Inc, Saskatoon, SK), 2 μL 10 mM dNTPs (Invitrogen, Carlsbad, CA), 1 μL each 20 mM
forward and reverse primers (Sigma-Aldrich, St Louis MO), and 1 U (0.2 μL) Taq (UBI), to a
final volume of 50 μL in DNase-free, RNase-free water. The following primer sequences for
the transgenes of interest were used: RIPCre (FW – gcggtctggcagtaaaaactatc and RV –
gtgaaacagcattgctgtcactt,

100

bp),

Z/HPAP

(FW-

ccgcttcccatatgtggctctgtcc;

RV-

gcatgagctcagtgcggttccacac, 548bp), and the internal control (FW- caaatgttgcttgtctggtg;
RV- gtcagtcgagtgcacagttt, 200 bp). All primer sequences were available from Jackson
Laboratories. PCR reactions were performed using an initial denaturation at 94 C for 3 min,
followed by 35 cycles of denaturation (30 sec at 94°C), primer annealing (1 min at 59°C), and
transcript extension (1 min at 72°C). cDNA was run on a 2% agarose gel as described in
Chapter 2.
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Supplemental Material
S5.1. Identification of LacZ-expressing tissues
To confirm the presence of β-galactosidase, sections from LacZ/AP mouse pancreas
were subjected to the X-gal reaction (1) containing X-gal reagent (5-bromo-4-chloro-indolylβ-D-galactopyranoside) (Sigma Chemical, St Louis, MO), potassium ferricyanide, and
potassium ferrocyanide. Cells expressing β-galactosidase demonstrated an indigo-blue
precipitate in RIPCreER;Z/AP+/+ mouse pancreas sections without tamoxifen administration
within the islet (Figure S5.1A, red circle). Conversely, RIPCreER;Z/AP+/+ mouse pancreas
sections stained for X-gal after tamoxifen induction did not contain the blue precipitate
(Figure S5.1B), and neither did sections from RIPCreER;Z/AP-/- mouse pancreas (Figure
S5.1C).

S5.2

Identification of HPAP-expressing tissues using NBT/BCIP

HPAP+ cells were identified using multiple methods: (A) the alkaline phosphatase
substrate

chromogen

Nitro-Blue

Tetrazolium

Chloride/

5-Bromo-4-Chloro-3'-

Indolyphosphate p-Toluidine Salt (NBT/BCIP, Sigma) which produces a purple-blue
precipitate in alkaline phosphatase-expressing cells; (B) a fluorescent substrate using the
Vector Red Alkaline Phosphatase Substrate Kit (Vector Labs, Burlingame, CA), which works
similarly to NBT/BCIP but by adding a red fluorescent tag; or (C) immunohistochemical
staining of HPAP+ cells using a Mouse-on-Mouse (MOM) kit (Vector Labs) with a mouse antihuman HPAP antibody (Sigma), or a rabbit anti-human HPAP antibody (Abcam, Cambridge,
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UK). Blocking of endogenous pancreatic alkaline phosphatase, but not HPAP, was
accomplished by pre-treatment with levamisole (2) (Dako, Glostrup Denmark), or by
incubating slides in 70°C PBS for 20 min for the chromogenic assays.
By NBT/BCIP staining, HPAP+ cells within islets could be visualized in P7 RIPCreER;Z/AP+/+
sections as indicated by the presence of purple-blue precipitate

after tamoxifen

administration (Figure S5.2A); islets from RIPCreER;Z/AP-/- mice did not stain (Figure S5.2B),
and neither did RIPCreER;Z/AP+/+ mouse pancreas sections not induced by tamoxifen (not
shown). Pancreas sections not pre-treated with levamisole/heating in PBS to block
endogenous alkaline phosphatase displayed substantial background staining, especially
within ducts (Figure S5.2C).

S5.3

Dose response to tamoxifen in RIPCreER;Z/AP+/+ pancreas and specificity
of HPAP to the β-cell
RIPCreER;Z/AP+/+ pancreas sections from P7 pups were stained for insulin (green)

and Vector Red alkaline phosphatase substrate (red) demonstrated no positive areas of
staining for AP when tamoxifen (TM) was not administered (Figure S5.3A). After induction
with TM, the HPAP protein clearly and faithfully tracked insulin in the β-cell, showing a
graded increase in AP presence after one (Figure S5.3B) and two injections of TM (Figure
S5.3C). However, there was considerable variability in staining frequency between islets
after 2 doses of tamoxifen when stained using either chromogenic method (between 1090%), likely due to the enzymatic nature of the NBT/BCIP and Vector Red substrate
reactions, and not directly to HPAP-expressing cells. More than 2 injections of TM were not
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tolerated by the pups (not shown). Moreover, any pup injected with tamoxifen were not
viable breeders as adults, indicating a negative effect on fertility. None of the non-insulin+
cells at P7 positive for AP (red) co-stained for glucagon (Figure S5.3D, green). Pancreas
sections not pre-treated with levamisole or heated to 70°C in PBS show endogenous
alkaline phosphatase presence, primarily around ducts (Figure S5.3E, red).
Due to the heterogeneity of Vector Red staining within islets, we utilized anti-HPAP
antibodies for quantification, although the enzyme-based methods were still used to quickly
and easily assess transgene induction presence.

References
1.

Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, Nagy A. Z/AP, a double
reporter for cre-mediated recombination. Dev Biol. 1999;208(2):281–292.

2.

Van Belle H. Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified
isoenzymes from humans. Clin Chem. 1976;22(7):972–6.

215

Appendix 3

A

B

C
Figure S5.1. X-gal staining for β-galactosidase presence in transgenic
(LacZ/HPAP) mouse pancreas.
RIPCreER;Z/AP+/+ mouse pancreas without tamoxifen injection (A). Blue
precipitate inside the islet (red circle) indicates areas of positive betagalactosidase enzyme, correlating with lacZ content. RIPCreER;Z/AP+/+ mouse
pancreas after tamoxifen induction (B) was absent for blue precipitate, as
were sections from RIPCreER;Z/AP-/- mouse pancreas (C). Cells were
counterstained with Carazzi’ s haematoxylin. Scale bars denote 50 μm, n > 3.
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Appendix 3

A

B

C
Figure S5.2. NBT/BCIP staining of alkaline phosphatase-expressing
pancreatic tissue.
RIPCreER;Z/AP+/+ islet stained for AP indicated by purple-blue precipitate
(A). RIPCreER;Z/AP-/- pancreas section pretreated with levamisole,
indicating a lack of blue precipitate (B). Pancreas section neither pretreated with levamisole nor 70°C PBS; positive staining for AP is seen
within the islet (red circle), however there is substantial background
staining for endogenous AP, especially within ducts (C, arrow). Cells were
counterstained with Carazzi’s haematoxylin. Scale bars denote 50 μm, n
> 3.
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Figure S5.3. Dose response to tamoxifen in RIPCreER;Z/AP+/+ pancreas, and
specificity of HPAP to the β-cell.
P7 RIPCreER;Z/AP+/+ pancreas sections stained for insulin (green) and Vector
Red alkaline phosphatase substrate (red) shows no staining for AP when
tamoxifen was not administered (A), minimal staining for AP after one dose of
TM (B), and a moderate proportion of AP staining in insulin-expressing cells (C)
after 2 injections of TM. Alpha (α)- cells immunostained for glucagon (green)
and AP (red) clearly occupy different cells within the islet (D). Pancreas section
not blocked for endogenous AP expression shows AP staining (red) around
ducts (E, white circle). Size bar represents 50 μm, n > 3.
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